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Abstract  
Epilepsy of infancy with migrating focal seizures (EIMFS) is characterised by the onset of 
frequent focal seizures in the first 6 months of life, a typical migratory EEG pattern and 
severe developmental delay. In this thesis, I report a cohort of patients with EIMFS, 
delineate clinical features and investigate the molecular genetic basis of this syndrome. In 
2012, heterozygous mutations in the sodium-gated potassium channel KCNT1, were 
described in patients with EIMFS. Using a variety of genetic techniques, I have identified 12 
patients with mutations in this gene. Four are novel, previously unreported mutations. 
Functional investigations, including protein homology modelling and electrophysiology in a 
xenopus oocyte model showed that all novel KCNT1 variants were gain-of-function 
mutations. In addition, I describe a new genetic cause of EIMFS. Within my cohort, I 
identified a consanguineous family with two affected children. Autozygosity mapping and 
whole exome sequencing revealed a novel, homozygous mutation in SLC12A5. SLC12A5 
encodes KCC2, the neuronal potassium chloride co-transporter that determines the 
direction and polarity of GABA-mediated signalling. Through international collaboration, I 
found a second family with two affected children harbouring compound heterozygous 
SLC12A5 mutations. All three SLC12A5 variants were investigated using an overexpression 
HEK293 cell model. Immunoblotting and immunohistochemistry revealed decreased cell 
surface expression of mutant KCC2. Electrophysiology experiments showed a 
depolarization of the chloride reversal potential and a delayed response to chloride 
loading. Taken together, these results indicate that loss of KCC2 function is likely to result 
in abnormal neuronal inhibition in this form of EIMFS. The genetic heterogeneity in EIMFS 
is strong evidence that a wide variety of different pathogenic mechanisms can result in the 
severe epilepsy and abnormal neurodevelopment observed in this condition. Further 
elucidation of causative genes in both animal and cell models is needed to identify novel 
therapeutic targets for this devastating disorder.  
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Chapter 1 Introduction and Overview 
1.1 Severe epilepsy in infancy and childhood 
Since antiquity, epilepsy has formed an integral part of the human experience. The first 
written description of epilepsy was in 2000 B.C., with seizures in infancy and childhood 
described since Babylonian times (Magiorkinis et al. 2010). The term epilepsy comes from 
the Greek “epilambanein”, meaning to seize, possess or afflict (Magiorkinis et al. 2010).  In 
the pre-Hippocratic era it became known as the “sacred disease” and was attributed to 
lunar influence or the displeasure of the Gods, but in his thesis “On the Sacred Disease”, 
Hippocrates asserted that epilepsy is due to natural causes and originates from the brain 
(Wolf 2014). Hippocrates also recognised that there were inherited forms of epilepsy and 
that earlier onset of epilepsy was associated with poorer prognosis (Magiorkinis et al. 
2010). Although many further advances in seizure semiology and classification emerged 
over the following millennia, the first description of a severe childhood epilepsy syndrome 
was the account by Dr West of infantile spasms in his own child in 1841 (West 1841; 
Capovilla et al. 2013). The emergence of this concept is further discussed in 1.2. 
Today, epilepsy is recognised as the commonest neurological condition of childhood, 
affecting 1 in 150 children (Aaberg et al. 2017). Onset of childhood epilepsy is commonest 
in the first two years of life and such early onset disease is commonly associated with 
reduced seizure freedom and cognitive impairment when compared to epilepsy with later 
onset in childhood (Eltze et al. 2013). The epilepsies of infancy and childhood include the 
epileptic encephalopathies, a devastating group of disorders characterised by multiple 
seizure types, florid epileptiform EEG abnormalities and developmental stagnation or 
regression (McTague et al. 2015). A number of age-related electroclinical syndromes with 
typical seizure types and EEG abnormalities are recognised (Table 1.1). Many of these 
syndromes can be caused by structural brain malformations as well as inborn errors of 
metabolism (Nordli 2012; Gaily et al. 2016) Both treatable metabolic disorders such as the 
Vitamin B6 responsive disorders and surgically treatable structural lesions should be 
excluded early in the investigative odyssey (Rahman 2012; Fridley et al. 2013) However, in 
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patients with normal brain imaging (or non-specific abnormalities) and negative metabolic 
investigations, a genetic cause is highly possible and should be pursued (Figure 1-1).  
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Figure 1-1 A diagnostic approach to early onset epilepsy. GLUT1 Glucose Transporter 1, NGS next generation sequencing 
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1.2 Epileptic Encephalopathy 
The term “encephalopathy” broadly describes an alteration of consciousness that can 
result from many different aetiologies including infectious, toxic and metabolic causes. 
Although the concept of an epileptic encephalopathy, that is an alteration of cognition or 
consciousness associated with epilepsy, appears to be a modern phenomenon, the co-
occurrence of frequent seizures with cognitive impairment was first described by Dr West 
in his own child who presented with infantile spasms and cognitive decline in 1841 (Eling et 
al. 2002; Duncan 2001). Subsequently, further clinical descriptions of “eclampsia nutans” 
and tic de Salaams” were published, but the associated chaotic inter-ictal EEG abnormality 
was not described until 1951 and was then subsequently characterized as “hysparhythmia” 
by Gibbs and Gibbs (Eling et al. 2002; Capovilla et al. 2013). This, therefore, was the first 
potential evidence of disturbance of cognitive function by inter-ictal discharges associated 
with severe epilepsy. From the 1950s, the clinical and electrographic delineation of other 
severe epilepsy syndromes such as Lennox Gastaut and Landau Kleffner syndromes have 
further contributed to the concept of inter-ictal EEG abnormalities resulting in a 
neuropsychological deficit, as discussed below (Capovilla et al. 2013).  
The concept of an epileptic encephalopathy was formally defined in the 2001 ILAE 
Classification Commission Report (Engel 2001) as a state in which the epileptiform 
abnormalities themselves contribute to the progressive decline in cognitive function seen 
in some severe epilepsies. This was further discussed in the 2006 ILAE Classification report 
(Engel 2006) where epileptic encephalopathy was defined as a condition associated with 
progressive neurodevelopmental impairment which is epilepsy-dependent, rather than 
solely resulting from an underlying cause such as an encephalitis or a metabolic disorder. 
In the subsequent 2009 ILAE report on classification and terminology (Berg et al. 2010) the 
concept was further developed to describe epilepsies where the epileptic activity itself 
contributes to progressive neurodevelopmental impairment, which is worse that would be 
expected due to the underlying pathology alone. In support of this concept, there is 
evidence from animal models that both early-life seizures and the occurrence of inter-ictal 
spikes, even without overt seizures, predispose to cognitive impairment compared to 
controls (Chapman et al. 2015) In several studies, longer periods of abnormal electrical 
activity have been associated with a poorer cognitive outcome in West syndrome of 
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undetermined aetiology (Matsumoto et al. 1981; Kivity et al. 2004; O’Callaghan et al. 
2011). Arguably, this may reflect the underlying cause, rather than the effect of EEG 
discharges on long-term developmental outcome. However, in studies investigating the 
impact of infantile spasms in either Down syndrome or tuberous sclerosis, it is evident that 
earlier, and even pre-symptomatic, treatment is associated with improved cognitive 
outcome (Humphrey et al. 2014; Jóźwiak et al. 2011). Indeed, in other epileptic 
encephalopathies, such as Landau-Kleffner syndrome, where disease-onset follows a 
period of normal development, there is a clear relationship between the onset of EEG 
abnormalities (in this case electrical status epilepticus in slow wave sleep, ESES), and the 
observed acquired aphasia and cognitive decline. Resolution of ESES usually, though not 
always, leads to cognitive improvement (Van Bogaert 2013). Furthermore, in Lennox 
Gastaut syndrome or epilepsy associated with Ring Chromosome 20, non-convulsive status 
epilepticus can confer an additional cognitive impairment which resolves with treatment 
(Chapman et al. 2015). Overall, it is likely that multiple complex factors contribute to the 
encephalopathy and motor/cognitive decline observed in different epilepsies. 
Over time, epileptic encephalopathy has become an umbrella term to describe many of 
the severe epilepsy syndromes of infancy and childhood (Table 1.1) where frequent 
seizures are accompanied by severe neurodevelopmental delay or regression, cognitive 
impairment and behavioural difficulties (McTague et al. 2015). However, more recently, 
the use of this term has become more controversial as the relationship with underlying 
aetiology has emerged (Howell et al. 2016; Korff et al. 2015). Some authors proposed the 
term “epileptogenic” rather than epileptic encephalopathy, stating that the underlying 
pathology leads to cognitive impairment which is independent from the epilepsy (Capovilla 
et al. 2013). Other authors also assert that the epileptic activity reflects the severity of 
brain dysfunction resulting from the underlying aetiology (Korff et al. 2015) and that, in the 
majority of circumstances, resolution of seizures and/or EEG abnormalities does not result 
in cognitive improvement. Indeed, there a number of chromosomal disorders where 
epilepsy is a major feature, such as Angelman syndrome, but where significant 
developmental delay is evident prior to seizure onset (Buiting et al. 2016). In the most 
common genetic epileptic encephalopathy, Dravet syndrome, cognitive slowing and 
decline tends to occur before the epilepsy becomes florid, suggesting the cognitive decline 
may follow a different time-course to the epilepsy, although both are likely to be related to 
the underlying SCN1A mutation (Nabbout et al. 2013; Dravet et al. 2011). Indeed, focal 
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knockdown of Scn1A in the basal forebrain led to cognitive impairment in the absence of 
seizures in a rodent model (Bender et al. 2013). In contrast to SCN1A-epilepsy, in STXBP1 
and KCNQ2 related encephalopathies, patients present with a severe early neonatal 
epilepsy which improves with time or burns out, but patients continue to manifest severe 
neurological impairment, often with the emergence of other neurological symptoms, such 
as non-epileptic movement disorders (Weckhuysen et al. 2013; Stamberger et al. 2016; 
McTague et al. 2015; Scheffer et al. 2017).  In the recent report of the ILAE Classification 
Committee, it was recognized that for many of the genetic early onset epilepsies, there is 
likely to be a developmental encephalopathy, where the impact of the genetic mutation 
leads to cognitive impairment which is independent of the electrical activity (Scheffer et al. 
2017). Increasingly, patients are described as having a developmental and/or an epileptic 
encephalopathy, based on the judged additional impact of the epileptic activity to the 
cognitive burden. It is likely that as we continue to move towards aetiology-led 
descriptions of early onset epilepsy, both of these terms will be replaced by concepts such 
as SCN1A or CDKL5 encephalopathy (Scheffer et al. 2017).  
While these may seem like semantic discussions, there are practical implications for 
patients. The importance of this concept lies in our approach to treatment. Aggressive 
treatment of inter-ictal EEG abnormalities could potentially lead to over-treatment with 
resultant increased drug load and side-effect burden. Conversely, failure to treat a 
reversible process could further disadvantage a child in terms of cognitive outcome. It is 
increasingly recognised that, rather than being a concept which can be applied to all 
severe epilepsies, there are a limited number of clinical scenarios in which resolution of an 
inter-ictal EEG abnormality may confer a cognitive gain for the patient. One of the 
hallmarks of these scenarios is where a previously developmentally normally infant or child 
develops an EEG abnormality such as in some cases of infantile spasms or Landau Kleffner 
syndrome. In addition, non-convulsive status epilepticus may confer additional cognitive 
impairment for children with Lennox Gastaut syndrome or other severe epilepsies. It is 
vital that appropriate neuropsychological and developmental assessment is utilised 
alongside medical interventions to monitor treatment response. However, for the majority 
of the genetic early onset epilepsies, it is much more likely that inter-ictal EEG 
abnormalities reflect the underlying brain dysfunction and abolishment of these 
discharges, even if it were possible, would be unlikely to be of cognitive benefit. Therefore, 
when the term epileptic encephalopathy (EE) is used throughout this thesis, it refers to a 
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severe epilepsy associated with an encephalopathy or disturbance of cognitive processes, 
without any imputation of the role of inter-ictal EEG activity in this process.  
1.3 Electroclinical syndromes in infancy and childhood 
An electroclinical syndrome is defined as the co-occurrence of clinical features including 
seizure types, EEG abnormalities and other features occurring at a specific age (Berg et al. 
2010). A number of electroclinical syndromes are recognised in infancy and childhood and, 
in the absence of a more specific aetiological diagnosis, remain an important part of 
epilepsy classification and diagnosis which may guide treatment and indicate prognosis 
(Scheffer et al. 2017). In the first two years of life, the majority of electroclinical syndromes 
are severe (Table 1.1) and many are described as epileptic encephalopathies, often 
associated with a poor neurodevelopmental outcome. Self-limited epilepsy syndromes 
such as familial or non-familial self-limited neonatal or infantile epilepsies do however 
occur (Gaily et al. 2016). Importantly, many patients present with severe epilepsies which 
do not fulfil the criteria of the electroclinical syndromes, commonly described as non-
specific epileptic encephalopathy. 
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Epilepsy 
syndrome 
Age at 
onset 
Seizures at onset 
 
EEG Epilepsy evolution and 
outcome 
Development 
OS 0-3 m  Tonic seizures.  
May have focal seizures and 
infantile spasms; myoclonus 
rare 
Interictal: BS 
Ictal: diffuse attenuation or low-voltage 
fast activity. Focal rhythmic spiking with 
focal seizures. 
Frequent evolution to hypsarrhythmia. 
75% evolve to WS 
Ongoing seizures in most 
Severe to profound delay 
EME  0-3m  Fragmentary myoclonus.  
May have tonic and focal 
seizures.  
Interictal: burst suppression which is 
worse in sleep and persists beyond 
infancy. 
Ictal: myoclonias do not show EEG 
correlate.  
No evolution in most, but 
persistent myoclonic and 
focal seizures  
Severe to profound delay 
EIMFS 0-6m  
(median 
7wks) 
Focal seizures that migrate 
from one hemisphere to the 
other. Often adversive, eye 
involvement, autonomic 
features, apnoeas. 
 
 
Interictal: may be normal initially, 
becomes slow with multifocal 
epileptiform abnormalities 
Ictal: migrating ictal focus between 
hemispheres  
May be preceded by or 
evolve into WS 
Ongoing seizures in some, 
others have infrequent 
seizures after first year of 
life 
May be normal before 
seizure onset 
Regression/plateau in many 
after seizure onset 
Outcome severe to profound 
delay in most. 
WS 2-12m  
(peak 6m) 
 
Infantile spasms  
 
 
Interictal: hypsarrhythmia  
Ictal: electrodecremental response or 
high-amplitude midline slow wave with 
admixed fast activity 
May evolve to LGS or 
develop other seizure 
types, 
May be normal or abnormal 
before onset 
Plateau or regression with 
spasm onset 
Outcome worse in those 
with known aetiology; 80% 
have developmental delay 
DS 5—16 m  
(peak 5-
8m)  
Febrile or afebrile hemiclonic 
or generalised tonic–clonic, 
often febrile status 
epilepticus  
 
Initial EEG normal and up to 1-2 years 
Generalised and multifocal epileptiform 
abnormalities later 
Photosensitivity 
Ongoing seizures 
From 1-5 years: focal, 
myoclonic, absence 
seizures, ± NCSE 
10 yrs onwards: brief 
nocturnal convulsive 
seizures ± focal 
Normal in first year of life 
(may have subtle visual 
problems) 
Slows between 1-2 years; 
mean age of walking 17 
months. Language relatively 
spared. Regression with 
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dyscognitive seizures, 
myoclonus and absences 
less common 
status epilepticus 
Outcome mild-severe delay 
(rare cases of normal 
development reported) 
Emerging gait ataxia in later 
life 
EMA  7m-6y 
(peak 3-
4y)  
 
Multiple seizure types: 
myoclonic-atonic 
±myoclonic, absence, tonic-
clonic, and episodes of non-
convulsive status epilepticus.  
Interictal: Hypersynchronous theta or 
delta slowing; generalized spike-wave or 
generalized polyspike-wave, increasing 
in sleep 
Photosensitivity in some 
 
Remission in most within 
3.5 years of onset 
Persistent seizures in more 
severe cases, usually as 
nocturnal tonic or tonic 
vibratory seizures  
Early development normal in 
most. Regression with 
epilepsy onset seen.  
Outcomes from normal 
intellect to severe ID  
LGS 1-8y, rare 
adult 
onset 
cases 
(peak3-5y)  
 
 
Multiple seizure types: tonic 
seizures ± atypical absences, 
atonic, myoclonic, GTCS, 
spasms, focal, episodes of 
tonic SE or NCSE 
Interictal: slow background, slow (<2.5 
Hz) spike-wave, generalized paroxysmal 
fast activity in sleep 
Ictal: electrodecrement or low voltage 
fast activity (tonic seizures), slow spike-
wave (atypical absences), generalized 
spike- or polyspike-wave activity 
(myoclonic seizures) 
Seizures persist into 
adulthood in most cases 
Developmental delay 
precedes epilepsy onset in 
20-60%. 
Cognitive impairment in 90% 
by 5 years after seizure 
onset. Learning difficulties in 
remainder. 
 
EAS 
(including 
LKS, CSWS, 
ABRE) 
 
 
3-7y LKS: rolandic seizures in 70%  
ECSWS: rolandic seizures 
ABRE: rolandic seizures, 
negative myoclonus, atonic  
Centrotemporal spikes, often bilateral 
independent and bilaterally synchronous 
increasing in sleep 
LKS and CSWS: electrical status in sleep 
(>85% non-REM sleep) 
Epilepsy age-limited, 
resolves by teenage years 
in almost all patients 
 
 
Most normal pre-seizure 
onset. Acquired epileptic 
aphasia at onset in LKS, more 
global delay or regression on 
other EAS disorders. 
Outcome from normal to 
severe delay 
Table 1.1 Severe electroclinical syndromes of infancy and childhood. Abbreviations: ABRE atypical benign rolandic epilepsy, BS burst suppression, 
CSWS continuous spike-wave in slow wave sleep, DS Dravet syndrome, EAS epilepsy aphasia spectrum, EIEE early infantile epileptic 
encephalopathy, EME early myoclonic encephalopathy, EMA epilepsy with myoclonic atonic seizures, EOEE early onset epileptic encephalopathy 
(epileptic encephalopathy starting before 3 months), LGS Lennox-Gastaut syndrome, LKS Landau Kleffner syndrome, m months, MAE epilepsy with 
myoclonic-atonic seizures, NCSE non-convulsive status epilepticus, OS Ohtahara syndrome, SE status epilepticus, WS West syndrome, y years. 
Adapted from McTague et al The Lancet Neurology 2015;15(3):304-16.  
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1.4 The genomic revolution and early onset epilepsy 
 
 
Figure 1-2 A timeline of genetic discovery in the early onset epileptic encephalopathies. 
1.2a Developments in genomic technologies and gene discovery.  aCGH array comparative 
genomic hybridization, NGS next generation sequencing. 1.2b Number of novel genes 
discovered by year (by Pubmed citation search). 
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In 2001, SCN1A was the first gene identified in an epileptic encephalopathy with the 
discovery of heterozygous de novo mutations in seven unrelated individuals with Dravet 
syndrome (Claes et al. 2001). SCN1A mutations had previously been identified in two 
families with generalised epilepsy with febrile seizures plus (GEFS+) (Escayg et al. 2000). 
Early gene discovery relied heavily in mapping and linkage studies in extended kindreds 
coupled with candidate gene Sanger sequencing. However, the advent of massively 
parallel, high throughput next generation sequencing (NGS) in the early 2000s led to an 
explosion in genetic discovery in many conditions, including the early onset epilepsies 
(Møller et al. 2015).  
At this point, it is pertinent to consider what constitutes an “epilepsy gene”. There are a 
large number of multi-system disorders, genetically-defined syndromes and 
neurodevelopmental disorders where epilepsy is one phenotypic feature. As an 
illustration, the Online Mendelian Inheritance in Man (OMIM) database contains 1989 
entries associated with the search term “seizures” and the ClinVar database has 5424 
genetic variants associated with “epilepsy” as a clinical manifestation of disease. Indeed, a 
recent study interrogated multiple databases and identified 693 genes associated with 
epilepsy (Wang et al. 2017). Many of these genes were implicated in metabolic disorders, 
developmental brain malformation disorders, dysmorphic syndromes or other neurological 
disorders where seizures were one of several phenotypic features. However, 84 genes 
were classified as “pure” epilepsy genes where mutations caused epilepsy or an epilepsy 
syndrome with few other additional features. But which genes should be considered to be 
important in the epileptic encephalopathies? Table 1.2 contains over 80 genes where 
epilepsy and developmental delay are the core phenotypic features. Although there may 
be a spectrum of associated features, particularly developmental delay/intellectual 
disability, movement disorders, and non-specific MRI abnormalities, these alone are not 
pathognomonic. Malformations of cortical development and inherited metabolic disorders 
are excluded. It is important to group these epileptic encephalopathy genes together for 
several reasons. Firstly, it is helpful for clinicians to understand which genes have been 
implicated in the EEs, and this may aid interpretation of diagnostic tests such as multiple 
gene panels or clinical exomes. Secondly, as many of these genes may lead to the same 
phenotype, it is important from a research perspective to consider how their diverse 
functions may lead to a shared mechanism of neurological dysfunction.  
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Gene  Age Sz 
onset 
Epilepsy 
syndromes 
(% of cases of 
this syndrome 
where known) 
Sz at onset 
 
Sz evolution 
EEG at onset 
 
EEG evolution 
Development 
at onset 
 
Development 
evolution 
 
 
Other features – 
neurologic 
Other features – 
non-neurologic 
Magnetic resonance 
brain imaging  
Protein function and 
mechanistic implications 
AARS 
 
AR 
 
3 
 
Simons 2015 
2-6 m Non-specific IS, M, F 
 
Refractory Sz 
MF 
 
UK 
UK 
 
Profound DD 
Microcephaly 
Spasticity 
Absent reflexes 
(likely 
neuropathy) 
Movement 
disorder (mixed) 
Congenital 
vertical tali 
Short stature 
Hypo-myelination 
Progressive atrophy 
(cerebral>cerebellar) 
 
Aminoacyl-tRNA-synthetase 
Mutations impair 
aminoacylation, affecting 
protein translation 
ALG13 
 
AD (de novo) 
 
5 
 
Timal 2012 
DeLigt 2012 
Epi4K 2013 
Michaud 2014 
Hino-Fukuyo 
2015 
4 m  
(not 
noted 
in 
some) 
WS 
WS à LGS 
Non-specific 
IS 
 
Refractory Sz - 
ES, F, T, aT, M 
 
 
Hyps 
 
SSW, MF 
Normal-mild 
DD  
 
Moderate-
severe DD 
None reported in 
most 
Optic atrophy 
 
females 
Reports of males 
with abnormal 
transferrin 
isoform pattern 
and multiorgan 
abnormalities, 
these not 
reported in 
females 
UK N-glycosylation of proteins 
AP3B2 
 
AR 
 
12 
 
Theveneon 2017 
0-9m WS 
Non-specific 
IS, M 
 
GTC, M 
 
Hyps in 3 Moderate-
severe DD 
(one walked 
at 12 years) 
Stereotypies 
Dystonia 
Hyperkinesia 
choreoathetosis 
Central hypotonia 
Peripheral 
hypertonia 
Post-natal 
microcephaly 
Optic atrophy Thin cc, cerebral and 
cerebellar atrophy in 
some 
neuron-specific subunit of 
non-clathrin and clathrin-
associated adaptor protein 
complex 3 which plays a key 
role in signal-mediated 
trafficking  
 
ARX mutations 
 
X-linked (males 
affected) 
 
>30 
1d in 
most 
Non-specific C, M, F 
 
Refractory Sz 
MF 
 
N/A 
 
N/A 
 
Profound DD 
 
 
‘XLAG’ phenotype 
Temperature 
instability 
Axial hypotonia 
Spastic 
quadriplegia 
‘XLAG’ 
phenotype 
Ambiguous 
genitalia 
 
Lissencephaly 
Agenesis corpus 
callosum 
Abnormal basal ganglia 
Transcription factor crucial for 
interneuron migration and 
function  
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Berry-Kravis 
1994 
Dobyns 1999 
Kitamura 2002 
Kato 2004 
Kato 2005 
Acquired 
microcephaly 
ARX expansions 
 
 X-linked (males 
affected) 
 
>30 
 
Stromme 2002 
Guerrini 2007 
Kato 2007 
0-7 m EIEE 
WS 
Non-specific 
IS, T 
 
Ongoing Sz in 
some - T, M or F, 
some Sz free 
after infancy  
  
Hyps, B-S 
 
N, MF 
DD in most 
 
Severe-
profound DD 
‘Non-
malformative’ 
phenotype 
Movement 
disorder (most 
commonly 
dystonia +/- 
episodes status 
dystonicus) 
 
‘Non-
malformative’ 
phenotype 
Micropenis in 
some 
 
Normal in 50% 
 
Non-specific 
abnormalities in 50% 
incl. basal ganglia 
cavitation/ signal 
change, cerebral 
atrophy 
Transcription factor crucial for 
interneuron migration and 
function  
 
BRAT1 
 
AR 
 
>15 
 
Puffenberger 
2012 
Saunders 2012 
Saitsu 2014 
Straussberg 
2015 
Hanes 2015 
Van de Pol 2015 
Mundy 2016 
Smith 2016 
Horn 2016 
Srivastava 2016 
0-7 d EIEE 
EOEE 
T, M, C, F 
 
Refractory Sz 
B-S, MF 
 
N/A 
 
N/A 
 
Profound DD 
 
 
Neonatal rigidity 
Hypertonia 
Dysautonomia 
Microcephaly 
 
Dysmorphism 
 
Normal or mild frontal 
lobe hypoplasia 
DNA repair and apoptosis 
CACNA1A 
AD (de novo) 
6 
EPi4K 2016 
Epi4K 2013 
 
1 day-
4w 
EOEE 
EIMFS 
LGS 
M, T, F, SE 
 
TC, F, SE 
MF, GSW, 
slowing 
Migrating ictal 
spikes in 1 
Moderate-
severe DD 
Hypertonia and 
hyperreflexia 
Ataxia in 1 
Hypotonia in 1 
Athetoid 
movements in 1 
Transient VT in 1 Increased T2 temporal 
lobe signal in 1 
Encodes alpha1 subunit of the 
Cav2.1 P/Q-type calcium 
channel, first reported in 
episodic ataxia type 2, 
spinocerebellar ataxia 6 and 
familial hemiplegic migraine 
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and tremor in 1 type 1. 
CDKL5  
 
X-linked  
(females and 
males affected) 
 
>30 
 
Kalscheuer 2003 
Weaving 2004 
Bahi-Buisson 
2008a and 
2008b 
Klein 2011 
Fehr 2013 
0-6 m EOEE (6%) 
WS 
T, TCS 
 
IS, then ongoing 
Sz in 80% 
(refractory in 
50%) -  T, M, F, 
atA and 
‘hypermotor-
tonic-spasms 
sequence’ 
 
Often N 
 
Hyps à MF 
(often 
‘pseudo-
periodic’) or N 
DD in most 
 
Severe DD  
Autistic 
features in 
some 
Hypotonia 
Poor visual 
interaction 
Deceleration head 
growth 
Rett-like features 
(hand 
stereotypies, hand 
apraxia, bruxism) 
- Cerebral atrophy 
Posterior white matter 
T2 hyperintensity 
Ubiquitously expressed kinase, 
involved in multiple cellular 
functions  
Mutations impair neuronal 
morphogenesis and 
transcriptional regulation 
CHD2  
 
AD (de novo) 
 
>30 
 
Carvill 2013 
Suls 2013 
Chenier 2014 
Thomas 2015 
 
9 m -4 y Non-specific  M, A, GTCS, 
A(EM), ‘aT-M-A’, 
prominent 
clinical 
photosensitivity 
 
Refractory Sz - as 
above plus T, aT, 
NCSE 
GSW, PSW, 
activates in 
sleep 
 
SSW, MF 
DD in most,  
 
Mild-severe 
DD 
Autistic 
features in 
some 
Ataxia 
 
 
- Normal or vermis 
hypoplasia 
Chromatin remodeler, specific 
function unknown 
DNM1 
 
AD (de novo) 
 
33 
 
Epi4K 
Consortium 
2013 
EuroEPINOMICS 
2014  
Nakashima 2016 
2-13 m WS 
WSà LGS 
FIRES 
IS 
 
Refractory Sz in 
most - T, aT, F, 
atA, M 
 
 
Hyps, MFD 
 
SSW, PFA, 
MFD 
DD in some  
 
Severe-
profound DD 
Hypotonia 
Extrapyramidal 
movement 
disorder in 1.  
- Normal or cerebral 
atrophy 
GTPase involved in activity-
dependent synaptic vesicle 
formation at inhibitory 
synapses. Mutations predicted 
to impair vesicle recycling and 
reduce T firing at synapses 
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Allen 2016 
Deng 2016 
EuroEPINOMICS 
2017 
DOCK7 
 
AR 
 
3 
 
Perrault 2014 
2-6 m EOEE 
EOEEà WS 
Non-specific 
T  
 
Refractory Sz  - 
IS, M, F, T, T-C 
MF 
 
Hyps, MF 
DD in some 
 
Moderate-
severe DD 
Cortical visual 
impairment 
 
Dysmorphism 
- Occipital atrophy and 
white matter 
abnormality 
Prominent pontobulbar 
sulcus, mild pontine 
hypoplasia 
Rac-guanine nucleotide 
exchange factor. Mutations  
impair neurogenesis and 
neuronal polarity 
EEF1A2 
 
12 
 
 
 
 
de Ligt 2012 
Veeramah 2013 
Nakajima 2015 
Inui 2016 
Lam 2016 
2m-2y Non-specific 
EOEE 
My 
 
IS, T-C, Abs 
MF Mild to severe 
delay 
Hypotonia Subtle facial 
dysmorphism: 
broad nasal 
bridge, tented 
upper lip, 
everted lower lip 
and downturned 
corners of the 
mouth  
Atrophy/thin corpus 
callosum in some 
Elongation factor with key role 
in protein synthesis, the 
delivery of amino- acylated 
tRNAs to the ribosome.  
 
FHF1(FGF12) 
 
AD (de novo) 
 
5 
 
 
Siekierska 2016 
Al-Mehmadi 
2016 
Day 2-
6w 
EOEE with 
cerebellar 
atrophy 
T, F, Focal SE, 
TCS 
 
T, TCS, F, SE 
Low voltage 
fast followed 
by long 
suppression  
 
Hyps 
Moderate to 
severe DD 
Hypotonia, ataxia, 
acquired 
microcephaly, 
poor visual 
development 
 
chronic 
constipation, 
hypohydrosis, 
and reduced 
lacrimation in 1.   
 
Cerebellar atrophy FHF1 encodes small cytosolic 
proteins that interact with the 
cytoplasmic tails of Nav and 
elevate the voltage 
dependence of neuronal 
sodium channel fast 
inactivation.  
Note all cases so far have the 
same p. R52H mutation.  
FOXG1 
mutations 
 
AD (de novo) 
 
>30 
 
Ariani 200831 
3 m-3 y 
in most 
 
Mid-
late 
child-
hood in 
some 
Non-specific    
 
Non-specificà 
LGS 
 
 
F, M, T, TCS 
 
Ongoing Sz in 
most, refractory 
in some  
F, MF 
 
F, MF, SSW 
DD  
 
Severe DD 
with absent 
language, 
most non-
ambulatory 
Rett-like features 
(‘congenital 
variant’)  
Hypotonia 
Spastic 
quadriplegia 
Movement 
disorders 
Mild postnatal 
growth 
impairment 
Scoliosis 
Gyral simplifications 
frontal lobes 
Corpus callosum 
hypoplasia 
Transcriptional repressor 
Mutations impair 
telencephalon development 
and postnatal neuronal 
survival 
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Kortum 2011 
Seltzer 2014 
Papandreou 
2016 
Cellini 2016 
Mitter 2017 
 
(stereotypies, 
dyskinesias, 
chorea) 
Acquired 
microcephaly 
FOXG1 
duplications 
 
AD (de novo) 
 
~15 
 
Yeung 2009 
Brunetti-Pierri 
2011 
Seltzer 2014 
Pontrelli 2014 
Bertossi 2014 
3-7 m WS IS 
 
None in most, 
refractory in few 
- T, M  
 
Hyps 
 
N, MF 
DD 
 
Severe DD 
with absent 
language, 
most 
ambulatory 
 
Autism 
Normal head size - Normal in most Transcriptional repressor 
Mutations impair 
telencephalon development 
and postnatal neuronal 
survival 
 
FRRS1L 
 
AR 
 
9 
 
Madeo 2016 
Shaheen 2016 
4-24 
months 
NS-EOEE  
EOEE with CSWS 
HC, GTC, my 
 
ES, GTC 
CSWS in one 
case, others 
not stated 
Normal until 
18-22 months 
then loss of 
language and 
ambulation 
Severe 
choreoathetosis 
Hypotonia, 
ballsim, cogwheel 
rigidity 
- Diffuse cortical and 
cerebellar volume loss, 
flattening of the heads 
of the caudate nuclei, 
periventricular FLAIR 
hyperintense signal 
Ferric chelate reductase 1-like, 
important component of the 
outer core of AMPAR 
accessory proteins. 
Loss of FRRS1L would affect 
AMPAR constituency and thus 
AMPAR function.  
GABRA1 
 
AD (de novo) 
 
11 
 
Epi4K 2013 
Carvill 2014 
Kodera 2016 
1-11 m DS/DS-like 
 
Also causes non-
EE epilepsy: FS, 
mild GGE 
FS, TCS, HC, SE 
 
Refractory Sz - 
TCS, A, MJ, F, aT 
F, GSW, some 
photo-
sensitive 
 
As above 
UK 
 
Mild-
moderate DD 
- - Normal in most Ligand-gated ion channel 
responsible for inhibitory 
neurotransmission 
Mutations result in loss of 
function 
GABRB1 
 
AD (de novo) 
 
3-12 m IS 
NS-EOEE 
FS 
 
Ep spasms, A, 
atA, My, aT 
Hyps at 35 m 
in 1. Slow.  
Global severe 
delay 
Ataxia - Thin corpus callosum GABAA receptor ß1 subunit. 
Funtional validation (Janve 
2016) showed altered GABA 
signalling.  
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2 
 
Epi4K 2013 
Lien 2016 
 
GABRB3 
 
AD (de novo) 
 
34 
 
Epi4K 2013 
Papandreou 
2016 
Le 2017 
Moller 2017 
5-10 m WS 
DS 
EMA 
FS 
Non-specific 
 
Also causes non-
EE epilepsy: CAE 
IS, F 
 
Refractory Sz in 
most - F, TCS, 
atA, T, aT, M 
Hyps, MF 
 
MF, hyps, SSW 
DD in some  
 
Moderate-
profound DD 
ADHD in some 
- - Normal in most Ligand-gated ion channel 
responsible for inhibitory 
neurotransmission 
 
GABRG2 
 
AD (de novo) 
 
16 
 
Harkin 2002 
Ishii 2014 
Zou 2017 
Shen 2017 
2-3 m DS/DS-like 
 
Also causes non-
EE epilepsy: 
GEFS+, mild GGE 
FS, TCS, HC 
 
Refractory Sz  - 
TCS, aT, M, A  
 
 
UK 
 
PSW, photo-
sensitive 
UK 
 
Moderate DD 
- - Normal Ligand-gated ion channel 
responsible for inhibitory 
neurotransmission 
GNAO1 
 
AD (de novo) 
 
25 
 
Nakamura 2013 
Law 2015 
Saitsu 2016 
Schorling 2017 
Danti 2017 
Arya 2017 
MArce-Grau 
2017 
0-2 m 
in most 
 
Mid-
child-
hood in 
some 
EIEE (5%) 
WS 
Non-specific 
T 
 
Refractory Sz  - 
IS, later to T +/- F 
 
 
B-S 
 
Hyps or MF, 
later to SSW, F 
B-S 
N/A 
 
Severe-
profound DD 
Movement 
disorder (most 
frequently 
choreoathetosis) 
- Normal early infancy 
 
Delayed myelination, 
thin corpus callosum, 
progressive cerebral 
atrophy from later 
infancy 
G protein subunit involved in 
cell signaling. Mutations 
impair adrenergic signaling 
and calcium current, reducing 
cortical excitability 
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GRIN1 
 
AD (de novo) 
 
21 
 
Epi4K 2013 
Ohba 2015 
Lemke 2016 
Zehavi 2017 
 
2-11m Non-specific IS, F, M 
 
Ongoing Sz, 
refractory in 
50%, controlled 
in  50% 
F, MF, ‘diffuse’ 
 
As above 
DD in some 
 
Severe DD 
Movement 
disorder (mixed, 
hyperkinetic 
including 
oculogyric crisis-
like eye 
movements, may 
precede Sz onset) 
Spasticity 
Rett-like features 
Acquired 
microcephaly 
- Cerebral atrophy 
Thin corpus callosum 
NMDA receptor subunit 
 
Functional effect of reported 
mutations not studied 
GRIN2A  
 
AD (de novo) 
 
>30 
 
Carvill 2013 
Lesca 2013 
Lemke 2013 
Turner 2015 
Gao 2017 
2-5 y EAS (9-20%) 
WS (single 
report) 
None or 
rolandic, negM, 
aT, IS 
 
Resolution by 
puberty 
CTS (with 
CSWS in 
most), hyps 
 
N 
Language 
delay in some 
 
Language 
regression at 
onset, 
ongoing 
language 
impairment 
post-
resolution  
Nil - Normal NMDA receptor subunit NR2A 
Mutations reported to 
produce variable effects on 
receptor function 
NR2A replaces NR2B as 
dominant NMDA receptor 
subunit in early development, 
which may explain age of Sz 
onset 
GRIN2B  
 
AD (de novo) 
 
34 
 
Epi4K 2013 
Lemke 2014 
Platzer 2017 
1 m – 9 
y 
WS 
LGS 
Non-specific 
IS, M 
 
Refractory Sz  - 
ES, T C, T, F, A 
 
 
Hyps 
 
SSW, UK 
UK 
 
Mild-severe 
DD 
 
Hypotonia 
‘Episodic 
hyperextension’ 
Movement 
disorder 
(dystonia) 
- Normal in most NMDA receptor subunit NR2B 
Mutations reported to result 
in gain of function 
HCN1 
 
AD (de novo) 
 
6 
 
Nava 2014 
4-13 m DS-like FS, TCS, HC, SE 
 
Refractory Sz - 
TCS, A, F, M 
 
 
N, GSW, PSW, 
MF 
 
GSW, PSW, 
MF 
UK 
 
Mild-severe 
DD 
Autism 
Major 
behavioural 
disturbance 
Ataxia in some - Normal Hyperpolarization-activated, 
cyclic nucleotide–gated 
channel  
Mutations can have either a 
gain of function or dominant 
negative effect on channel 
function 
  
31 
 
IQSEC2 
 
X-linked 
(affected males 
and females 
reported) 
 
18 
 
Morleo 2008 
Shoubridge 
2010 
Epi4K 2013 
Mau-Them 2014 
Gandomi 2014 
Tzschacht 2015 
Zerem 2016 
15 m- 4 
y 
IS 
LGS 
Non-specific 
 
 
M, IS, atA 
 
Refractory Sz - 
M, TCS, aT 
 
 
Hyps, UK 
 
SSW, UK 
UK 
 
Moderate-
severe DD 
Autistic 
features 
Hypotonia 
Movement 
disorder 
(stereotypies) 
Strabismus 
Microcephaly and 
macrocephaly 
reported 
- Normal or mild cerebral 
and cerebellar atrophy 
Guanine nucleotide exchange 
factor for the ARF family of 
GTP-binding proteins, roles 
include regulation of organelle 
formation and vesicular 
transport 
KCNA2 
 
AD (de novo) 
 
15 
 
Pena 2015 
Syrbe 2015 
Hundallah 2016 
Corbett 2016 
5-17 m DS-like 
EMA-like 
Non-specific 
FS, HC, TCS, M, F, 
SE 
 
Refractory Sz  
(but offset at 4-
15 y in some) - 
FS, F, M, TCS, A, 
A(EM) 
N or F 
 
MF with 
marked sleep 
activation, 
GSW, PSW 
Normal  
 
Mild-severe 
DD 
Ataxia 
Movement 
disorder (tremor, 
myoclonus) 
Hypotonia 
‘Hyperkinetic’ 
behaviour 
- Normal Potassium channel 
Mutations can result in loss or 
gain of channel function. 
KCNQ2  
 
AD (de novo for 
EE, usually 
inherited in 
‘benign’ 
epilepsies) 
 
>30 
 
Weckhuysen 
2012 and 2013 
Kato 2013 
Pisano 2015 
Most in 
week 1  
EIEE (20%) 
EOEE 
 
Also causes non-
EE epilepsy: 
BFNS 
T, F 
 
Most settle by 3 
y  - T, F, TCS, M 
Evolution to IS 
rare 
 
 
B-S, MF, F 
 
MF 
 
 
N/A 
 
Moderate-
profound DD 
Axial hypotonia 
+/- spastic 
quadriplegia 
Movement 
disorder 
(dystonia) in some 
- Basal ganglia and 
thalamic hyperintensity 
in infancy 
Potassium channel 
‘EE’ mutations can result in 
loss or gain of function, BFNS 
mutations typically loss of 
function 
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Miceli 2015 
Hortiguela 2017 
 
BFNS: Singh 
1998 
MEF2C 
 
AD (de novo) 
 
>30 
 
Engels 2009 
Bienvenu 2013 
Novara 2013 
Paciokowski 
2013 
0-18 m 
in 
most, 
child-
hood in 
some 
WS 
Non-specific 
 
IS, M, FS 
 
Some Sz-free, 
some ongoing Sz 
Hyps, MF, 
GSW 
 
UK 
DD in some 
 
Severe DD 
with absent 
language, 
many 
ambulant 
Autistic 
features 
Hypotonia 
Movement 
disorder 
(hyperkinesis and 
stereotypies) 
Inappropriate 
laughter 
High pain 
tolerance 
 
Abnormal 
gastrointestinal 
motility 
Strabismus 
Dysmorphism 
Corpus callosum 
dysgenesis 
Mild asymmetry/ 
enlargement lateral 
ventricles 
Delayed myelination 
Transcription factor. 
Mutations lead to abnormal 
dendrite and synaptic 
development and loss of 
synaptic plasticity. 
Same cellular pathway as 
MECP2 and CDKL5, which 
have overlapping clinical 
features 
PCDH19  
 
X-linked (male 
sparing unless 
mosaic) 
 
>30 
 
Juberg 1971 
Ryan 1997 
Scheffer 2008 
Dibbens 2008 
Depienne 2009 
Marini 2010 and 
2012 
Terracciano 
2016 
Liu 2017 
4 m – 3 
y 
EFMR 
 
DS-like 
Can manifest in 
mosaic males 
FS, F, SE 
 
Sz-free in ~30% 
Ongoing Sz 
clusters in ~70%, 
less frequent 
over time  - F, FS, 
M, A, SE 
 
 
N, F, GSW 
 
As above  
Normal-mild 
DD 
 
Normal-
moderate DD 
Autistic 
features  
Unsteady gait in 
some 
- Normal in most Cadherin family of cell-cell 
adhesion molecules, involved 
in a variety of functions 
‘Cellular interference model’ 
proposed, in which mixed 
population of wild-type and 
mutant cells required to 
produce disease (therefore 
affecting females and mosaic 
males) 
PIGA 
 
X-linked  
 
12 
 
Johnston 2012 
0-9 m EME 
EIEE 
EOEE 
WS 
Non-specific 
M, T, F, IS. SE 
 
Refractory Sz in 
most  - M, T, F, 
ES 
 
 
B-S, hyps, N 
 
MF, UK 
N/A or DD in 
most 
 
Profound DD 
 
 
Axial hypotonia 
Spastic 
quadriplegia 
 
Polyhydramnios 
Joint 
contractures 
Facial 
dysmorphism 
Teeth/gum 
anomalies 
Delayed myelination 
Thin CC 
Cerebral and cerebellar 
atrophy 
Diffusion restriction in 
some 
Biosynthesis of 
glycosylphosphotidylinositol 
anchors, required to attach 
cell surface proteins to plasma 
membrane 
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Van der 
Crabben 2014 
Swoboda 2014 
Kato 2014 
Kim 2016 
Elevated ALP 
Iron overload  
Vesicoureteric 
reflux 
PLCB1 
 
AR 
 
4 
 
Kurian 2010 
Poduri 2012 
Ngoh 2014 
Schhonjans 
2016 
2-10 m EIMFS 
EOEEàWS 
Non-specific 
F, T, IS 
 
Refractory Sz - F, 
T, T-C 
 
B-S, hyps, MF 
 
UK 
DD 
 
Severe-
profound DD 
Axial hypotonia  
+/- spastic 
quadriplegia 
- Normal or  
Mild cortical atrophy 
Mildly hypoplastic 
corpus callosum 
Phospholipase enzyme 
involved in signal transduction 
across cell membrane 
PNKP 
 
AR 
 
12 
 
Shen 2010 
Poulton 2012 
Nakashima 2014 
1-6 m Non-specific 
LGS 
 
 
Also associated 
with non-EE 
epilepsy: 
spinocerebellar 
atrophy with 
neuropathy 
phenotype 
F, FS 
 
Refractory Sz in 
most - F, UK 
 
 
UK 
 
As above 
DD in some, 
UK in some 
 
Severe DD 
Hyperactive 
behaviour 
Congenital 
microcephaly 
- Mildly simplified gyral 
pattern 
Cerebellum 
proportionate to 
cerebrum 
DNA repair enzyme with both 
kinase and phosphatase 
activity Mutations result in  
increased apoptosis and 
reduced cell proliferation 
PURA 
 
AD (de novo) 
 
7 
 
Hunt 2014 
Lalani 2014 
0-14 m 
in most 
LGS 
Non-specific  
ES, M 
 
Refractory in 
some, not 
reported in 
others - M, T, 
TCS, F, aT 
 
 
UK 
 
MF, UK 
DD 
 
Severe DD in 
most 
Neonatal onset 
hypotonia, 
respiratory 
difficulties, poor 
feeding 
‘Myopathic’ facies 
Excess startle 
Recurrent 
aspiration 
Nystagmus 
Strabismus 
Multiple 
fractures 
Normal or delayed 
myelination 
Roles in DNA transcriptional 
regulation and mRNA 
trafficking in postnatal brain 
development 
QARS 
 
AR 
 
Most in 
week 1 
EIMFS 
EIEE 
Non-specific  
F, T, SE 
 
Refractory Sz 
B-S, MF, hyps 
 
UK 
N/A 
 
Profound DD 
Microcephaly 
(congenital in 
some, progressive 
in all) 
- Progressive atrophy of 
cerebrum and 
cerebellum (vermis >> 
hemispheres) 
Glutaminyl-tRNA synthetase, 
role in protein translation. 
Mutations lead to reduced 
neuronal survival  
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7 
 
Zhang 2014 
Kodera 2015 
Salvarinova 
2015 
Hypotonia +/- 
spastic 
quadriplegia 
Episodes in 
childhood of 
agitation, 
excitement, 
thrashing, poor 
sleep, excess 
sweating during 
which Sz are 
absent and may 
à rhabdomyolysis 
Delayed myelination, 
reduced white matter, 
thin corpus callosum 
SCN1A  
 
AD (de novo or 
inherited) 
 
>30 
 
Dravet 1978 
Claes 2001 
Harkin 2007 
Freilich 2011 
Catarino 2011 
Brunklaus 2012 
Kim 2014 
 
 
GEFS+:  
Escayg 2000 
Wallace 2001 
4-15 m  DS (90%) 
Rare reports in 
EIFMS, EMA, 
EAS, other 
multiocal 
infantile 
epilepsy  
 
Also causes non-
EE epilepsy: 
GEFS+, others 
 
FS, TCS, HC, SE 
 
Refractory Sz - 
M, A, F, TCS, FS, 
SE 
 
 
N, GSW, some 
photo-
sensitive 
 
GSW, PSW, 
MF, some 
photo-
sensitive  
 
 
Normal in 
most 
 
Normal (rare) 
to severe DD 
Neurologic 
decline in 
adulthood 
 
 
Crouch gait in 
mid-childhood 
Dysphagia in 
adulthood 
- Normal in ~90% 
Cerebral atrophy or 
temporal/hippocampal 
changes in 10% 
Sodium channel subunit 
Nav1.1, expressed on 
GABAergic interneurons. 
Mutations produce loss of 
function 
SCN2A  
 
AD (de novo for 
EE, usually 
inherited in 
‘benign’ 
epilepsies) 
 
>30 
0-3 m 
in most 
Early 
child-
hood in 
some 
EIEE (10%) 
EIMFS (25%) 
EOEE 
WS 
Non-specific 
 
Also causes non-
EE epilepsy: 
BFNIS 
F, T, IS 
 
Refractory Sz - F, 
IS, T, M 
 
 
B-S, MF 
 
MF, N 
N/A or normal 
in most 
 
Severe-
profound DD 
in most, some 
normal  
 
 
Movement 
disorders (mixed) 
Hypotonia +/- 
spastic 
quadriplegia 
Early handedness 
Episodic Ataxia 
Severe 
gastrointestinal 
symptoms 
 
Variety of non-specific 
findings  
Signal change in white 
matter, basal ganglia, 
thalami, brainstem 
Atrophy (cortical +/- 
cerebellar) 
 
 
Sodium channel subunit 
Nav1.2, expressed on 
excitatory neurons 
Effect of mutations on channel 
function not well understood 
Genotype-phenotype 
difference between ‘EE’ and 
BFNIS not understood 
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Kamiya 2004 
Nakamura 2013 
Howell 2015 
Schwarz 2016 
 
BFNIS: 
Heron 2002 
 
SCN8A 
 
AD (de novo) 
 
>30 
 
Veeramah 2012 
Carvill 2013 
Epi4K 
consortium 
2013 
Ohba 2014 
Larsen 2015 
Kong 2015 
Anand 2016 
0-22 m EIMFS 
WS 
Non-specific 
Also causes non-
EE epilepsy: 
BFNS 
F, IS, T 
 
Refractory Sz in 
most  - F, T, C, 
M, atA, SE 
 
 
N, F, MF, hyps 
 
MF, SSW 
Normal or DD  
 
Moderate-
profound DD 
 
 
Movement 
disorders (mixed, 
may precede Sz 
onset) 
Excess startle 
Hypotonia 
Spastic 
quadriplegia in 
some 
Ataxia in some 
SUDEP 
- Normal  
or atrophy, thin corpus 
callosum, delayed 
myelination 
Sodium channel subunit 
Nav1.6, expressed on 
excitatory and inhibitory 
neurons 
Mutations produce gain of 
function with increase in 
persistent sodium current and 
incomplete channel 
inactivation 
Nav1.8 replaces Nav1.2 as 
dominant sodium channel in 
excitatory neurons in infancy, 
which may explain later age of 
Sz onset with SCN8A 
mutations than SCN2A 
SIK1 
 
AD (de novo) 
 
6 
 
Hansen 2015 
0-4 m EME 
EIEE 
WS 
Non-specific 
M, IS, T 
 
Refractory Sz - 
M, ES, T, TCS, aT 
 
 
B-S, hyps 
 
Hyps, UK 
N/A in most 
 
Severe DD in 
infant onset 
cases (no 
language, 
some 
ambulant) 
Autism 
 
 
Repetitive and 
self-injurious 
behaviours 
 
 
Scoliosis in some Normal or mild frontal 
lobe hypoplasia or 
mildly simplified 
gyration 
Salt-inducible kinase with 
roles in circadian rhythm, 
transcription of 
corticotrophins in 
hypothalamus and effects on 
MEF2C pathway. Truncation 
mutations result in loss of 
function.  
ACTH increases SIK1 activity, 
may be potential mechanism 
of treatment response to 
steroids in infantile spasms. 
SLC1A2 
AD (de novo) 
3 
 
Epi4K 2016 
Epi4K 2013 
2 days-
1m 
EOEE 
EME 
WS 
IS, M 
 
T, TCS, SE, F 
MF, slow, 
Hyps 
Severe DD Quadriplegia 
Hypotonia 
Kyphoscoliosis 
Joint 
contractures 
Delayed myelination, 
cerebral atrophy, thin 
corpus callosum 
Encodes major glutamate 
transporter, EAAT2. In null 
mouse model, excess 
glutamate leads to 
excitotoxicity, spontaneous 
seizures and early death.  
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SLC1A4 
 
AR 
15 
Conroy 2016 
Heimer 2015 
2m-1y IS 
Non-specific 
EOEE 
IS, F 
 
My, F, IS 
Hyps 
MF 
Moderate to 
severe DD 
Spasticity 
Acquired 
microcephaly 
 Thin corpus callosum, 
progressive white 
matter volume loss, 
markedly delayed 
myelination  
 
CNS serine transporter 
SLC13A5 
 
AR 
 
8 
 
Thevenon 2014 
Week 1 EOEE F 
 
Refractory in 
most (with 
periods of 
relative stability 
in childhood) 
MF 
 
UK 
N/A 
 
Severe-
profound DD 
 
Axial hypotonia  
+/- spastic 
quadriparesis 
 
Teeth anomalies UK Cytoplasmic sodium-
dependent citrate carrier 
Mutations impair citrate 
transport, impacting multiple 
cellular functions 
SLC25A22 
 
AR 
 
9 
 
Molinari 2005, 
2009 
Poduri 2013 
Cohen 2014 
0-6 m EME 
EIMFS 
WS 
Non-specific 
M, F 
 
Refractory Sz - 
IS, M, T 
 
 
B-S, MF 
 
MF, SSW, hyps 
N/A or DD 
 
Profound DD 
Axial hypotonia 
Spastic 
quadriparesis 
Acquired 
microcephaly 
Abnormal 
ERG/VEP in some 
 
Dysmorphism 
 
Normal or a variety of 
findings including 
atrophy and delayed 
myelination 
Mitochondrial glutamate 
transporter 
 
 
SLC2A1  
 
AD (de novo or 
inherited) 
 
>30 
 
De Vivo 1991 
Seidner 1998 
Brockmann 
2001 
Suls 2008 
Suls 2009 
Mullen 2011 
0-12 m 
in most 
Early 
child-
hood in 
some 
‘Glut1 deficiency 
syndrome’ 
EO-AE (10%) 
EMA (5%) 
 
 
TCS, A, F, M, T 
 
Ongoing Sz 
tendency, most 
on ketogenic 
diet are Sz free 
MF, F, GSW 
 
As above 
Normal-DD 
 
Mild-severe 
DD  
Acquired 
microcephaly 
Movement 
disorders 
(paroxysmal 
dystonia, 
dyskinesia) 
Ataxia 
Spasticity 
- Normal in most Transports glucose across 
blood-brain barrier 
Mutations result in 
inadequate glucose transport 
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SLC6A1 
 
AD (de novo) 
 
10 
 
Rauch 2012 
Sanders 2012 
Carvill 2015 
1-5.5 y EMA (4%) M, aT, A 
 
Sz free by 3-8 y 
in ~40% 
Ongoing Sz in 
~60% - M, aT, M-
aT, A,   
 
 
GSW, PSW, 
some photo-
sensitive 
 
As above 
DD  
 
Mild-severe 
DD 
Autistic 
features 
Tremor or ataxia 
in some 
- Normal in most Voltage-dependent GABA 
transporter responsible for 
synaptic GABA reuptake. 
Mutations reduce GABA 
transport activity. 
SMC1A 
 
X-linked 
dominant 
de novo 
(truncating) 
 
20 
 
Lebrun 2015 
Jansen 2016 
Symonds 2017 
Gorman 2017 
Huisman 2017 
1m-
28m 
IS, focal infantile 
epilepsy 
EIMFS 
F in clusters, EM 
 
IS 
Hyps 
Migrating ictal 
foci 
MF, GSW 
Severe DD Stereotypies (Rett-
like) 
Progressive 
microcephaly 
Dysmorphic 
features in some: 
mild synophris, 
small hands and 
feet, thin nose 
and upper lip, 
retrognathia, and 
triangular shaped 
face  
Short stature 
Structural cardiac 
anomalies 
 
Small cc SMC proteins (structural 
maintenance of chromosome 
proteins) are important part of 
functional kinetochores which 
allow correct segregation of 
chromosomes during cell 
division.   
 
Missense or in-frame 
deletions cause Cornelia du 
Lange syndrome 
SPTAN1 
 
AD (de novo) 
 
7 
 
Saitsu 2010 
Hamdan 2012 
Writzl 2012 
Nonoda 2013 
Tohyama 2015 
0-3 m 
in most 
Rare 
child-
hood 
onset 
cases 
WS 
Non-specific à 
WS 
Non-specific 
IS, M 
 
Refractory Sz in 
most – T 
Hyps, MF 
 
MF 
DD  
 
Profound DD 
Axial hypotonia 
Spastic 
quadriplegia 
Acquired 
microcephaly 
 
- Severe hypomyelination 
Progressive cerebral, 
brainstem and 
cerebellar atrophy 
Membrane scaffolding protein  
Mutations with dominant 
negative effect lead to altered 
clustering of sodium channels 
at axon initial segment and 
impaired integrity of 
myelinated axons. 
Haploinsufficiency thought not 
to cause EE  
STXBP1  
 
AD (de novo) 
0-3 m EIEE (30%) 
EOEE 
WS (2%) 
T, F, IS, M, FS, 
TCS 
 
B-S, MF, hyps 
 
MF, unusual 
N/A or DD 
 
Severe-
Movement 
disorder (tremor - 
‘figure of 8 head 
- Frontal cortical 
hypoplasia/atrophy 
Thin +/- dysmorphic CC 
Synaptic protein 
Mutations disrupt synaptic  
transmission 
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>30 
 
Saitsu 2008 
Deprez 2010 
Otsuka 2010 
Mignot 2011 
Milh 2011 
Carvill 2014 
DI Meglio 2015 
Stamberger 
2016 
DS 
May have ID 
without epilepsy 
May settle then 
recur in later 
infancy 
Sz free by 2 y in 
~50%, refractory 
Sz in ~50% - F, T, 
M, A, TCS, aT, FS 
back-ground 
fast without 
IEDs 
profound DD 
in most 
tremor’) 
Hypotonia 
Spastic 
quadriplegia 
Extrapyramidal 
features in 2 adult 
patients 
 
Hypo- or delayed 
myelination 
SYNGAP1 
 
AD (de novo) 
 
18 
 
Hamdan 2009, 
2011 
Vissers 2010 
Berryer 2013 
Carvill 2013 
Dyment 2014 
6 m – 4 
y 
Non-specific  M, A, TCS, F 
 
Many refractory 
GSW (usually 
posterior-
predominant), 
SSW, MFD 
 
As above 
DD in some 
 
Moderate-
severe DD in 
most 
Autism  
Acquired 
microcephaly in 
some 
- Normal in most RAS/RAP GTP-activating 
protein, part of the NMDAR 
complex  
Mutations result in impaired 
interaction between RAS, and 
NMDA and AMPA receptors  
SYNJ1 
AR 
6 
 
Hardie 2016 
Day 1-
2.5m 
Other 
focal/multifocal 
infantile 
epilepsy 
M, IS, F, C 
 
 
M, T, IS 
Hyps, MF, F Severe DD Spastic 
quadriplegia 
Visual impairment 
Dystonia in 1 
All gastrostomy 
fed 
Complex III and 
IV deficiency in 
liver and 
fibroblasts in 1.  
Thin corpus callosum, 
limited gliosis and 
atrophy of the 
periventricular white 
matter in 1, rest normal. 
Synaptojanin 1 is vital to 
shedding of the clathrin coat 
and vesicle exocytosis and 
recycling.  
Homozygous missense SYNJ1 
associated with early onset 
parkinsonism.  
TBC1D24  
 
AR 
 
>30 
 
Corbett 2010 
Guven 2012 
Milh 2013 
Afawi 2013 
2-3 m 
in most 
EIFMS 
Other 
focal/multifocal 
infantile 
epilepsy 
 
Also causes non-
EE epilepsy: 
FIME 
F, SE, M, TCS, A 
 
Refractory Sz - F, 
M 
 
 
MF, UK 
 
As above 
DD in some 
 
Mild-profound 
DD 
DOORS syndrome 
Cerebellar signs 
Hearing 
impairment 
DOORS syndrome  
Nail anomalies 
Bony anomalies 
Subtle cortical 
thickening, progressive 
signal change and 
atrophy in cerebellar 
lobules 
GTPase-activating protein 
involved in cycling of synaptic 
vesicles, membrane recycling, 
actin remodelling and neurite 
development 
Mutations produce loss of 
function  
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Campeau 2014 
Balestrini 2016 
Ngoh 2016 
FIME:  
Falace 2010 
UBA5 
 
AR 
 
9 
Muona 2017 
3-12m IS 
Other 
focal/multifocal 
infantile 
epilepsy 
 
IS, M Not stated Severe DD Irrritability and 
jitteriness in 
neonatal period, 
early onset 
dystonia and 
choreoathetosis 
Truncal hypotonia 
 Delayed myelination, 
cortical atrophy, 
increased 
periventricular and 
frontal WM signal 
Ubiquitin fold modifier 1 
(UFM1) cascade is a ubiquitin-
like modification system  
WDR45 
 
X-linked 
dominant 
 
6 
 
Xixis 2015 
Abidi 2016 
Nakashima 2016 
Redon 2017 
3-6m in 
most 
IS 
Other focal 
infantile 
epilepsy 
F, ES 
 
ES 
Hyps 
 
MF, slow 
waves 
Severe DD Dystonia 
Spastic 
quadriplegia  
- Brain iron accumulation 
on MRI in 2 patients 
WD40- repeat protein with 
essential role in the budding 
of autophagosomes during 
autophagy  
WRD45 mutations in females 
(rarely seen in males) cause 
BPAN with severe dystonia 
and childhood onset seizures.  
WWOX 
 
AR 
 
17 
 
Mallaret 2014 
Abdel-Salam 
2014 
Mignot 2015 
Ben-Salam 2015 
Tabarki 2015 
0-5m in 
most 
 
Up to  
2 y in 
some 
WS 
Non-specific 
 
IS, F, T, TCS, M 
 
Refractory Sz  - 
T, F, M 
 
 
Hyps, MF 
 
MF, SSW 
DD in some 
 
Moderate-
profound DD 
(profound DD 
in all with ‘EE’ 
phenotype) 
 
 
‘EE’ phenotype: 
Axial hypotonia 
Limb rigidity/ 
spasticity 
Hypokinesia 
Acquired 
microcephaly 
Retinal 
abnormalities or 
optic atrophy in 
many 
 
Spinocerebellar 
ataxia (SCAR) 
phenotype: 
Ataxia 
- Normal or cerebral 
atrophy, thin/ 
hypoplastic corpus 
callosum, cerebellar 
sparing 
WW-domain containing 
oxidoreductase, involved in a 
variety of pre- and postnatal 
cellular processes (unclear 
which are relevant to epilepsy 
pathogenesis) 
 
Null mutations produce ‘EE’ 
phenotype, hypomorphic 
mutations ‘SCAR’ phenotype 
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Table 1.2 Genes, phenotypic features and pathogenic mechanisms of major single gene causes of epileptic encephalopathies. This table refers 
predominantly to non-malformation, non-metabolic, non-chromosomal (e.g. CNV, Ring 20) causes of each genetic epilepsy syndrome. Genes associated 
with (i) mild epilepsies only (ii) those in which only one patient/family is reported (iii) causation is otherwise unclear and (iv) where minimal phenotypic 
information is available, are not included. AD autosomal dominant, AR autosomal recessive, BFNIS benign familial neonatal-infantile seizures, BFNS benign 
familial neonatal seizures, CAE childhood absence epilepsy, DS Dravet syndrome, d day, DD developmental delay, DOORS syndrome: deafness, 
onychodystrophy, osteodystrophy, retardation and seizures syndrome, EAS epilepsy aphasia spectrum, EFMR epilepsy limited to females with mental 
retardation, EIEE early infantile epileptic encephalopathy (Ohtahara syndrome), EIMFS epilepsy of infancy with migrating focal seizures, EMA epilepsy with 
myoclonic atonic seizures, EME early myoclonic epileptic encephalopathy, EO-AE early onset absence epilepsy, EOEE early onset epileptic encephalopathy, 
IGE idiopathic generalised epilepsy, FIME familial infantile myoclonic epilepsy, FIRES febrile infection related epilepsy syndrome, FS febrile seizures, GEFS+ 
genetic epilepsy with febrile seizures plus, GGE genetic generalized epilepsy, LGS Lennox-Gastaut syndrome, m month, Sz seizures, UK unknown, XLAG X-
linked lissencephaly with ambiguous genitalia, WS West syndrome, y years. Seizure types: A absence, A(EM) absence with eyelid myoclonia, aT atonic, atA 
atypical absence, C clonic, ES epileptic spasms, F focal, FS febrile seizures, IS infantile spasms, M myoclonic, SE status epilepticus, T tonic, TCS tonic clonic 
seizure. EEG features: B-S burst-suppression, F focal, GSW generalized spike-wave, MF multifocal, PSW polyspike-wave, SSW slow spike-wave.  Adapted 
from McTague et al The Lancet Neurology 2015;15(3):304-1 
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Several sequencing methods/platforms are now available but all share the basic principles 
of NGS. Essentially, genomic DNA is sheared, then hybridised to a library of probes which 
either aims to capture all coding regions of the genome (the exome) or a limited panel of 
genes (multiple gene panel). The high-throughput nature of the technology allows 
multiplexing of samples. Over time, the cost of sequencing an exome has fallen sharply 
(Figure 1-2, Møller et al. 2015).  
Many large cohort studies in epileptic encephalopathy have used a trio design, where the 
exomes of both the proband and parents are simultaneously sequenced (Veeramah et al. 
2013; Allen et al. 2013; Euro-EpinomicsConsortium et al. 2014). Using this approach, an 
average of 1.58 de novo mutations per proband were detected, allowing rapid 
identification of causative variants in ~30% of patients with an epileptic encephalopathy 
(Allen et al. 2013). Although it has been clear for some time that familial epilepsies were 
likely to have a genetic basis, these large scale genetic studies demonstrated that causative 
de novo dominant mutations are a commonly observed in sporadic childhood epileptic 
encephalopathies. Whole exome approaches are increasingly utilized in clinical practice, 
yielding genetic diagnoses in a significant proportion of children with neurological diseases 
(Yang et al. 2013; Mefford 2015; Tarailo-Graovac et al. 2016). 
Targeted sequencing using NGS technology in the form of gene panels has been extremely 
important in providing accurate diagnoses for families, as well as advancing genetic 
understanding of the severe epilepsies. Genes are selected for panel inclusion based on a 
number of factors. Firstly, known EE disease genes which affect multiple individuals and 
which meet American College of Medical Genetics and Genomics (ACMG) guidelines for 
pathogenicity are prioritised. A gene may also be included based on evidence from animal 
or other model systems or biological function. Candidate genes may also be selected from 
previous whole exome or copy number variant data and this approach has been fruitful in 
large resequencing studies which have confirmed putative disease genes such as CHD2 and 
SYNGAP1 (Carvill et al. 2013). The selected genes are included in panels of 50 to several 
hundreds of genes, and large cohorts can be rapidly sequenced for pathogenic variants.  
The diagnostic pick-up rate in studies varies considerably in the literature from 10-50% 
(Lemke et al. 2012; Carvill et al. 2013; Kwong et al. 2015; Zhang et al. 2017; Gokben et al. 
2017; Parrini et al. 2017; Myers et al. 2016). This is likely due to cohort variability (including 
how much previous genetic testing was done for different patients) affecting the pre-test 
probability of detecting a genetic disorder in addition to variations in panel design. 
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However gene panels are an extremely powerful tool in routine clinical practice, as 
demonstrated by one study which identified pathogenic gene variants in 18% of those 
tested (Trump et al. 2016), increasing to 39% in the group of patients presenting with 
seizure onset under 2 months.  
Chromosomal micro-arrays are another important diagnostic tool in the epileptic 
encephalopathies and arguably should be undertaken as a first line investigation. In one 
study of 349 patients with EE, up to 8% were found to have a causative or potentially 
contributing copy number variant (CNV) (Mefford et al. 2011). CNVs are present in all 
human genomes and those frequently reported in the control populations indicate normal 
genetic variability. When a CNV is identified, careful assessment is required to assess 
whether it is pathogenic. CNVs which are large, occur de novo, are not present in 
databases of genomic variation such as DECIPHER, and which encompass disease-causing 
genes are most likely to be pathogenic. CNVs of uncertain significance can play an 
important role in novel gene discovery, as exemplified by the discovery of STXBP1 and 
CHD2, where deletions encompassing the candidate gene were initially identified, with 
subsequent detection of intragenic mutations in patients with similar phenotypes 
thereafter (Saitsu et al. 2008; Carvill et al. 2013). In contrast, discovery of intragenic 
missense mutations in a gene in EE can also help confirm the causative gene responsible 
for patients with small chromosomal deletions associated with complex 
neurodevelopmental phenotypes, as in the case of PURA in patients with 5q31.3 deletions 
(Hunt et al. 2014; Lalani et al. 2014; Myers & Mefford 2016). Increasingly CNVs can also be 
identified by NGS sequencing using sequencing read-depths, and an NGS-first approach 
may be possible in the future as technology improves (Yamamoto et al. 2016).   
While de novo dominant variants are most commonly reported in the EEs, autosomal 
recessive and X-linked disorders are also recognised. Autosomal recessive inheritance is 
particularly suspected when a family is consanguineous (homozygous variants likely) or in 
an outbred family with more than one affected member (compound heterozygous variants 
more likely). X-linked inheritance may occur in X-linked dominant disorders such as ARX, in 
X-linked recessive disorders such as DCX, or in PCDH19-related epilepsy, where females are 
affected and males are generally unaffected carriers.   
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1.5 Important genetic concepts in the early onset epilepsies 
1.5.1 The importance of a genetic diagnosis 
While many new aetiologies for early onset epilepsies have been revealed, some clinicians 
question the impact of these recent advances for patients. It is clear that for patients with 
rare diseases and their families, the diagnostic journey is fraught and arduous. Recent 
reports from Rare Disease UK and Genetic Alliance UK (https://www.raredisease.org.uk, 
www.geneticalliance.org.uk), highlight the prolonged wait for diagnosis and the emotional, 
psychosocial and financial burden this places on individuals and their families.  The major 
impact of identifying a genetic aetiology is the ability to offer an accurate diagnosis which 
may allow prognostication on disease course and associated co-morbidities such as 
developmental outcome. In addition, a specific diagnosis should prevent the need for 
further unnecessary, often invasive, investigations. Qualitative research which has been 
undertaken into the impact of receiving a genetic diagnosis in familial epilepsies, albeit in 
adult patients, has revealed that patients value this certainty (Vears et al. 2015) and this 
has been borne out in a study of the impact of a SCN1A diagnosis in Dravet syndrome 
(Brunklaus et al. 2013). There can also be psychological benefits to this certainty; parents 
may blame themselves or other factors for their child’s epilepsy. Furthermore, parents 
may be able to access patient support groups specific to the genetic condition. An accurate 
genetic diagnosis also has an impact on the wider family, with parents able to receive 
genetic counselling including information about recurrence risk, enabling an informed 
choice regarding future pregnancies, including the use of pre-implantation or prenatal 
diagnosis. Receiving a specific genetic diagnosis may also have a direct impact upon 
management of the epilepsy. Although initial hopes of a new era of precision medicine 
have not, as yet, materialised, there are a number of EEs where the genetic diagnosis 
alters disease management. Quinidine as a precision therapy in KCNT1-related epilepsies is 
discussed further in Chapter 4. GLUT1 transporter deficiency due to heterozygous 
mutations in SLC2A1 can be effectively treated with the ketogenic diet and an early 
accurate diagnosis may reduce disease burden and possibly improve cognitive outcome 
(Klepper 2012; Saul A Mullen et al. 2011; Leen et al. 2010; Ramm-Pettersen et al. 2013). 
Sodium channel blockers (SCBs) such as Lamotrigine are known to worsen myoclonic 
seizures in Dravet syndrome; the presence of a causative SCN1A mutation altered 
medication choice in 69% of cases in one study (Brunklaus et al. 2013). In the same study, 
the specific genetic diagnosis also appeared to improve access to other therapies such as 
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physiotherapy, occupational therapy, and speech and language therapy. Conversely, 
recent genetic discovery has revealed that SCBs can be very effective in SCN2A and SCN8A 
encephalopathies (where a gain of function is implicated) and in KCNQ2 encephalopathy 
(possibly due to co-localisation and interaction of voltage-gated sodium and potassium 
channels)  (Wolff et al. 2017; Howell et al. 2015; Larsen et al. 2015; Numis et al. 2014).  
The ability to make a genetic diagnosis in 20-40% of patients presenting with early onset 
epilepsy has revolutionised clinical practice for both paediatric and adult neurologists 
(Scheffer 2014) and appears to have direct clinical benefits for patients. However, there is 
a pressing need for further translation of genomic advances into clinical practice.  
1.5.2 The Online Mendelian Inheritance in Man (OMIM) early infantile epileptic 
encephalopathy phenotypic series 
Within the Online Mendelian Inheritance in Man (OMIM) database, genes causing early 
onset epileptic encephalopathy are organized in a phenotypic series. To date 54 genes 
have been included (Table 1.3) and the series is included here by way of comparison with 
Table 1.2. However, there are several limitations to such a classification system. Several 
genes are included where only a small number of affected individuals with no further cases 
published in the interim (e.g. PNKP) or a single consanguineous family, (e.g. SZT2) (Shen et 
al. 2010; Basel-Vanagaite et al. 2013) have been described, and some without supportive 
functional validation of mutation pathogenicity. This may lead to the erroneous impression 
that these genes are as important or as frequently encountered in EE than others which 
are not included in the OMIM series. Conversely, other well-described epilepsy genes such 
as CHD2 are not included (Carvill et al. 2013). There is also inevitably a great deal of 
phenotypic overlap between the different genes. Therefore, it should not be viewed as 
either a clinical classification of early onset epileptic encephalopathy or as a 
comprehensive source of all genes important in the EEs.  
 
  
45 
 
 
 
OMIM classification OMIM phenotype number Gene Inheritance Phenotype(s) 
Epileptic encephalopathy, 
early infantile, 1 
308350 ARX XLR OS WS XLAG 
Epileptic encephalopathy, 
early infantile, 2 
300203 CDKL5 XLD OS WS  
Epileptic encephalopathy, 
early infantile, 3 
609304 SLC25A22 AR EMEE, OS, EIMFS 
Epileptic encephalopathy, 
early infantile, 4 
612164 STXBP1 AD OS, WS 
Epileptic encephalopathy, 
early infantile, 5 
613477 SPTAN1 AD WS, NS-EOEE 
Epileptic encephalopathy, 
early infantile, 6 
607208 SCN1A AD DS, WS, EIMFS 
Epileptic encephalopathy, 
early infantile, 7 
613720 KCNQ2 AD OS, WS, BFNIS 
Epileptic encephalopathy, 
early infantile, 8 
300607 ARHGEF9 XLR Hyperekplexia, NS-EOEE 
Epileptic encephalopathy, 
early infantile, 9 
300088 PCDH19 XL (female sparing) EFMR 
Epileptic encephalopathy, 
early infantile, 10 
613402 PNKP AR MCSZ 
Epileptic encephalopathy, 
early infantile, 11 
613721 SCN2A AD OS, WS, EIMFS, BFNIS 
Epileptic encephalopathy, 
early infantile, 12 
613722 PLCB1  WS, EIMFS, NS-EOEE 
Epileptic encephalopathy, 
early infantile, 13 
614558 SCN8A AD WS, NS-EOEE 
Epileptic encephalopathy, 
early infantile, 14 
614959 KCNT1 AD EIMFS, ADNFLE, WS, OS 
Epileptic encephalopathy, 615006 ST3GAL3 AR WS, NS-EOEE 
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early infantile, 15 
Epileptic encephalopathy, 
early infantile, 16 
615338 TBC1D24 AR EIMFS, FIME, DOORS 
Epileptic encephalopathy, 
early infantile, 17 
615473 GNAO1 AD WS, NS-EOEE 
Epileptic encephalopathy, 
early infantile, 18 
615476 
 
SZT2 AR NS-EOEE 
Epileptic encephalopathy, 
early infantile, 19 
615744 GABRA1 AD DS 
Epileptic encephalopathy, 
early infantile, 20 
300868 PIGA XLR MCAHS2 
 
Epileptic encephalopathy, 
early infantile, 21 
615833 NECAP1 AR NS-EOEE 
Epileptic encephalopathy, 
early infantile, 22 
300896 SLC35A2 XLD NS-EOEE, CDGIIm 
Epileptic encephalopathy, 
early infantile, 23 
615859 DOCK7 AR NS-EOEE 
Epileptic encephalopathy, 
early infantile, 24 
615871 HCN1 AD FS-EOEE (Dravet-like) 
Epileptic encephalopathy, 
early infantile, 25 
615905 SLC13A5 AR NS-EOEE 
Epileptic encephalopathy, 
early infantile, 26 
616056 KCNB1 AD NS-EOEE 
Epileptic encephalopathy, 
early infantile, 27 
616139 GRIN2B AD WS 
Epileptic encephalopathy, 
early infantile, 28 
616211 WWOX AR WS, NS-EOEE 
Epileptic encephalopathy, 
early infantile, 29 
616339 AARS AR NS-EOEE 
Epileptic encephalopathy, 
early infantile, 30 
616341 SIK1 AD OS, WS, NS-EOEE 
Epileptic encephalopathy, 
early infantile, 31 
616346 DNM1 AD WS 
Epileptic encephalopathy, 
early infantile, 32 
616366 KCNA2 AD NS-EOEE 
Epileptic encephalopathy, 616409 EEF1A2 AD NS-EOEE 
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early infantile, 33 
Epileptic encephalopathy, 
early infantile, 34 
616645 SLC12A5 AR EIMFS 
Epileptic encephalopathy, 
early infantile, 35 
616647 ITPA AR NS-EOEE 
Epileptic encephalopathy, 
early infantile, 36 
300884 ALG13 XLD WS, NS-EOEE, CDGIs 
Epileptic encephalopathy, 
early infantile, 37 
616981 FRRS1L AR NS-EOEE 
Epileptic encephalopathy, 
early infantile, 38 
617020 ARV1 AR NS-EOEE 
Epileptic encephalopathy, 
early infantile, 39 
612949 SLC25A12 AR NS-EOEE 
Epileptic encephalopathy, 
early infantile, 40 
617065 GUF1 AR WS 
Epileptic encephalopathy, 
early infantile, 41 
617105 SLC1A2 AD WS, NS-EOEE 
Epileptic encephalopathy, 
early infantile, 42 
617106 CACNA1A AD FHM1, EA2, SCA6, NS-EOEE 
Epileptic encephalopathy, 
early infantile, 43 
617113 GABRB3 AD WS, NS-EOEE 
Epileptic encephalopathy, 
early infantile, 44 
617132 UBA5 AR WS, NS-EOEE 
Epileptic encephalopathy, 
early infantile, 45 
617153 GABRB1 AD NS-EOEE 
Epileptic encephalopathy, 
early infantile, 46 
617162 GRIN2D AD WS, NS-EOEE 
Epileptic encephalopathy, 
early infantile, 47 
617166 FGF12 AD NS-EOEE 
Epileptic encephalopathy, 
early infantile, 48 
617276 AP3B2 AR WS, NS-EOEE 
Epileptic encephalopathy, 
early infantile, 49 
617281 DENND5A AR NS-EOEE 
Epileptic encephalopathy, 
early infantile, 50 
616457 CAD AR NS-EOEE 
Epileptic encephalopathy, 617339 MDH2 AR NS-EOEE 
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early infantile, 51 
Epileptic encephalopathy, 
early infantile, 52 
617350 SCN1B AR DS-like FS-EOEE 
Epileptic encephalopathy, 
early infantile, 53 
617389 SYNJ1 AR WS, NS-EOEE 
Epileptic encephalopathy, 
early infantile, 54 
617391 HNRNPU AR FS-EOEE, NS-EOEE 
Table 1.3 OMIM classification of early infantile epileptic encephalopathy (EIEE). ADNFLE autosomal dominant nocturnal frontal lobe epilepsy, AD 
autosomal dominant, AR autosomal recessive, CDGIIm congenital disorder of glycosylation type IIm, CDGIs congenital disorder of glycosylation 
type Is,  DOORS deafness, onychodystrophy, osteodystrophy, and mental retardation syndrome, DS Dravet syndrome, EA2 episodic ataxia Type 2,  
EFMR epilepsy in females with mental retardation, EIMFS Epilepsy of infancy with migrating focal seizures, FHM1 familial hemiplegic migraine type 
1, FIME familial infantile multifocal epilepsy, FS-EOEE fever-sensitive EOEE, OS Ohtahara syndrome, MCAHS2 multiple congenital anomalies-
hypotonia-seizures syndrome-2, MCSZ microcephaly seizures, NS-EOEE non-specific early onset epileptic encephalopathy, SCA6 spinocerebellar 
ataxia Type 6, WS West syndrome, XLAG X-linked abnormal genitalia, XL X-linked, XLD X-linked dominant,  XLR X-linked recessive. 
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1.5.3 Genetic heterogeneity 
Following the explosion in genetic discovery and advent of a multiple gene testing 
approach, it has become clear that the epilepsy syndromes are genetically heterogeneous 
(Table 1.4). Even the prototypical monogenic epileptic encephalopathy, Dravet syndrome, 
in which over 80% of patients are found to carry a SCN1A mutation, may also be caused by 
mutations in other genes such as STXBP1 and GABRA1, albeit in a small number of cases 
(Carvill et al. 2014). As genetic causes are identified, sub-phenotypes with similar but 
subtly different clinical features can be discerned, as with epilepsy with myoclonic atonic 
seizures due to CHD2, SLC2A1 and SLC6A1 where there can be variability in the degree of 
developmental delay or presence of movement disorders (Mullen et al. 2011; Carvill et al. 
2013; Carvill et al. 2015). As further patients are studied, these disorders may become 
distinct clinical entities rather than part of an electroclinical syndrome. For Ohtahara 
syndrome, (Kato et al. 2004; Absoud et al. 2010; Fullston & Hons 2011; Saitsu et al. 2012; 
Nakamura et al. 2013; Nakamura et al. 2013b; Allen et al. 2013; Touma et al. 2013; Lund et 
al. 2014; Martin et al. 2014; Higurashi et al. 2013), West syndrome (Otsuka et al. 2010; 
Osborne et al. 2010; Edvardson et al. 2013; Allen et al. 2013; Kato et al. 2013; Kato et al. 
2014; Lemke et al. 2014; Michaud et al. 2014; Nakashima et al. 2016; Kodera et al. 2016; 
Møller et al. 2017) and Lennox Gastaut syndrome (Allen et al. 2013; Lund et al. 2014; 
Zerem et al. 2016) , many genes have been identified, with a small number of cases per 
gene (Table 1.2, 1.4).This may reflect that the electroclinical syndromes represent an age-
related manifestation of a number of genetic defects, which converge on common 
pathways to result in a similar phenotype, rather than distinct clinical disorders 
(Paciorkowski et al. 2011).  
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Epilepsy 
syndrome 
Genes (with approximate proportion of cases with this syndrome and causative gene, 
where known) 
OS STXBP1 in ~30% 
KCNQ2 in ~20%* note this is an emerging gene encephalopathy, 
SCN2A in ~10% 
AARS, ARX, BRAT1, CACNA2D2, GABRA1, GNAO1, KCNT1, NECAP1, PIGA, PIGQ, SCN8A, 
SEPSECS, SIK1, SLC25A22, ZEB2 
EME  ErbB4, PIGA, SETBP1, SIK1, SLC25A22, WWOX 
EIMFS KCNT1 in ~30-50% 
SCN2A in ~25% 
ALG1, ALG3, PLCB1, QARS, RFT1, SCN1A, SCN8A, SLC25A22, TBC1D24, SLC12A5 
WS CDKL5 in ~10%* note this is an emerging gene encephalopathy, 
STXBP1 in ~2% 
ARX, ALG13, CACNA1A, DOCK7, DNM1, FOXG1 (duplications), GABRB1, GABRB3, GNAO1, 
GRIN1, GRIN2A, GRIN2B, KPNA7, MAGI2, MEF2C, NACC1, NEDDL4, NDP, NRXN1, PIGA, 
PLCB1, PTEN, SCA2, SCN1A, SETBP1, SIK1, SLC25A22, SLC35A2, SPTAN1, ST3Gal3, 
TBC1D24, TCF4, UBA5, WDR45, WWOX 
DS SCN1A in 90% cases (mutations in >85%, CNV in <5%; >90% occur de novo; 5-10% 
inherited (mostly missense mutations) 
PCDH19*, GABRA1, GABRG2, HCN1*, STXBP1 
* note most cases have a DS-like syndrome  
EMA  SLC2A1 in 5%, SLC6A1 in 4% 
CHD2, GABRA1, GABRG2, GABRB3, SCN1A, SCN1B, KCNA2 
LGS ALG13, CACNA1A, CDKL5, CHD2, DNM1, FLNA, GABRB3, GRIN2B, HNPRNU, HNRNPH1, 
IQSEC1, iQSEC2, KCNQ3, KPNA7,  MTOR, SCN1A, SCN2A, SCN8A, STXBP1 
EAS  GRIN2A in 10-20% cases 
Table 1.4 Electroclinical syndromes and known genetic determinants. ABRE atypical 
benign rolandic epilepsy, DS Dravet syndrome, EAS epilepsy aphasia spectrum, EIEE early 
infantile epileptic encephalopathy, EME early myoclonic encephalopathy, EMA epilepsy 
with myoclonic atonic seizures, EOEE early onset epileptic encephalopathy (epileptic 
encephalopathy starting before 3 months), LGS Lennox-Gastaut syndrome, MAE epilepsy 
with myoclonic-atonic seizures, OS Ohtahara syndrome. Adapted from McTague et al The 
Lancet Neurology 2015;15(3):304-1.  
1.5.4 Phenotypic pleiotropy and mosaicism 
As the genomic revolution has unfolded, it has become clear that mutations in one gene 
may lead to either varied severity of phenotype or to different phenotypes altogether 
(Table 1.2). It should be noted that the quality and depth of phenotypic data that is 
reported with novel genes or novel variants in known genes is quite variable, with often 
extensive data in some small case series and scant information in some large gene panel 
and exome sequencing studies. This impacts upon the accuracy of the phenotypic 
spectrum that is reported and should be taken into consideration by clinicians.  Databases 
such as ClinVar attempt to improve the phenotypic annotation of reported variants 
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(Landrum et al. 2014) but the diagnostic categories are broad and often lack detail. Large 
databases such as ClinVar require uniformity of vocabulary and therefore phenotypic data 
is often reduced to simplified MeSH terms (PubMed medical subject heading) or Human 
Phenotype Ontology (HPO) terms (Robinson et al. 2008).  However efforts such as the 
Monarch Initiative to combine sources of phenotypic data (Mungall et al. 2017), improved 
curation and advances in search technology may improve the quality and depth  of 
phenotypic data. Phenotypic variability can either occur within families or unrelated 
individuals. In the 10% of SCN1A-positive Dravet syndrome patients with inherited 
mutations, other family members may be affected by the same mutation but manifest with 
febrile seizures or other phenotypes which are part of the milder GEFS+ phenotype 
(Depienne et al. 2010; Singh et al. 2001). This suggests that other modifier genes, 
epigenetic or environmental factors may be contributing to the expression of the 
phenotype in these individuals. Mosaicism may be another explanation for the variable 
phenotypes observed in the genetic EEs. Mosaicism refers to the existence of two 
populations of cells within a human being, one bearing a mutated allele and one with the 
wild-type, normal allele (Poduri et al. 2013). Mosaicism may be either somatic or gonadal. 
Somatic mosaicism occurs during embryonic development and therefore affects cells of 
certain tissue types or cell lineages. This is an emerging area of interest in childhood 
neurological disorders such as hemimegalencephaly, where somatic mutations in mTOR 
pathway genes are found within the abnormal brain tissue but not in the peripheral blood 
(Poduri et al. 2012). It is conceivable that tissue-level mosaicism is relevant to non-
malformation disorders such as the genetic EEs but currently the lack of available brain 
tissue precludes investigation. Somatic mosaicism may provide an explanation for 
transmission of dominantly inherited variants by unaffected or mildly affected parents, as 
has been documented in Dravet syndrome. In 12 cases where parental mosaicism was 
identified, levels of parental mosaicism varied from 0.04% to 85% of cells, with higher 
levels correlating with the severity of the phenotype in the parent (Depienne et al. 2010). 
Gonadal or germline mosaicism is confined to the egg or sperm, conferring risk of mutation 
inheritance to offspring. Parents are clinically unaffected and such germline mosaic 
mutations are not detectable on leucocyte DNA testing of the parent. This phenomenon 
has been reported in Dravet syndrome and must be remembered when counselling 
families for seemingly de novo mutations. Although in this scenario, the likely disease 
mechanism is de novo occurrence of the mutation post-fertilisation during early 
  52 
embryogenesis, gonadal mosaicism, though rare, remains a small possibility with 
associated recurrence risk (Depienne et al. 2006; Marini et al. 2006; Morimoto et al. 2006).  
Another factor which may account for transmission of a dominant variant by a healthy 
parent, or the presence of the same variant in a healthy unaffected sibling, is reduced or 
altered penetrance. This is well-documented particularly in autosomal dominant focal 
epilepsy genes such as CHRNA4 and LGI1 and is discussed further in Chapter 4 relating to 
KCNT1 (Leniger et al. 2003; Rosanoff & Ottman 2008; Cooper et al. 2013).  
Altered penetrance and mosaicism must also be considered when examining WES data for 
new dominant EE genes. Indeed, given the observations in SCN1A-related epilepsy, as well 
as other dominant genetic epilepsies, it is increasingly important not to immediately 
exclude inherited heterozygous variants including those rarely reported in public 
databases in “control” individuals, without further interrogation as to whether they could 
be disease-causing (Jenkinson et al. 2016).   
In addition to intrafamilial phenotypic variation, wide variation in phenotypes can be seen 
between unrelated individuals. For example, self-limited familial neonatal and infantile 
seizures are relatively benign disorders where the majority of infants do not have long-
term neurodevlopmental problems after the resolution of their epilepsy, usually by the age 
of 12 months (Pettit & Fenichel 1980). 80% of individuals have inherited mutations of 
KCNQ2, the voltage-gated potassium channel KV7.2 (Singh et al. 1998), thought to be due 
to haploinsufficiency (Biervert & Steinlein 1999) with loss of a single allele due to 
nonsense, splice or frameshift variants.  However, it became clear that there were 
individuals both within families and with sporadic de novo missense KCNQ2 mutations with 
a severe Ohtahara-like encephalopathy (Dedek et al. 2003; Weckhuysen et al. 2012; 
Weckhuysen et al. 2013). These mutations are thought to have a greater detrimental 
functional impact, with some authors finding more markedly abnormal channel function 
than in benign variants, possibly due to a dominant negative effect of encephalopathy-
associated mutations (Orhan et al. 2014; Miceli et al. 2013). A single gene can also lead to 
quite different epilepsy phenotypes, as is evident for de novo KCNT1 mutations leading to 
both epilepsy of infancy with migrating focal seizures and the later onset autosomal 
dominant nocturnal frontal lobe epilepsy syndrome, discussed further in Chapter 4 (Barcia 
et al. 2012; Heron et al. 2012). Therefore, many factors may contribute to phenotypic 
pleiotropy including the nature and timing of mutations during development, the 
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functional domains affected by the mutation, epigenetic factors and genetic background 
including possible modifier gene effects (Table 1.5).  
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Gene Phenotypic variability Postulated molecular mechanism(s) for variability 
ARX Malformation vs non-
malformation 
phenotypes 
Location and functional effect of mutation within gene: malformation phenotypes are caused by truncating mutations 
(resulting in complete loss of function) and most missense mutations within homeobox (DNA binding) domain. Non-
malformation phenotypes result from missense mutations outside the homeobox domain or expansions of the 
polyalanine tracts. Increased size of polyalanine expansion correlates with increased phenotypic severity in most cases.  
KCNQ2 EE vs BFNS Functional impact of mutation: Most BFNS mutations result in haploinsufficiency. Multiple (conflicting) mechanisms have 
been reported in EE-causing mutations, including haploinsufficiency, dominant negative effect and gain of channel 
function. 
CDKL5 Variable severity of 
epilepsy and 
developmental 
impairment 
Location of mutation within gene: Patients with missense mutations in the ATP binding site typically have a less severe 
phenotype than those with mutations in the kinase domain or frameshift mutations in the C-terminal region.  
SCN1A 1. DS vs milder 
phenotypes (GEFS+ etc.) 
in members of families 
with the same mutation  
 
2. Phenotypic variability 
within DS 
1. Differences can be due to mosaicism or (presumed) modifier genes.  
Mosaicism: There are multiple reports of children with DS who have inherited an SCN1A mutation from a mildly affected 
or unaffected mosaic parent. Mosaicism levels of 0.04% to 85% are reported, with more severe parental phenotypes at 
levels of > 45%. 
Modifier genes: specific modifier genes are not well established, although models of SCN1A mutant mice suggest that 
concurrent SCN9A or SCN8A mutations can lower or raise the seizure threshold respectively compared with SCN1A-only 
mutants. 
2. Functional impact of mutation: Truncating mutations are associated with slightly earlier age of myoclonic and absence 
seizure onset compared with missense mutations. 
SCN8A EE vs ID without epilepsy Functional impact of mutation: gain of function mutations are associated with EE, heterozygous loss of function 
mutations result in ID without epilepsy in both humans and mouse models. 
GRIN2A EOEE vs EAS Functional impact of mutation: mutations in EAS result in haploinsufficiency, two mutations associated with the more 
severe EOEE associated with gain of NMDA receptor complex function (each producing increased current flow via 
different mechanisms).  
Table 1.5 Examples of the proposed molecular bases of phenotype-genotype variability. Abbreviations: ADNFLE autosomal dominant nocturnal frontal 
lobe epilepsy, BFNS benign familial neonatal seizures, DS Dravet syndrome, EAS epilepsy aphasia spectrum, EIEE early infantile epileptic encephalopathy, 
EIMFS Epilepsy of infancy with migrating focal seizures, EOEE early onset epileptic encephalopathy, GEFS+ Genetic epilepsy with febrile seizures plus, ID 
intellectual disability, OS Ohtahara syndrome. Adapted from McTague et al The Lancet Neurology 2015;15(3):304-1. 
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1.6 Genes and mechanisms in the early onset epilepsies 
Advances in genetic discovery for the severe epilepsies has revealed a large number of 
different possible disease mechanisms (Figure 1-3 and Table 1.2). While channelopathies 
remain perhaps the most common group, genes with key roles in transcriptional 
regulation, chromatin remodelling, DNA repair, transporter function and cellular 
metabolism have been implicated. Synaptic dysfunction (associated with mutations in 
genes encoding proteins involved in synaptic vesicle formation and recycling and synaptic 
signaling) is an emerging unifying mechanism for some genetic forms of EE (Figure 1-3 ). 
Data from animal and recent human-derived induced pluripotent stem cell (iPSC) studies 
has revealed that certain neuronal sub-types seem to play a significant role in epileptic 
encephalopathies. In ARX and SCN1A related encephalopathies, abnormalities of 
interneuron development, migration or function are implicated (Galanopoulou 2013; 
Olivetti & Noebels 2012; Sun et al. 2016).  
Bioinformatic methods to use statistical gene network analyses using gene expression and 
protein interaction databases have highlighted forebrain-expressed genes and GABAergic 
genes in West syndrome (Paciorkowski et al. 2011). It is also clear from bioinformatics 
studies that certain protein networks such as the FRAX protein network may link neuronal 
firing to neuronal protein synthesis and regulation (Allen et al. 2013; Barcia et al. 2012).  
In conclusion, a large number of genes are now associated with the early onset epileptic 
encephalopathies which have provided insight into the diverse molecular mechanisms at 
play. In the following chapters I will investigate the molecular genetic basis of EIMFS and 
examine the insights into disease pathogenesis that the genomic era has brought for this 
particularly severe early onset epilepsy.  
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Figure 1-3 Disease mechanisms in childhood epileptic encephalopathies. Schematic 
drawing of neuron, axon, pre and post synaptic compartments. Many areas of abnormal 
neuronal function including DNA repair, transcriptional regulation, axon myelination, 
metabolite transport and peroxisomal function in addition to channelopathies and synaptic 
dysfunction are implicated in severe childhood epilepsies. Adapted from McTague et al The 
Lancet Neurology 2015;15(3):304-1.
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Chapter 2 General Methods 
2.1 Clinical data collection 
2.1.1 British Paediatric National Surveillance Unit (BPNSU) Study 
A national surveillance study of EIMFS was proposed to the BPSNU scientific committee by 
Dr Rachel Kneen (Paediatric Neurologist, Alder Hey Children’s Hospital), and was approved. 
The project was discussed with the local research ethics committee (LREC) for Alder Hey 
Children’s Hospital but as this was an anonymised surveillance study, it was deemed that 
ethical approval was not required. A research proforma was designed to collate 
anonymised clinical information regarding the patient’s clinical phenotype including 
seizure onset, semiology, associated clinical features, EEG and other investigation results, 
response to treatment and developmental outcome (see Appendix). Members of the 
British Paediatric Neurology Association (including UK neurologists and paediatricians with 
an interest in neurology) were emailed once per month over a 2-year period from 2008 to 
2010 and asked if they had a current or previous patient fulfilling the diagnostic criteria for 
EIMFS. If the answer was affirmative, a proforma was emailed to the clinician and followed 
up by reminder emails until completion of the questionnaire. The proformas along with 
anonymised clinical data and reports were collated and the data was tabulated in Excel. 
2.1.2 Patient recruitment to genetics of early onset epilepsy study 
Following the completion of the BPNSU study it was clear that further genetic 
investigations were required in these patients as none had an established aetiology for 
their clinical symptoms. As part of a larger Early Onset Epileptic Encephalopathy (EOEE) 
cohort, I recruited EIMFS patients from Great Ormond Street Hospital (GOSH) that I either 
saw in Dr Kurian’s specialist Neurogenetic clinic or referred by colleagues, UK patients 
referred by GOSH colleagues, as well as UK patients referred by other paediatric 
neurologists and geneticists and international patients referred by clinical colleagues and 
collaborators. The patients were recruited as part of a collaborative study under the 
project title: “Genetic and biochemical investigations of children with symptoms suspicious 
for an inherited metabolic disease”, of which Dr Kurian is a co-investigator. This 
encompassed all neurological diseases that are suspected to be (i) genetic in origin and (ii) 
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due to a gene defect encoding a protein which disrupts any process involved in cell 
metabolism (including channels, transporters, enzymes and other cell proteins). The study 
was approved by the National Research Ethics Service (NRES) (London – Bloomsbury, REC 
reference: 13/LO/0168, IRAS project ID: 95005). Patients were consented using age-
appropriate consent forms and parents were supplied with information sheets. Patient 
data was entered and stored on a secure database for analysis. EIMFS recruited to this 
study underwent research testing, including targeted single gene analysis (KCNT1, KCC2) 
and/or whole exome sequencing.  
2.1.3 Ethical approval for patients tested on the diagnostic panel 
Some patients had diagnostic multiple gene panel testing as part of routine clinical care 
and were found to have a KCNT1 mutation. For these patients, I undertook an approved 
case note review project (Great Ormond Street Hospital Research and Development 
Department, 16NM11). I reviewed anonymised clinical information in conjunction with 
anonymised EIEE diagnostic panel data.  
2.1.4 Clinical endophenotyping 
I collated and reviewed all clinical data. EEG data were reviewed as raw EEG data where 
possible and EEG reports where this was not available.  Professor J Helen Cross and Dr 
Krishna Das from Great Ormond Street assisted in reviewing EEG data. MRI and MRS data 
were reviewed with Dr Shivram Avula, Alder Hey Children’s Hospital, Liverpool (Chapter 3), 
and Dr Kling Chong, Great Ormond Street Children’s Hospital (Chapters 4 and 5).  
Neuropathology specimens and data were reviewed by two consultant neuropathologists, 
Dr Michael A Farrell, Beaumont Hospital, Dublin and Dr Thomas Jacques, Great Ormond 
Street Hospital for Children 
2.2 Materials 
2.2.1 Chemical reagents 
BioMix Red       Bioline 
Agarose       Bioline 
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SYBR Safe DNA gel stain      Invitrogen 
Tris-Borate-EDTA (TBE) buffer     Sigma 
Hyperladder 100bp      Bioline 
GC rich solution of FastStart Taq DNA Polymerase   Roche Diagnostic 
Distilled Water (dH2O)      Gibco 
MicroCLEAN       Web Scientific 
Sodium Acetate 3M      Ambion   
Ethanol 100%/70%      Haymankimia 
TE 1x buffer pH 8.0      Applichem 
Accuprime Pfx Supermix     Invitrogen 
NEbuffer 3.1       New England Biolabs 
EcoRI        New England Biolabs 
SalI        New England Biolabs 
T4 DNA ligase       New England Biolabs 
T4 DNA ligase 10x Buffer     New England Biolabs 
Agar powder       Sigma Aldrich 
LB powder        Sigma Aldrich 
10 cm petri dishes      Falcon 
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One Shot™ TOP10 Chemically Competent E. coli   Invitrogen 
Ampicillin sodium salt      Sigma Aldrich 
DMEM        Gibco 
HBSS        Gibco 
MEM        Sigma Aldrich 
OptiMEM       Life Technologies 
HEK293 (ATCC® CRL-1573)      ATCC  
Fugene6       Promega 
Pencillin-Streptomycin (10,000units/ml)    Life Technologies 
2.2.2 Kits 
BigDye Terminator Cycle Sequencing Kit version 3.1 (Applied Biosystems Inc., Life 
Technologies Corporation)
Qubit dsDNA BR Assay Kit (Invitrogen) 
Stratagene QuikChangeTM Site-Directed Mutagenesis Kit (Agilent) 
QIAquick Gel Extraction Kit (Qiagen) 
QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent) 
QIAprep Spin Miniprep Kit (Qiagen) 
HiSpeed Plasmid Maxi Kit( Qiagen).  
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2.3 DNA sequencing  
2.3.1 DNA extraction and measurement 
DNA was extracted either by local referring laboratories or by the Great Ormond Street 
Hospital North East Thames Regional Genetics Service Laboratory using standard methods. 
I measured aliquots of DNA either using a Nanodrop (ThermoScientific) spectrophotometer 
or Qubit. The Qubit assay system is a fluorometric system and the Qubit dsDNA BR Assay 
Kit (Invitrogen) was used according to the manufacturers protocol. In general DNA stock 
concentrations were in the region of 150-250ng/µl which were diluted to provide working 
concentrations of 20-40ng/µl for PCR and sequencing purposes.  
2.3.2 Polymerase chain reaction (PCR) 
The polymerase chain reaction, a method of rapidly producing numerous copies of DNA 
sequence from a single-stranded template, was one of the most important scientific 
advances of the 20th century (Saiki et al. 1985). DNA is heated or denatured, leading to 
separation of the double-stranded structure. Following denaturation, the temperature is 
lowered to allow binding or annealing of a primer to each strand of DNA. The primers 
direct the polymerase to a specific section of the template DNA, allowing amplification of a 
specific DNA fragment. A heat-stable polymerase, Taq polymerase which was isolated from 
thermus aquaticus, a bacterium found in hot springs, then synthesizes two new strands 
using the original strands as templates. Each of these strands can then be denatured and 
further strands synthesised, with an exponential increase in DNA copies with each cycle in 
the chain reaction leading to billions of copies or amplicons by the end of the reaction.  
I performed PCR reactions in 20 µl aliquots as below: 
      
Final Concentration  Volume 
• DNA (40-80ng)   (2ng/µl)   2µl 
• dH20        7.2µl 
• BioMix Red 2X   (1x)    10µl 
• Forward primer 10µM   (0.2µM)   0.4µl 
• Reverse primer 10µM  (0.2µM)   0.4µl 
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BioMix Red is a pre-mixed 2X reaction solution containing an ultra-stable Taq DNA 
polymerase. It also contains an inert red dye to allow easy visualisation during agarose gel 
electrophoresis. PCR reactions were performed in thin-walled 50µl tubes or 96-well plates. 
For each set of reactions, a control DNA sample (from a normal subject) and a negative 
sample containing dH20 instead of DNA was included.  
PCR was performed using an Applied Biosystems Thermocycler. The standard PCR settings 
were an initial denaturation of 950C for 5 minutes; followed by 40 cycles of 950C for 45 
seconds, annealing at 600C for 45 seconds, extension at 720C for 1 minute; followed by 
720C for 5 minutes. 
For GC-rich templates, the PCR reaction was adapted as below:   
Final Concentration  Volume 
• DNA (40-80ng)   (2ng/µl)   2µl 
• dH20        3.2µl 
• BioMix Red 2X   (1x)    10µl 
• Forward primer 10µM   (0.2µM)   0.4µl 
• Reverse primer 10µM  (0.2µM)   0.4µl 
• GC rich solution       4 µl 
2.3.3 Primer design and optimization for sequencing 
I mainly used Primer3 (http://fokker.wi.mit.edu/primer3/input.html) (Untergasser et al. 
2012) to design primers. The parameters in Primer3 were set as: length 18-20 nucleotides, 
50% maximum GC content, exclusion of sequences with hairpin loops or self-
complementarity, product size of 300-500 base pairs. I also specified that the TM or melting 
temperature of the oligonucleotides should not differ by more than 50C. For smaller exons 
or where intronic length allowed, I designed primers to cover two exons at once. Following 
successful primer generation, I blasted the sequences against the human genome using 
BLASTN to ensure they were specific to the targeted region of interest.  
Where Primer3 was not able to generate primers, I used manual primer design with the 
Ensembl transcript as a template. The following criteria were used: (i) oligonucleotide 
length 18-20 base pairs (ii) no more than 50% GC content (iii) 3” sequence ending in a G or 
a C and (iv) a product size of 250-500 base pairs. Again, these were blasted to ensure 
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specificity. In addition, I checked them in Primer3 to ensure there was no self-
complementarity or potential to form secondary structures.   
In general, I tested primers with control DNA at 600C and a standard thermocycling regime 
of 950C for 5 minutes; 40 cycles of 950C for 45 seconds, 600C for 45 seconds 720C for 1 
minute; followed by 720C for 5 minutes.  
Where there was no band, or a weak PCR product of the correct size, the TM or melting 
temperature of the primer pairs was taken into consideration and I adjusted the annealing 
temperature either using a gradient PCR, where a range of annealing temperatures is 
tested simultaneously, or with sequential trials of different temperatures. Annealing 
temperature was thus manipulated until a strong clean band was obtained.  Furthermore, I 
often modified PCR conditions (such as adjusting the temperature, annealing time or cycle 
numbers) for PCR optimisation. If these strategies were unsuccessful, design of new 
primers was necessary.  
Where there were multiple non-specific PCR products present, specificity was mainly 
achieved by increase of the annealing temperature but I also tested decrease of annealing 
time and cycle numbers. When these strategies were not effective, I designed new primers 
were designed. For some fragments (e.g. KCNT1 exon 29, Chapter 4) where primer re-
design and adjustments of the PCR parameters was initially not successful, I used 
touchdown (TD) PCR. In TD PCR, the initial annealing temperature is set above the TM and 
decreases over subsequent cycles, conferring an advantage to the specific annealing of 
primers to template over the non-specific priming that may occur at lower temperatures 
(Don et al. 1991). This can be useful where mispriming may be a factor as in GC-rich 
sequences (Lorenz 2012) (see below). Where primer dimers were present the primers 
were diluted further in case of excess primer concentrations. 
Although the average guanine-cytosine (GC) content of the human genome varies widely 
from 35-60% (Romiguier et al. 2010; Lander et al. 2001), some genes are particularly GC-
rich. A good example of this is KCNT1 (Chapter 4) which has 61.7% GC content 
(http://grch37.ensembl.org/biomart). PCR and sequencing of GC-rich genes can be difficult 
as the G-C bonds are particularly stable due to base stacking leading to stable secondary 
structure formation and mispriming during PCR (Jensen et al. 2010). Various strategies are 
available including use of DMSO, which reduces secondary structure formation, or betaine 
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and increasing annealing temperature (Strien et al. 2013). Several commercial GC-
enhancer solutions are also available. I used GC-RICH Reaction Buffer, 5X concentrated, 
which contains 7.5 mM MgCl2 and DMSO.  
Lastly, where the negative sample contained a DNA band suggesting a DNA contamination, 
I repeated the reaction with fresh primer dilutions. If the negative contamination 
persisted, new primer stocks and reagents or a change of set-up location were used which 
was effective.  
2.3.4 Agarose gel electrophoresis 
I verified PCR products by running samples on horizontal agarose gels to ensure the PCR 
product was the correct size and that there was no contamination. Gels were 1.5% agarose 
made by adding 1.5 grams of agarose powder to 100mls of 1X TBE Buffer. This was 
dissolved in a 250ml conical flask using a standard domestic 800W microwave, cooled to 
hand-hot temperatures and 5µl of SybrSafe (10,000X concentration) was added. SybrSafe 
enables DNA denaturation and visualisation. The agarose was poured onto a gel casting 
tray and left for 15-25 minutes to solidify under an extraction hood. I then loaded samples 
and 5µl of ladder into the wells created by inserting plastic combs during the solidification 
process. After electrophoresis at 120V for 30-40 minutes, the gel was visualised using a Gel 
Doc™ XR+ Gel Documentation System and ImageLab software.  
2.3.5  Sanger sequencing of PCR products 
The chain termination or dideoxy technique, which was developed by Sanger in 1977, 
exploits the fact that dideoxynucleotides (ddNTPs) cannot be incorporated into DNA during 
an extension reaction due to the lack of a 3’ hydroxyl group (Heather & Chain 2016). As 
chemical ddNTP analogues are incorporated into the DNA strand, they result in chain 
termination. The technique was further refined as dye-terminator sequencing, where 
fluorescently labelled ddNTPs emit signal at differing wavelengths as they are incorporated 
during DNA extension. This innovation led to the development of automatic sequencers 
such as the ABI PRISM sequencer used in this study.  
I purified PCR products using MicroCLEAN (Web Scientific) to remove reaction buffers, 
enzymes, primers, primer dimers or dNTPs which could interfere with downstream 
processing. 2.5-3.5 µl of microclean was added to the equivalent volume of PCR product in 
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a 96 well plate. This was centrifuged at 4000rpm at 40C for 40 minutes, followed by 
another short centrifugation step in which the unwanted chemicals were removed by 
inverting the plate. The cleaned-up PCR product was resuspended in distilled water. 
2.3.5.1 Sequencing reaction set-up 
I set up each 10µl reaction as follows: 
• PCR product re-suspended in dH20    4.5µl  
• dH20       2µl 
• BigDye Sequencing buffer 5X    2µl 
• BigDye 1.1 Reaction Mix    0.5µl 
1µl of either forward or reverse primer was then added to each well.  
I ran the sequencing reaction on an Applied Biosystems Thermocycler using the following 
parameters: 960C for 3 minutes; followed by 35 cycles of 960C for 30 seconds, 500C for 15 
seconds and 600C for 4 minutes. 
2.3.5.2 Precipitation of sequenced DNA 
Following the sequencing reaction, I added 2µl of Sodium Acetate (3M) and 50µl of 100% 
ethanol to each well. The reaction was mixed by briefly vortexing and left at room 
temperature for 20 minutes. The plate was then centrifuged at 3000rpm for 40 minutes at 
40C and subsequently inverted and centrifuged at 300rpm for 1 minutes to remove excess 
ethanol. A further precipitation sand centrifugation step with 70% ethanol at 3000rpm for 
10 minutes was followed by centrifugation of the inverted plate at 300 rpm for 1 minute. 
The plate was air dried to eliminate excess ethanol and 10 µl of TE was added to each 
reaction.  
2.3.5.3  Sequencing reaction and analysis 
The samples that I prepared for sequencing were run by laboratory technicians within the 
Great Ormond Street Hospital NE Thames Regional Genetics Service Laboratory on an ABI 
PRISM 3730 DNA Analyzer (Applied Biosystems Inc). This is part of a mutual agreement and 
is the standard service for sequencing within the UCL Institute of Child Health. I analysed 
sequencing data either with Chromas (Technelysium Pty Ltd, Australia) or Sequencher 
(GeneCodes Corporation, USA) software. I checked samples for read quality before aligning 
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to a control sequence to analyse sequence for coverage of exon and exon-intron 
boundaries and the presence of abnormal variants.  
2.4 Mapping and single nucleotide polymorphism(SNP) arrays 
Illumina CytoSNP12 arrays were performed by the local UCL Genomics Service in both 
parents, affected and unaffected children from Family 1 (Chapter 5), see Appendix for 
methods. Analysis of SNP data is considered in 5.2.1. 
2.5 WES and analysis 
For Family 1, described in Chapter 5, whole exome sequencing was performed by the 
Institute of Neurology(IoN) Next Generation Sequencing service (Molecular Neurosciences, 
Institute of Neurology, London). The methods used in the IoN laboratory are detailed in 
the Appendix. WES described elsewhere in this thesis was performed externally and 
methods are also described in the Appendix. I received the data from IoN as a .csv file 
which I then analysed in Excel, using series of filtering steps based on the hypothesis that 
the underlying condition was a rare, likely recessive disorder. Firstly, I excluded all 
synonymous variants and retained non-synonymous single nucleotide variants (SNVs), 
frameshift and non-frameshift deletions or insertions and stop-loss or stop-gain SNVs. 
Secondly, I excluded all variants with a mean allele frequency of >0.01 in genome 
databases (1000 Genomes, Exome Variant Server) to retain only rare variants. 
Subsequently I selected homozygous and compound heterozygous variants. Within this 
data I then focused my analysis on variants lying within the homozygous regions identified 
by autozygosity mapping.  
Further WES described in Chapters 3, 4 and 6 was performed externally to UCL and 
methods are described in the Appendix. Analysis is described in the relevant chapters.  
2.6 In situ mutagenesis of pCMV6-XL5-KCC2 plasmid  
2.6.1 Preparation of materials for bacterial culture 
2.6.1.1 Lucia Bertani (LB) medium 
I mixed 10g of LB broth base (Sigma) with 500ml of water and the solution was autoclaved 
to sterilize the solution.  
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2.6.1.2 Ampicillin solution  
I added 1 gram of ampicillin sodium salt (Sigma Aldrich) to 10mls of distilled water under a 
fume hood. For sterilisation, the solution was passed through a washed 0.22 µm filter, 
aliquoted and stored at -200C. 
2.6.1.3 Ampicillin agar plates 
I mixed 8g of LB broth base and 6g of agar powder with 400ml of distilled water and 
autoclaved the solution. Once cooled to a hand-hot temperature (approximately 500C), 
400µl of 100mg/ml ampicillin was added. Before pouring into 10cm petri dishes, the 
opening of the bottle was flamed with a Bunsen burner to ensure sterile conditions and 
left to set under a fume hood.  
2.6.2 Amplification of commercial SLC12A5 clone in E coli  
I obtained a pCMV6-XL5 plasmid with a full length SLC12A5 wild-type human insert from 
Origene (catalogue number SC304801) (Figure 2-1).  
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Figure 2-1 pCMV6-XL5-KCC2 plasmid map 
For amplification of the plasmid, I transformed One Shot™ TOP10 Chemically Competent E. 
coli. with 1µl of the resuspended clone. After incubation on ice for 30 minutes, the cells 
were heat shocked at 420C for 30 seconds in a water bath and then put back on ice. I 
added 250µl of SOC medium and the cells were incubated at 370C for 1 hour with shaking. 
To ensure only amplification of cells containing the plasmid, I plated them onto warmed 
LB-Agar Ampicillin plates using two different volumes, 10µl and 100µl, and incubated 
overnight at 370C. The following day, I picked discrete colonies which were then inserted 
into 5mls of LB medium with 5µl of ampicillin (100mg/ml) followed by incubation at 370C 
overnight with shaking. From the overnight cultures, I purified DNA using a Qiaprep Mini 
Prep kit (Qiagen) in accordance with the manufacturers protocol. I measured DNA using a 
Nanodrop and then sequenced this directly with cDNA primers (see Chapter 5 Methods) to 
verify the presence of the full-length wild type SLC12A5 cDNA insert without mutations. 
Following confirmation of the correct sequence, I inoculated 250mls of LB broth containing 
CMV	enhancer
pCMV6-XL5-KCC2
10,371	bp
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250µl of ampicillin (100mg/ml) with 2.5mls of the overnight culture which was incubated 
with shaking overnight at 370C. I extracted the plasmid DNA using a Qiaprep Maxi Prep kit. 
I then measured the DNA and sequenced it directly with cDNA primers.  
2.6.3 In situ mutagenesis  
In situ, or site-directed, mutagenesis is the introduction of a mutation into a gene of 
interest at a specific location. Several methods are available, but one of the most efficient 
uses complementary mutagenesis primers and a high-fidelity non-strand displacing 
polymerase such as pfu polymerase to amplify plasmid DNA in a thermocycler.  This 
creates a nicked circular DNA containing the desired mutation. As the template DNA has 
been created within E coli it will be methylated and can be digested with the methylation 
sensitive restriction enzyme DpnI. However, the mutated plasmids have been generated in 
vitro and are therefore unmethylated and will escape digestion. Hence, I chose to use a 
Stratagene Quikchange Site-Directed Mutagenesis kit which is based on this principle.  I 
designed mutagenesis primers for each of the SLC12A5 mutations in keeping with guidance 
in the Stratagene QuikChangeTM manual using Primer3 (detailed in Chapter 5). In brief, 
the primers should be 25-45 nucleotides in length, with the desired mutation in the middle 
of the primers and a TM ≥780C with minimum TM mismatch between primers. In accordance 
with the kit instructions, I set up the mutagenesis reaction in 50µl aliquots, keeping 
primers in excess of the DNA template. Cycling parameters were: 950C for 1 minute; 
followed by 18 cycles of 950C for 50 seconds, 600C for 50 seconds and extension at 680C for 
10 minutes (1 minute per Kb of plasmid); followed by 680C for 7 minutes. Subsequently, 
the reaction was placed on ice, DpnI was added and samples incubated at 370C for 1 hour. 
E. coli were then transformed and plated onto ampicillin LB Agar plates as detailed above.  
The following day I selected colonies which were added to 5mls of LB medium containing 
ampicillin and incubated overnight.  I extracted DNA the following day using a Qiaprep kit 
as above. Plasmid DNA was sequenced using cDNA primers to verify the introduction of the 
mutation and to ensure no additional mutations had been generated during mutagenesis. 
Using this method, I successfully introduced all three SLC12A5 mutations into the pCMV6-
XL5-KCC2 plasmid.  
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2.7 Cloning of pRK5 plasmid 
To investigate the impact of SLC12A5 mutations on transporter function, I planned to 
express the mutants in a cell system. For this purpose, the insertion of the wildtype and 
mutated SLC12A5 sequence into a robust expression plasmid was required. The pRK5 
plasmid was kindly provided by Professor Robert Harvey (Figure 2-2). This is an expression 
plasmid previously successfully used by the Harvey lab in studies of glycine receptor 
function (Rees et al. 2006).  
 
 
 
Figure 2-2 pRK5-KCC2 plasmid map. pRK5 sequence based on publicly available Addgene 
data https://www.addgene.org/browse/sequence_vdb/3944/ 
SalI(4375)		
EcoRI		(919)
pRK5-KCC2
8094	bp
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2.7.1 Amplification of insert 
PCR-based cloning involves PCR-based amplification of the gene of interest from a donor 
plasmid with incorporation of restriction enzyme recognition sites. This enables the insert 
to be cut out and incorporated into a recipient plasmid or vector. Using NEBcutter, I 
interrogated the donor plasmid (pCMV6-XL5-KCC2) and recipient plasmid (pRK5) sequence 
for common bacterial enzyme recognition sites located within the multiple cloning site 
(MCS) and which were unique in the recipient plasmid and the SLC12A5 cDNA sequence to 
prevent cutting elsewhere in the vector or the insert. As a result, I chose EcoRI and SalI as 
enzymes which would cut out the SLC12A5 insert from the donor plasmid and also cut the 
recipient pRK5 plasmid, resulting in complementary ends between the donor and recipient 
plasmids. I also chose a different restriction enzyme site for each end to avoid re-ligation of 
the donor plasmid. I manually designed primers with a three-base overhang or initial 
sequence followed by the recognition for the upstream restriction enzyme in the forward 
primer and the downstream restriction site in the reverse primer. I then incorporated a 
Kozak sequence, the eukaryotic translation initiation consensus sequence which helps to 
align the ribosome with the start codon. Inclusion of a Kozak sequence in primers can 
improve expression (Kozak 1986). This was followed by the ATG start codon for the 
forward primer and the first 18 nucleotides of the gene, and the stop codon and last 18 
nucleotides for the reverse primer. Both primers were finally checked in Primer3 for self-
complementarity and secondary structure formation. Primer details are found in Chapter 
5.  
I performed the PCR in the Harvey laboratory using an in-house protocol. 25µl reactions 
were set up as follows: 
      Final concentration Volume 
• Forward primer (10µM)  0.4 µM   1µl 
• Reverse primer (10µM)  0.4 µM   1µl 
• Accuprime Pfx Supermix     22µl 
• pCMV6-XL5-KCC2 DNA (50ng/µl)    1µl 
I set up reactions were set up for pCMV6-XL5-KCC2 wild type and all three mutations. 
Thermocycler conditions were as follows: 950C for 3 minutes; followed by 25 cycles of 950C 
for 1 minute; 500C for 1 minute and 680C for 16 minutes (2 minutes per Kb).  
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After the PCR, I added 1 µl of DpnI restriction enzyme, followed by incubation at 370C for 
90 minutes. The PCR product was run on an agarose gel to ensure successful amplification. 
A QIAquick Gel Extraction Kit was then used for extraction of the DNA from the agarose gel 
according to the manufacturers protocol. 
2.7.2 Restriction digest  
I performed a double digest on both the gel-extracted PCR product (amplified from the 
donor plasmid) and the recipient plasmid as follows: 
Donor plasmid (25µl): 
• NEbuffer 3.1    3µl 
• EcoRI     1µl 
• SalI     1µl 
pRK5 plasmid (2µl): 
• NEbuffer 3.1    2µl 
• dH20     14µl 
• EcoRI     1µl 
• SalI     1µl 
The digests were pulsed for 30 seconds in a bench-top centrifuge and incubated at 370C for 
2 hours.  
2.7.3 Phenol-chloroform extraction 
I added distilled water to the vector and insert to result in a final volume of 100µl. 100µl of 
phenol-chloroform isoamyl alcohol was added to each sample under the fume hood and 
tubes were centrifuged at 13000rpm for 10 minutes. The aqueous phase of each sample 
was each added to a tube containing 250µl 96% ethanol, 10µl 3M sodium acetate and 
1.5µl Glycogen.  
The mixture was chilled on dry ice for 30 minutes and then centrifuged for 18 minutes. I 
discarded the supernatant and the pellet washed with 250µl 80% ethanol, centrifuged and 
air dried. The pellet was then eluted in 14µl EB buffer for the insert and 50µl for the pRK5 
vector.  
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2.7.4 Ligation  
The next step of the cloning process it to ligate the insert, which has been cut from the 
surrounding donor plasmid DNA, into the recipient plasmid which has been cut at the same 
restriction sites. The T4 DNA ligase enzyme forms phosphodiester bonds between the 3'-
hydroxyl of one DNA terminus with the 5'-phosphoryl of another using ATP as a co-factor.  
 Varying ratios of vector to insert were trialled but 1:3 was the most successful. I set up the 
ligation reaction as follows: 
• Insert     3µl 
• Vector     1µl 
• 10X ligation buffer   1µl 
• T4 DNA ligase    1µl 
Tubes were spun for 1 minute and then incubated at 40C overnight.  
2.7.5 Transformation of E coli  
I transformed TOP10 cells as detailed above and plated them onto ampicillin LB Agar 
plates. As described previously, colonies were selected into mini cultures and I extracted 
DNA using the Qiaprep Mini Prep kit.  
I performed a diagnostic double digest to ascertain whether the gene had been 
successfully inserted using EcoRI and SalI as described above. The digest was separated 
and visualised by gel electrophoresis at 120mV for 2 hours on a 0.8% agarose gel. Only the 
DNA of plasmids that possibly contained the insert was sent for sequencing using cDNA 
primers to ensure the presence of the gene of interest. Once the success of the cloning 
was confirmed, I performed a maxi prep to generate DNA stocks for each mutation.  
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Figure 2-3 Agarose gel electrophoresis of diagnostic digest of pRK5 cloning product for 
wild-type KCC2 and L311H. 0.8% gel run at 120mV for 2 hours. For 5 samples (red arrows), 
2 bands at~ 5Kb and ~3Kb are seen, indicating successful insertion of the 3.3 Kb KCC2 
insert into the pRK5 plasmid 
2.8 In situ mutagenesis of pRK5 plasmid 
As PCR-based cloning was not successful for all of the mutations, I undertook in situ 
mutagenesis of the generated pRK5-KCC2 wild-type plasmid to generate the L426P and 
G551D mutant plasmids. Essentially the principles and the primers used are as described 
above, but a QuikChange Lightning Site-Directed Mutagenesis Kit was used. I set up 50µl 
reactions as follows: 
      Final Concentration  Volume 
• Lightning Reaction Buffer      5µl 
• Template DNA        1µl 
• Forward primer(10µM)  0.4 µM     1µl 
• Reverse primer(10µM)  0.4 µM     1µl 
• dNTP mix        1µl 
• QuikSolution        1.5µl 
• dH20         39.5µl 
• LightninqQuik enzyme       1µl 
Thermocycling parameters were as follows: 950C for 2 minutes; followed by 18 cycles of 
950C for 20 seconds, 600C for 10 seconds and extension at 680C for 4 minutes (30 seconds 
per Kb of plasmid); followed by 680C for 5 minutes. 2µl of Dpn was then added to digest 
the parental DNA template. To amplify the mutant plasmids, E. coli were transformed and 
cultured under selective conditions as above. To ensure the presence of the mutant KCC2 
pRK5-KCC2 WT pRK5-KCC2 
L311H 
1Kb ladder 
5Kb 
4Kb 
3Kb 
  75 
insert, I extracted and sequenced DNA as above. Using these methods, I successfully 
generated the remaining two mutant plasmids.  
2.9 Cell culture and transfection 
2.9.1 Maintenance of HEK293 cells in culture 
I grew HEK293 cells in 25cm2 flasks in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% FBS and 1% pencillin-streptomycin (5 ml of 10,000units/ml) and 
incubated in a CO2 incubator at 370C.  
2.9.2 Transfection of HEK293 cells for electrophysiology experiments 
Once cells were confluent, I split for transfection into 100mm round Petri dishes. Cells 
were washed with HBSS and 1ml of Trypsin-EDTA was added. I agitated the culturing flask 
until cells detached and then reconstituted the cells in 9mls of DMEM. Cells were added 
1:10 to the 100mm dishes and a further aliquot added to a new 25cm2 flask of DMEM to be 
kept in culture. After 24 hours in culture, the cells in the 100mm dishes were washed with 
HBSS twice to remove any DMEM to avoid interference with downstream processing. I 
prepared a transfection mixture was prepared for each construct: 
• Optimem     230µl 
• Fugene      30µl 
• Plasmid DNA 4 µg per construct  varying by concentration 
I co-transfected cells with three constructs:  
1. pRK5-eGFP 
2. pRK5-GlyR α2 subunit 
3. pRK5-KCC2, either wild type or mutant, or pRK5 alone (empty vector) 
The Optimem and Fugene were combined and incubated for 5 minutes, followed by 
addition of the DNA with incubation at room temperature for 15 minutes. 9ml of MEM was 
added to the cells. As DMEM contains glycine and the cells were transfected with a glycine 
receptor (Chapter 5), it was essential that only MEM was used post-transfection. I dropped 
the transfection mixture onto the cells and they were incubated for 24 hours. 
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2.9.3 Preparation of transfected cells for electrophysiology 
I aspirated the medium from the transfected cells and HBSS was used to wash the cells. 
Cells were detached with 1ml of Trypsin-EDTA and 9ml of MEM added. The contents of the 
dish were transferred to a 15cm Falcon tube and centrifuged at 1000rpm for 2 minutes. 
The supernatant was discarded, and the pellet was resuspended in 1ml of perfusion 
solution (see below).  
2.10 Electrophysiology 
I undertook electrophysiology experiments under close supervision from Dr Arnaud Ruiz. I 
prepared the cells for patching and set up the electrophysiology rig including pipette and 
solution preparation. I worked alongside Dr Ruiz who patched the majority of the cells 
from which the experimental data is derived but as I acquired better technical skills, I was 
able to successfully patch several cells, generating data that was included in the analysis. 
Patch pipettes (3-5 MΩ) were pulled from borosilicate glass (1.5 mm outer diameter, 0.5 
mm wall thickness) and recordings were obtained from eGFP-positive HEK293 cells under 
infra-red differential interference contrast imaging. I prepared the perfusion solution 
containing NaCl (140mM), KCl (4mM), MgCl2 (1mM), CaCl2 (2mM), D-glucose (5mM), 
HEPES (10mM) (pH 7.2, osmolarity 298mOsm.l–1). Currents were recorded with a 
Multiclamp 700-B amplifier (Molecular devices), filtered at 2 kHz (internal 4-pole low-pass 
Bessel filter) and sampled at 10 kHz. The access resistance, monitored throughout the 
experiments was <15 MW and results were discarded if it changed by more than 20 %. The 
pipette solution contained CsCl (50mM), NaCl (10mM), CsF (60mM), EGTA (20mM), HEPES 
(10 mM) (pH 7.2, osmolarity 310mOsm.l–1). Local pressure application of glycine (1mM in 
control HEPES solution) was delivered via a patch pipette connected to a Picospritzer 
(General Valve Corporation). The puff pipette was positioned roughly 10-20µm away from 
the recorded cell and the bath perfusion arranged to keep it downstream of this position. 
Cells were first held at –80mV while several glycine applications were made at 30 seconds 
intervals to ensure that no desensitisation occurred. Glycine puffs (3-5 ms, 5-10 PSI) were 
then delivered every minute at different holding potentials (–80 mV to +20 mV, 20 mV 
increment). A linear regression of IGly amplitude plotted against the holding potential was 
used to analyse the voltage dependence. The intercept of the I-V relation with the abscissa 
was then extrapolated as ECl. (As experiments were performed in bicarbonate-free solution 
buffered with HEPES IGly was solely mediated by Cl− and thus we report ECl). ECl predicted 
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from the Nernst equation was -21.3 mV. Data are expressed as mean ± S.E.M and were 
considered significant if P < 0.05. 
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Chapter 3 Epilepsy of Infancy with Migrating Focal Seizures 
3.1 Historical background and first description 
Epilepsy of infancy with migrating focal seizures was originally described in 1995 (Coppola 
et al. 1995) in a series of 14 children with severe epilepsy. Since this original report, over 
170 patients have been described (Coppola et al. 1995; Coppola et al. 2006; Coppola et al. 
2007; Okuda et al. 2000; Wilmshurst et al. 2000; Gross-Tsur et al. 2004; Marsh et al. 2005; 
Hmaimess et al. 2006; Hahn et al. 2007; Jocic-Jakubi & Lagae 2008; Caraballo et al. 2008; 
Caraballo et al. 2014; Caraballo et al. 2016; Cilio et al. 2009; Nabatame et al. 2010; 
Bedoyan et al. 2010; Djuric et al. 2011; Freilich et al. 2011; Gilhuis et al. 2011; Irahara et al. 
2011; Sharma et al. 2011; Vendrame et al. 2011; Carranza Rojo et al. 2011; Chien et al. 
2012; Fasulo et al. 2012; Barcia et al. 2012; Lee et al. 2012; Need et al. 2012; Poduri, 
Chopra, et al. 2012; Annapurna Poduri et al. 2013; Dhamija et al. 2013; Ishii et al. 2013; 
Merdariu et al. 2013; Milh et al. 2013; Ünver et al. 2013; De Filippo et al. 2014; Iyer et al. 
2014; Bearden et al. 2014; Ohba et al. 2015; Segal et al. 2014; Shimada et al. 2014; Howell 
et al. 2015; Mikati et al. 2015; Møller, Heron, et al. 2015; Saade & Joshi 2015; Selioutski et 
al. 2015; Stödberg et al. 2015; Appavu et al. 2016; Barba et al. 2016; Mori et al. 2016; Rizzo 
et al. 2016a; Saitsu et al. 2016). Coppola reported children presenting with frequent focal 
seizures with onset before six months of age in most patients, associated with a unique, 
multifocal, shifting pattern of EEG activity, amounting to an unusual focal status 
epilepticus. In this seminal paper, several key features were delineated, including: 
• Disease onset before six months of age 
• Frequent focal seizures that are intractable to treatment 
• Ictal EEG showing rhythmic alpha or theta activity independently involving multiple 
areas of the cortex and moving from one area to another in consecutive seizures 
• Normal development prior to onset of seizures followed by developmental 
regression  
Although a poor developmental outcome was seen in ten of 14 patients, two patients had 
seizure control after one year and made subsequent developmental progress, attaining 
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independent walking by three years of age. Other clinical features were noted, including a 
choreoatheoid movement disorder in two patients, acquired microcephaly and severe 
hypotonia.   
EIMFS has been previously termed migrating partial seizures of infancy, migrating focal 
seizures of infancy and malignant migrating partial seizures of infancy. With the 
reorganisation of epilepsies proposed by the International League against Epilepsy (ILAE, 
http://www.ilae.org) in 2010 (Berg et al. 2010), the term malignant was removed as this 
was felt to be an emotive and upsetting term. In line with other focal epilepsies, the term 
partial was changed to focal. While there is no formal ILAE classification of electroclinical 
syndromes, EIMFS currently remains the preferred descriptor (Scheffer et al. 2016; 
Scheffer et al. 2017). 
3.2 The British Paediatric Neurology Surveillance Unit study of EIMFS 
At the beginning of my research project, I noted that EIMFS was purported to be a rare 
condition. However, an increasing number of cases were being reported in the literature 
and I had met a number of affected families in my clinical practice. I therefore aimed to 
determine the incidence and prevalence of EIMFS in the UK.  A national surveillance study 
was undertaken in conjunction with the British Paediatric Neurology Surveillance Unit 
(BPNSU, www.bpnsu.co.uk) to investigate the incidence of EIMFS and to further delineate 
the clinical features of this disorder. 
3.2.1 Methods 
A national surveillance study was performed in conjunction with the BPNSU over a 27-
month period (February 2008 to May 2010). Study inclusion criteria (Coppola et al. 1995) 
were as follows: 
• Seizure onset before age of nine months   
• Focal motor seizures at onset  
• Multifocal seizures proving intractable to conventional anti-epileptic drugs 
• EEG criteria: initial EEG can be normal but characteristic changes emerge over 
time, including interictal multifocal spikes and ictal independent, unilateral and 
migrating involvement of varying cortical areas with electroclinical correlation. 
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• Developmental delay or developmental regression with seizure onset. 
• Presentation not consistent with another recognised electro-clinical syndrome 
(although evolution from/to other syndromes e.g Ohtahara and West syndrome 
may occur) 
These features were derived from the first description of EIMFS by Coppola et al in 1995 as 
discussed above. British Paediatric Neurology Association (BPNA) members (285 paediatric 
neurologists, paediatricians with an interest in neurology and clinical trainees) were sent a 
monthly email during a two year period and asked to notify new or previous cases of 
EIMFS. Those who responded positively were sent a proforma (see Appendix) to collect 
anonymised clinical data regarding disease evolution, EEG features, neuroimaging, 
neurometabolic and genetic investigations.  
3.2.2 Results 
3.2.2.1 Epidemiology 
Over the course of this study overall response rate was 68.4%. Of 17 patients notified to 
the BPNSU study, 14 met the inclusion criteria.  Based on these figures, I estimated the UK 
prevalence of EIMFS to be 0.11 per 100,000 over the two years of the study.  The incidence 
of new cases of EIMFS was 0.26 cases and 0.55 cases per 100,000 live births in the first and 
second years of the study respectively.  
3.2.2.2 Clinical features 
All identified patients were singleton cases with no affected siblings. There was no parental 
consanguinity. In three cases, there was a family history of adult-onset generalised or focal 
seizures but not in a first degree relative. One patient was born at 35 weeks, whilst the rest 
were born at full term. Mean birth weight was 3.0kg (10th-16th centile, range: 2.18-3.69 kg). 
Three of the children manifested early feeding difficulties; one of these had concurrent 
neonatal seizures.  
The median age at seizure onset was seven weeks (range: four days to five months). Most 
had focal motor seizures at onset. Adversive seizures with head turning and eye deviation 
or eye flickering were frequent. Autonomic features such as facial flushing, drooling, 
apnoea, epiphora and changes in pupil size were seen in 12 (88%) of the patients. Patients 
without autonomic features at disease onset did not develop such symptoms later in the 
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disease course. Notably, five patients did not manifest motor seizures at onset but all 
patients had frequent focal motor seizures by six months of age.  
Over time, all patients developed multiple seizure types. Multifocal or clinically migrating 
seizures were seen in six patients. Infantile spasms with hypsarrhythmia were evident in 
two of the patients at two and eight months of age respectively. As the disease progressed, 
seizures became very frequent in all patients, ranging from three to over 100 episodes 
each day. Clustering of seizures was common, most frequently on waking and falling 
asleep. Within the cohort, age at peak seizure frequency was variable from three weeks to 
three years. However, in the seven patients where the clinician reported a reduction over 
time in seizure frequency, the median age of peak seizure frequency was four months 
(range three weeks to one year).  
None of the patients had specific dysmorphic features as reported by their paediatric 
neurologist but five were reported to have coarse facial features. All patients had a normal 
occipito-frontal head circumference (OFC) at birth which then declined with age, resulting 
in microcephaly in seven patients. Most patients had a normal neurological examination at 
presentation. However three patients displayed abnormalities of tone with central 
hypotonia and/or peripheral limb spasticity. After 12 months from onset of the disorder, 
one patient had developed spasticity with increased peripheral reflexes and seven had 
become hypotonic.  
I also identified several less commonly reported clinical features. Firstly, a variety of non-
epileptic movement disorders were seen in four patients. One patient manifested a severe 
cervical dystonia, one a limb dystonia with subsequent four limb dyskinesia, and two 
patients displayed generalised choreoathetosis. Secondly, a very severe gastrointestinal 
dysmotility disorder was reported in three patients.  
All patients received multiple antiepileptic medications in varying combinations and none 
resulted in seizure freedom for a significant period of time. Some reduction in seizures or a 
brief period of seizure freedom was seen with oxcarbazepine, phenytoin, topiramate, 
levetiracetam, vigabatrin, stiripentol and lacosamide. Bromide salts were used in three 
patients with no evidence of efficacy and excessive sleepiness in one leading to cessation. 
Corticosteroids were used in nine patients and effective in two; ACTH in one case and oral 
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prednisolone combined with the ketogenic diet in another. Nine patients were treated 
with the ketogenic diet of which one became seizure free for approximately two years.  
The outcome for patients in this UK cohort was uniformly poor. Over half of the cohort 
died at between two months and eight years of age. In seven patients, there was a gradual 
reduction of seizures over time; however although they seemed to have “burnt out” in 
terms of seizure frequency, the patients were not completely seizure free and had 
significant neurodisability. The developmental outcome in general was poor with two-
thirds of children showing developmental regression at seizure onset and the remainder 
having never made any significant developmental progress. The best developmental stage 
attained beyond one year of age was at three to four month level with some degree of 
head control, rolling and visual fixing and following.  
3.2.2.3 EEG Features 
While in the majority the inter-ictal EEG showed multifocal spikes and background slowing, 
the initial inter-ictal EEG was normal in three patients. Novel inter-ictal abnormalities 
included periods of relative suppression in two patients and frank burst suppression in one 
patient. In addition, hypsarrhythmia (Figure 3-1) was noted in three patients, with infantile 
spasms evident in 2/3 of these infants.  
 
Figure 3-1 EEG recording reveals modified hypsarrhythmia at 2 months of age in Patient 9. 
The EEG reveals arrhythmic, high-amplitude, asynchronous delta activity with independent, 
multifocal spike discharges which is more prominent in the left sided electrodes than the right 
(red box). It is also interspersed by periods of lower-amplitude semirhythmic delta and theta 
activities (blue box). Adapted from McTague et al, Brain 2013;136:1578-91. 
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Ictal EEG was performed in all patients and captured either migrating ictal foci within the 
same seizure or closely overlapping seizures with differing sites of onset (Figure 3-2). The 
majority of seizures showed a characteristic pattern with one seizure dying out and 
another seemingly independent seizure starting in a different cortical location. 
 
 
Figure 3-2 Migrating ictal foci at 5 months of age. 3.2a Rhythmic theta activity detected in 
the right temporo-parietal electrodes (black oval). 3.2b The right temporo-parietal activity 
wanes, as similar theta activity begins independently in the left temporo-parietal 
electrodes (grey circle). (Adapted from McTague et al, Brain 2013;136:1578-91.).  
 
3.2.2.4 Radiological features 
MRI and MRS data were reviewed by me with expert input from Dr Shivaram Avula, 
Consultant Radiologist, Alder Hey Children’s Hospital. Six of the fourteen patients had 
normal brain magnetic resonance imaging (MRI); however, five of these only had a single 
scan with the latest performed at five months of age. One patient did have two normal 
scans but again the last scan was undertaken at only five months of age. Of the eight 
patients who had abnormal cranial imaging, the initial scan was normal in four. The most 
frequently identified abnormality was cerebral atrophy, detected in seven patients. The 
a 
b 
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earliest age at which this abnormality was identified was four months (range four to 42 
months). Delayed myelination with increased T2 signal in the white matter was seen in 
four patients (Figure 3-3).  
 
Figure 3-3 Axial T2 weighted MRI at 16 months of age. Relative hyperintensity of the 
deep white matter (white arrowhead) is suggestive of delayed myelination. Adapted 
from McTague et al, Brain 2013;136:1578-91. 
Lastly in Patient 7, abnormal bilateral increased signal in the putamen and caudate nuclei 
was seen accompanied by cerebral atrophy (Figure 3-4). Comprehensive metabolic 
investigations and an autopsy were unrevealing in this patient (see below). Magnetic 
resonance spectroscopy (MRS) was performed in four patients. In three patients, a 
reduced N-acetyl aspartate (NAA) peak relative to the choline and creatine peaks was 
seen, in keeping with delayed neuronal maturation (Figure 3-5).   
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Figure 3-4 T2 weighted MRI at 39 months of age. Bilateral symmetrical signal 
abnormality of putamen (black arrowheads) and caudate (black arrows) is seen in 
addition to cerebral atrophy, indicated by increased extra-axial spaces (yellow arrow).  
Adapted from McTague et al, Brain 2013;136:1578-91. 
 
Figure 3-5 Single voxel MRS: (A) MRS at 24 months of age demonstrating a relatively high 
myoinositol (mI) peak (red circle) and a relatively low NAA peak (circled in yellow) in 
relation to the creatine (Cr) and choline (Cho) peaks signifying immaturity.  (B) For 
comparison, MRS obtained with similar acquisition parameters of a normal 24 month old 
child is shown with mI peak (red circle) much lower than the NAA peak (yellow circle). 
Adapted from McTague et al, Brain 2013;136:1578-91. 
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3.2.2.5 Pathological features 
Two patients from the cohort underwent post mortem (PM). Post-mortem data were 
reviewed by two consultant neuropathologists, Dr Michael A Farrell, Beaumont Hospital, 
Dublin and Dr Thomas Jacques, Great Ormond Street Hospital for Children.  Patient 12 died 
of respiratory failure at nine months of age. On PM there was bilateral hippocampal gliosis 
with neuronal loss in the CA4 regions bilaterally and areas of granule cell dispersion in the 
dentate gyri. There was some minor extension into CA3 but CA2 and CA1 were well-
preserved (Figure 3-6). Patient 7 died at 54 months due to respiratory complications. As 
seen in Patient 12, there was again bilateral hippocampal sclerosis in CA4 and CA3 and also 
in CA1 (Figure 3-7). In addition, there was striking bilateral putaminal atrophy with marked 
neuronal loss and gliotic changes, also seen to a lesser degree in the caudate nucleus 
(Figure 3-8). 
 
Figure 3-6 Hippocampal sections from Patient 12 revealing a pattern of hippocampal 
sclerosis. Right and left CA4 layers show depletion of neurones and end folial sclerosis. 
R-DG (right dentate gyrus) and L-DG (left dentate gyrus) have an extra band of cells 
(black arrows) due to granule cell dispersion by proliferation of glial cells. Right CA2/CA1 
normal (see R-CA3. R-CA2 and R-CA1). Adapted from McTague et al, Brain 
2013;136:1578-91. 
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Figure 3-7 CA3, CA4 layers and dentate gyrus of hippocampus from Patient 7.  
Evidence of cell depletion consistent with a form of hippocampal sclerosis. Adapted 
from McTague et al, Brain 2013;136:1578-91. 
 
 
Figure 3-8 Abnormal putaminal findings in Patient 7. 7a: Large perivascular spaces 
(yellow arrow) (Luxol Fast Blue/Nissl). 7b: Neuronal depletion and gliosis with focal 
calcification as indicated by deep purple staining (blue arrow) (Hematoxylin and eosin). 
7c: Glial fibrillary acidic protein stain reveals astrocytosis (red arrow). Adapted from 
McTague et al, Brain 2013;136:1578-91. 
 
3.2.2.6 Other investigations 
As part of their diagnostic work-up, all patients had comprehensive metabolic testing 
including muscle biopsies in seven patients. Three of these were abnormal with slightly low 
  88 
Complex I levels (Patients 6, 7 and 9). A number of patients had targeted single gene 
testing and comparative genomic hybridization (CGH) micro-array performed (Table 3.1). 
In addition, six patients underwent testing with a multiple gene next generation 
sequencing (NGS) panel. None of these investigations revealed a genetic diagnosis.  
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 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Single 
gene 
testing 
ARX - N - - - - N N - - - - - - 
CDKL5 - N N - - N N - - - - - - - 
SCN1A N N N N - - N N N N N N - - 
MECP2 N N N N - - N - - - - - - - 
SLC25A22 - - - - - - N - - - - - - - 
PLCB1 - - - - - - N - - - - - - - 
SLC2A1 N - - - - - N - - - - - - - 
STXBP1 - - - - - N - - - - - - - - 
CGH micro-array - - - - - N N N N - N - N - 
Multiple NGS gene 
panel including exon-
level CGH* 
- - - - - N N N N - - N N - 
 
Table 3.1 Molecular genetic investigation of BPNSU cohort 
- Investigation not undertaken,   
N Negative (no abnormality identified),  
*  CDKL5, MECP2, ARX, ATRX, SLC9A6, SLC16A2, ADSL, CNTNAP2, NRXN1, PNKP, 
KIAA1279, UBE3A, EHMT1, FOXG1, MEF2C, SIP1, ZEB2, TCF4, STXBP1, SLC25A22, PCDH19, 
SCN1A, PLCB1, SPTAN1, KCNQ2, ARHGEF9, SCN2A, MAGI2.  
CGH Comparative genomic hybridization 
Adapted from McTague et al, Brain 2013;136:1578-91. 
.
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3.3  Further expansion of the clinical cohort 
Following the completion of the BPNSU study in 2010, clinicians from both the UK and 
overseas continued to refer patients with EIMFS. From 2010-2016, a further twenty 
patients were ascertained, yielding a total cohort of 34 patients recruited for research 
molecular genetic investigations. Written informed consent was obtained, and clinical 
information was gathered. Original EEG data and MRI brain imaging were reviewed where 
possible. My strategy for molecular genetic investigation is described in Chapters 4 and 5. 
Overall a monogenic aetiology was identified in 16/29 (55%) patients (Table 6.1, Chapters 
4, 5, 6). 
3.4 Discussion 
At the time of the BPNSU study there had been 100 published cases describing patients 
with EIMFS. My study was the first attempt to establish the prevalence and incidence of 
EIMFS. A rare disease is defined by the European Union as affecting less than 5 per 10,000 
of the general population (http://www.raredisease.org.uk). Therefore, the estimated 
prevalence and incidence would be in keeping with EIMFS being a rare disorder.  
This study has a number of limitations in epidemiological terms. Firstly, this may not be a 
true population-based estimate as only one method of data capture was employed. 
Secondly, only 68.4% of BPNA members responded, so it is possible that not all EIMFS 
cases were reported during the time period of the BPNSU study. Thirdly, there may have 
been patients presenting to clinicians who were not members of the BPNA and hence not 
reported through this surveillance study. This is unlikely, given the complexity and severity 
of this condition. Since the findings of this study were published (McTague et al. 2013), a 
further twenty-six papers have been published, with a total of 173  EIMFS patients with a 
clinical diagnosis of EIMFS now described (Coppola et al. 1995; Okuda et al. 2000; 
Wilmshurst et al. 2000; Gross-Tsur et al. 2004; Marsh et al. 2005; Coppola et al. 2007; 
Coppola et al. 2006; Hmaimess et al. 2006; Hahn et al. 2007; Jocic-Jakubi & Lagae 2008; 
Caraballo et al. 2008; Cilio et al. 2009; Nabatame et al. 2010; Djuric et al. 2011; Vendrame 
et al. 2011; Freilich et al. 2011; Gilhuis et al. 2011; Irahara et al. 2011; Carranza Rojo et al. 
2011; Sharma et al. 2011; Lee et al. 2012; Fasulo et al. 2012; Chien et al. 2012; Poduri, 
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Chopra, et al. 2012; Barcia et al. 2012; Merdariu et al. 2013; Milh et al. 2013; Ünver et al. 
2013; Dhamija et al. 2013; Ishii et al. 2013; De Filippo et al. 2014; Shimada et al. 2014; 
Poduri et al. 2013; Ohba et al. 2014; Bearden et al. 2014; Caraballo et al. 2014; Iyer et al. 
2014; Selioutski et al. 2015; Saade & Joshi 2015; Caraballo et al. 2015; Ohba et al. 2015; 
Møller et al. 2015; Howell et al. 2015; Stödberg et al. 2015; Mikati et al. 2015; Rizzo et al. 
2016b; Mori et al. 2016; Barba et al. 2016; Saitsu et al. 2016; Need et al. 2012; Appavu et 
al. 2016; Caraballo et al. 2016; Segal et al. 2014; Bedoyan et al. 2010; Veneselli et al. 2001). 
I will now discuss the clinical features of EIMFS as revealed in the BPNSU study in relation 
to the current literature (Table 3.2). 
The most frequently reported initial seizure types in the BPNSU series were focal motor 
seizures, accompanied by head and eye deviation. This was also borne out in the published 
cases where 78% presented with focal motor seizures at onset (Table 3.2). In the 
remaining patients, subtle seizures with behavioural arrest, apnoea and cyanosis or 
generalised tonic or tonic-clonic seizures are seen. Over time, all patients in the BPNSU 
study developed focal motor seizures, as reported in the literature (Table 3.2). However, 
many infants with EIMFS may also manifest subtle seizures which are barely noticeable 
clinically, as is the case in other neonatal epilepsies (Plouin & Kaminska 2013).  
Clinically migratory seizures, defined as focal motor seizures affecting alternating sides of 
the body were not seen at onset but later developed in approximately half of our study 
patients. In the cases reported to date, alternating focal motor seizures were reported in 
44.5% of patients. Although this is not a pathognomonic feature, it would be strongly 
suggestive of EIMFS, although differential diagnoses include alternating clonic seizures in 
self-limited familial and non-familial neonatal epilepsies (previously known as benign 
familial/non-familial neonatal seizures) (Panayiotopoulos 2005).  
 Autonomic features such as facial flushing, salivation, apneas and cyanosis were seen in 
the majority of the patients on our study. However, only 50.3% of reported cases describe 
autonomic features (Table 3.2). I actively sought the presence of autonomic features in my 
BPNSU cohort, through direct questions in my proforma (see Appendix). I found the most 
commonly reported autonomic features to be facial flushing followed by hypersalivation, 
whereas apnoea and cyanosis are most frequently described in the literature (Table 3.2). 
Autonomic seizures are a well-described feature of neonatal epilepsies due to diverse 
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aetiologies, including self-limited familial and non-familial neonatal and infantile epilepsies 
(Panayiotopoulos 2005) and temporal lobe seizures in older patients (Jan 2007).  
I also identified two EIMFS patients with infantile spasms associated with hypsarrhythmia. 
There are now 14 reported cases of infantile spasms in patients with EIMFS, of which four 
manifest the EEG correlate of hypsarrhythmia (Coppola et al. 1995; Jocic-Jakubi & Lagae 
2008; Carranza Rojo et al. 2011; Lee et al. 2012; Chien et al. 2012; Caraballo et al. 2015). As 
in our study, infantile spasms have emerged either prior to or after the onset of EIMFS. 
Indeed, one patient presented with early myoclonic encephalopathy associated with 
typical burst suppression on EEG, followed by an EIMFS phenotype which then developed 
into infantile spasms with hypsarrhythmia (Chien et al. 2012). This observation may reflect 
the age-dependent manifestation of the underlying epilepsy aetiology, as is well-
documented in the evolution from Ohtahara syndrome to West syndrome (Ohtahara & 
Yamatogi 2006a).  
The natural history of EIMFS appears to fall into a continuum of three phases. As illustrated 
by the BPNSU study, the early stage is characterised by the onset of seizures at a median of 
seven weeks (range: 4 days to 5 months), similar to that observed in published cases 
(median age of onset 8.5 weeks, mean 6.6 weeks, range one day to nine months of age) 
(Table 3.2). Of note there are four cases reported with disease onset at greater than six 
months but these were accepted as EIMFS as they met the remainder of the diagnostic 
criteria (Coppola et al. 1995; Barcia et al. 2012; De Filippo et al. 2014). Phase two of 
disease is typically characterised by a stormy period with increasing seizure frequency to a 
peak seizure frequency at a median of 16 weeks of age (range: 1 to 40 weeks) with up to 
200 seizures per day. Infants develop either a form of focal status epilepticus or frequent 
clusters of focal seizures. In the third phase, for many patients there is a reduction of 
seizures with time, leading to either survival with continuing but less frequent seizures or 
death. Of the reported cases, 25 have died at between five months and six years of age. 
This is likely to be an underestimate as the majority of published papers are single case 
reports or case series rather than longitudinal or cohort studies. SUDEP is uncommon in 
the literature with four cases reported (Hmaimess et al. 2006; Fasulo et al. 2012; Milh et al. 
2013). The remainder of patients die of respiratory failure, infection, status epilepticus or 
unstated causes. 
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As we reported, the developmental outcome is extremely poor for EIMFS, with all but ten 
of the 186 cases published to date displaying severe developmental delay. However, six of 
the reported patients have achieved independent ambulation (Coppola et al. 1995; Marsh 
et al. 2005; Carranza Rojo et al. 2011; Howell et al. 2015) with normal development before 
and after seizures in one patient (Howell et al. 2015). Unfortunately, in general the best 
developmental stage achieved for most patients is rolling and visual fixation, although 
some patients regain developmental milestones following periods of good seizure control 
(Merdariu et al. 2013; Bearden et al. 2014; Caraballo et al. 2015; Mikati et al. 2015; Mori et 
al. 2016). 
The BPNSU study also highlighted the presence of non-epileptic abnormal movements in 
EIMFS. A spectrum of movement disorders has now been reported in 19 EIMFS patients 
(Table 3.2) with dystonia in seven patients and choreoathetosis in five (Coppola et al. 
1995; Hahn et al. 2007; Cilio et al. 2009; Caraballo et al. 2008; Møller, Heron, et al. 2015; 
Ohba et al. 2014; Ohba et al. 2015; Howell et al. 2015; Barba et al. 2016). Non-epileptic 
movement disorders are increasingly recognized in a number of early onset epileptic 
encephalopathies due to genetic abnormalities, as will be discussed further in Chapter 4.  
The BPNSU study revealed both typical and unusual EEG findings in the EIMFS cohort. 
Inter-ictal EEG can be normal initially but slowing of the background with multi-focal 
abnormalities emerge over time. Ictal discharges are often of theta or alpha frequency and 
are located in the centro-temporal or temporo-occipital regions initially. In general there is 
good electro-clinical correlation with head and eye deviation and eye jerking associated 
with occipital discharges, focal tonic seizures associated with contralateral frontal EEG 
discharges, rolandic changes with contralateral limb clonic seizures and behavioural arrest 
and oral automatisms associated with temporal involvement (Coppola et al. 1995; 
Caraballo et al. 2008). The characteristic migrating ictal focus, where seizure onset will 
appear in one area of the cortex and then wane as independent discharges commence in 
another region (commonly the contralateral hemisphere), may take some time to emerge. 
Although this characteristic EEG appearance is required for the diagnosis of EIMFS, 
migration of ictal foci is described in other neonatal epilepsies, particularly self-limited 
familial neonatal seizures (Wilmshurst et al. 2000). This may be an aetiology-related 
phenomenon, as interestingly, mutations of SCN2A have been identified in both of these 
epilepsies. Fast intra-ictal activation may also be seen in infants with neonatal seizures due 
to a wide range of causes including hypoxic ischaemic encephalopathy (Alix et al. 2016). 
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The pathophysiology of these migrating ictal discharges is unclear. Some have postulated 
that they reflect an abnormally excitable cortex resulting in multifocal discharges. Another 
explanation could be a deficit of interhemispheric inhibition normally mediated by 
transcallosal pathways (Freilich et al. 2011). The occurrence of EIMFS in a patient with 
Aicardi syndrome and an absent corpus callosum might lend weight to this theory (Jocic-
Jakubi & Lagae 2008) but further study is needed.  
Our study also identified hypsarrhythmia, electrodecrement and periods of EEG 
suppression. These are classically features of West syndrome and Ohtahara syndrome 
respectively and again are likely to reflect the continuum of age-related electroclinical 
manifestations of cerebral dysfunction.  
The most commonly reported abnormality on MR imaging of the brain is cerebral atrophy, 
seen in 41.6% of reported cases. The BPNSU study also identified delayed myelination and 
white matter hyperintensity, which has since been noted in further published cases. It has 
been postulated that the cerebral atrophy may result from excitotoxic damage to the 
developing brain due to excessive glutamatergic neurotransmitter activity (Gross-Tsur, 
Varda, Ben-Zeev, Bruria, Shalev, Ruth S 2004).  However, another possibility is a failure of 
normal brain development and growth. This would be supported by the abnormally 
delayed myelination seen in our patients and other reported cases, as well as the acquired 
microcephaly that is frequently seen in EIMFS. We found MRS changes in our patients, also 
in keeping with delayed myelin development and brain maturation as similarly reported in 
three other cases (Gross-Tsur, Varda, Ben-Zeev, Bruria, Shalev, Ruth S 2004; Cilio et al. 
2009; Freilich et al. 2011) although MRS was normal in three other studies (Poduri, Chopra, 
et al. 2012; Chien et al. 2012; Dhamija et al. 2013). The basal ganglia changes identified in 
one of our patients are unusual. Recently, eight of 12 EIMFS patients with de novo SCN2A 
mutations were reported to have a variety of basal ganglia abnormalities on MR imaging, 
including basal ganglia swelling and T1 and T2 hyperintensities of basal ganglia and thalami 
(Howell et al. 2015). These resolved in one patient with time, but were persistent in the 
remainder. Of note Patient 7 was not found to have pathogenic variants of SCN2A on 
whole exome sequencing.   
The treatment of EIMFS is extremely difficult. In our study one of the more effective 
treatments was the ketogenic diet. This has been used in 32 of the reported patients, was 
partially effective in 13 and led to seizure freedom in one patient (Caraballo et al. 2015). 
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Potassium bromide or triple bromides were found to be effective in 16 patients, with three 
patients becoming seizure free (Fasulo et al. 2012; Ünver et al. 2013; Caraballo et al. 2014). 
However significant side effects including bromoderma and excessive sedation were seen 
in two patients (Nabatame et al. 2010; Mori et al. 2016). A wide range of standard 
antiepileptic medications in various combinations have been reported to be useful in 
EIMFS including levetiracetam, rufinamide, stiripentol and clonazepam. Most recently 
cannabinoids have been used with some effect in one patient (Saade & Joshi 2015). 
However, although new treatments may result in early reductions in seizure burden, a lack 
of longitudinal data means that it is difficult to judge the efficacy of these interventions on 
long-term seizure control and outcome.  
Post-mortem data on EIMFS is reported for five patients reported in the literature. In the 
original case series, Coppola described neuronal loss and gliosis in the hippocampal CA1 
region in two patients (Coppola et al. 1995). Microcephaly and low brain weight was noted 
in another patient (Hahn et al. 2007) with a normal post-mortem examination in the fourth 
patient (Wilmshurst et al. 2000). Fasulo et al described several different types of cortical 
malformation in one patient, with polymicrogyria, microscopic cortical features consistent 
with focal cortical dysplasia and neuronal loss in CA1, CA3 and CA4 in keeping with 
hippocampal sclerosis (Fasulo et al. 2012). Bilateral hippocampal damage was seen in both 
patients from the BPNSU study who underwent autopsy. It is unclear whether these 
changes are secondary to the extremely frequent focal seizures or whether there may be a 
pre-existing developmental brain malformation. Indeed, one patient displayed left 
temporal lobe atrophy, hippocampal sclerosis and cortical-subcortical blurring on MRI 
imaging (Coppola et al. 2007). However, this is an unusual case and the majority of 
patients do not have focal MRI abnormalities. One patient in the BPNSU study had 
evidence of marked putaminal injury. This patient underwent extensive metabolic testing 
including muscle and skin biopsies which were unrevealing.  
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 BPNSU cohort Published cases 1995-2017 
Mean/median age  and age range at disease onset 
(weeks) 
10/7, range 4-20 7/9, range 0.1-36 
Mean/median age and age range at peak seizure 
frequency (weeks) 
38/20, range 3-
150* 
17/16, range 1-40 
Number of seizures at peak  9-150 1-200 
Focal motor seizures at onset (%) 15 (100) 135 (78) 
Generalized tonic-clonic seizures (%) 9 (65) 20 (12) 
Head and eye deviation (%) 6 (43) 105 (61) 
Clinically migrating seizures (%) 8 (57) 77 (50) 
Epileptic spasms 2 7 
Autonomic features (%) 12 (86) 87 (50) 
Apnoea/cyanosis 2 73 
Facial flushing 9 57 
Lacrimation 1 4 
Tachycardia 0 2 
Salivation 3 9 
Chewing 0 2 
Hyperthermia 0 2 
Hyperventilation 0 1 
Movement disorder (%) 4 (28) 19 (7) 
Choreoathetosis 1 5 
Dystonia 2 7 
Ataxia 0 2 
Myoclonus 0 1 
Tremor 0 2 
Dyskinesia 1 0 
Hypotonia (%) 8 (57) 117 (42) 
Increased tone/spasticity 3 31 
Developed cerebral atrophy on MRI 7 72 
Deaths  
                SUDEP 
8  
0 
25  
4 
 Table 3.2 Clinical Features of the BPNSU cohort in comparison to 173 reported patients with EIMFS. *in 
those whose seizures reduced with time, median age of peak seizure frequency was 16 weeks (range 3 
weeks to 1 year).  
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When EIMFS was first described, the aetiology was largely unknown and possible 
metabolic, structural and genetic aetiologies were considered. In general, extensive 
metabolic investigations of patients described to date have been unrevealing. However, 
recently four patients with congenital disorder of glycosylation Type 1 (CDG-I) were 
described (Barba et al. 2016). They presented with the electroclinical features of EIMFS in 
addition to a spectrum of multi-systemic involvement including gastro-intestinal problems, 
coagulopathy, dysmorphic facial features and a spastic quadriparesis. MRI brain revealed 
cerebellar atrophy in all four patients, with brainstem atrophy in three. Transferrin 
isoelectric focussing (TIEF) testing was consistent with CDG-I. Although the remaining 12 
patients of this CDG-I cohort did not manifest the clinical features of EIMFS, it would be 
prudent to consider testing TIEF in patients presenting with EIMFS, particularly in those 
with multisystemic features and cerebellar atrophy on MRI. The specific association of 
CDG-I with EIMFS is interesting and further research may provide insights into EIMFS 
pathogenesis. In general, MRI imaging has not revealed structural abnormalities other than 
in one case as described above (Coppola et al. 2007). Whilst structural abnormalities are 
often reported in other electroclinical syndromes such as Ohtahara’s syndrome (Ohtahara 
& Yamatogi 2006b), there is no convincing evidence for an underlying structural aetiology 
in EIMFS patients. 
The first evidence for a possible genetic basis for EIMFS came from the finding of a patient 
with a 16p11.2 duplication, previously associated with autism and epilepsy (Bedoyan et al. 
2010). This finding has not been replicated in other EIMFS patients. Furthermore, 
mutations in genes within this duplicated region have not been reported in EIMFS. 
Although PRRT2 was within the duplicated region, the associated infantile convulsions with 
choreoathetosis (ICCA) phenotype differs from the reported clinical features and is also 
due to haploinsufficiency (Ebrahimi-Fakhari et al. 2015). Therefore, the relevance of this 
duplication is unclear. With the recent explosion in genetic discovery for the early onset 
epilepsies, the genetic basis of EIMFS has now begun to emerge and will be further 
explored in Chapters 4 and 5.  
In conclusion, EIMFS is a rare electroclinical syndrome characterised by onset of frequent 
focal seizures in the first six months of life associated with migrating ictal EEG foci, evolving 
into a severe epileptic and developmental encephalopathy. As demonstrated by both the 
BPNSU study and the reported cases, typical and atypical features are seen, possibly 
representing overlap with other severe electroclinical syndromes such as Ohtahara and 
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West syndromes. Other than the ketogenic diet, response to treatment is poor. It should 
be noted that the accumulated knowledge on EIMFS is based on single case reports or 
small series. The BPNSU study represents a national cohort of patients, but to fully 
understand the natural history, evolution of seizure disorder and developmental 
trajectory, longitudinal data is required. This would necessitate an international patient 
registry collecting prospective patient data following a diagnosis of EIMFS, which could be 
achieved by collaboration between national and international epilepsy or rare disease 
networks. In addition, a longitudinal study with serial EEGs could further delineate the 
evolution of the ictal and inter-ictal abnormalities.  This data would be essential to future 
assessment of the effevts of novel therapies on both sezure frequency and developmental 
outcomes.  As with other electroclinical syndromes, EIMFS likely represents the age-
related manifestation of a range of aetiologies, although these are most likely to be mainly 
genetic in origin, rather than  underlying metabolic or structural causes.  Further 
investigation of the aetiology of EIMFS is essential to understand to attempt to understand 
disease mechanisms amd how these disparate aetiologies may result in a similar 
phenotype, and this will now be explored in the remainder of this thesis.  
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Chapter 4 Heterozygous mutations of KCNT1 in Epilepsy of Infancy 
with Migrating Focal Seizures 
4.1 Introduction 
In 2012, autosomal dominant gain of function mutations of KCNT1 were identified in 
patients with EIMFS (Barcia et al. 2012). KCNT1, also known as KCa4.1, SLACK (sequence 
like a calcium-dependent potassium channel) and Slo2.2, encodes the sodium-activated 
potassium channel responsible for slow hyper-polarisation following action potential 
generation (Kaczmarek 2013). Mutations of KCNT1 have since been identified in a wide 
spectrum of epileptic disorders.  
In order to investigate KCNT1-related epilepsy in my expanded EIMFS cohort, I sought to 
undertake (i) deep endophenotyping to delineate the salient clinical features and (ii) 
molecular genetic investigations by Sanger sequencing of KCNT1 in the research 
laboratory.  
4.2 Methodology  
4.2.1 Patient recruitment:  
Following the BPNSU study during which 14 patients were ascertained, I recruited a further 
20 patients to a research study, resulting in an EIMFS cohort of 34 patients (Chapter 3). 28 
of the total EIMFS cohort (n=34), including 9 from the BPNSU study, were tested for 
mutations in KCNT1 using a variety of different genetic approaches.  I undertook direct 
Sanger sequencing in the research laboratory. NGS multiple gene panel and diagnostic 
microarray and karyotype were taken in local diagnostic molecular genetic laboratories. 
Whole exome sequencing was undertaken at Duke University and I analysed the data as 
described below (Table 4.1, Patients 1,3, 6-9, 11-13, 15-32, 34). Of the remaining 
unscreened six cases, one (Patient 33) was the similarly affected sibling of Patient 32; this 
sibship is further discussed in Chapter 5. For the other 5 patients, either DNA was not 
available for the proband, or parents did not consent to further genetic investigations 
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(Table 4.1). Written informed consent was obtained from families in whom research 
genetic investigations were undertaken. The study was approved by the National Research 
Ethics Service (NRES) (London – Bloomsbury, REC reference: 13/LO/0168, IRAS project ID: 
95005). In order to better understand genotype-phenotype correlations in KCNT1-related 
epilepsy, two additional patients with non-EIMFS presentations (EOEE1 and 2, Table 4.1) in 
whom a KCNT1 mutation was identified on routine local diagnostic multiple gene panel 
testing (n=2) were also included in this study. Anonymised data from patients tested on 
the diagnostic NGS panel (n=2) was collected as part of an approved case note review 
project (Great Ormond Street Hospital Research and Development Department, 16NM11).   
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EIMFS 
Cohort 
Patient No 
Phenotype Screening Method Diagnostic 
chromosomal 
microarray 
Diagnostic 
karyotype Research-
based 
Sanger 
sequencing 
 
NGS 
Diagnostic 
Panel* 
WES 
1 EIMFS + - + - N 
2 EIMFS No DNA 
3 EIMFS + - + - N 
4 EIMFS No DNA 
5 EIMFS No DNA 
6 EIMFS + - - N - 
7 EIMFS + - + N - 
8 EIMFS + - - N - 
9 EIMFS + - + N - 
10 EIMFS No DNA 
11 EIMFS + - - N - 
12 EIMFS + - - - N 
13 EIMFS + - + N - 
14 EIMFS Parents did not consent to further testing 
15 EIMFS + + - - - 
16 EIMFS + - - - N 
17 EIMFS + - - N - 
18 EIMFS - + - N - 
19 EIMFS + - - N - 
20 EIMFS - + - N - 
21 EIMFS - + - N - 
22 EIMFS + - - N - 
23 EIMFS + - - N - 
24 EIMFS + - - N - 
25 EIMFS + - - N - 
26 EIMFS + - - N - 
27 EIMFS + - - N - 
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28 EIMFS + + - 11.8 Mb 
heterozygous 
deletion  
Chr 20q11 
copy number 
variant of 
uncertain 
significance 
- 
29 EIMFS - + - N - 
30 EIMFS - + - N - 
31 EIMFS - + - N  
32 EIMFS - - + N  
33# EIMFS - - - N - 
34 EIMFS - - + N - 
EOEE1 NFLE-like - + - 2.4Mb 
heterozygous 
duplication 
Chr 15q14 
Inherited 
from mother 
- 
EOEE2 NFLE-like - + - N - 
Table 4.1 Summary of genetic investigation for KCNT1 mutations in the EIMFS cohort and 
in two patients with early onset epilepsy. EIMFS epilepsy of infancy with migrating focal 
seizures, N normal, NFLE nocturnal frontal lobe epilepsy, NGS next generation sequencing, 
WES whole exome sequencing. * Patients 6-9, 12 and 13 had NGS panel testing which did 
not include KCNT1 (Table 3.1). # Patient 33 had direct sequencing of SLC12A5 only as he is 
the affected sibling of Patient 32 (Chapter 5).  
4.2.2 PCR sequencing 
All annotations are as described in the NCBI GRCh37.p13 build. The DNA template for the 
longest protein-coding transcript of KCNT1 (ENST00000298480.5) located at Chromosome 
9: 138,594,031–138,684,992 was obtained from the Ensembl genome browser. Primer3 
(http://fokker.wi.mit.edu/primer3/input.html) was used to design primers (as described in 
Methods 2.3.3) to cover all exons and exon-intron boundaries of KCNT1, ensuring 
coverage across all nine protein-coding transcripts (Table 4.2). Where Primer3 could not 
successfully generate an appropriate oligonucleotide, primers were designed manually. 
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Transcript number Primer  Primer Sequence Annealing 
temperature 
0C 
GC rich solution Product size 
202 002 001 201 004 005 007 006 010 
1F 1F 1F       1F aacgcgagggaagaaggt 60 - 243 
1R 1R 1R       1R ggaacttgggggtcttaggt    
   1bF 1bF 1bF  1bF  1bF cgggtgcttgaaccttctc 58 - 499 
   1bR 1bR 1bR  1bR  1bR gtgggcttaggaggggagac    
2F 2F     1F  1F 2dF atgacagctcccgtccc 62 yes 585 
2R 2R     1R  1R 2dR gaagccgggaaaagttgaag    
   2bF  2bF 2bF 2bF  2bF ccatctgtctgtctactgcc 58 - 215 
   2bR  2bR 2bR 2bR  2bR gctctcacacctctaagagc    
3F 3F 2F 3F 2F 3F 3F 3F 2F 3F cagttggaaagttggaagaagtc      60 - 358 
3R 3R 2R 3R 2R 3R 3R 3R 2R 3R gtctcagacagtgtgaagctaag    
4F 4F 3F 4F 3F 4F 4F 4F 3F 4F cagagagcccagccagac 60 - 346 
4R 4R 3R 4R 3R 4R 4R 4R 3R 4R ctttttccatcctgggacag    
5F 5F 4F 5F 4F 5F 5F 5F 4F 5F cttgtctcccaggtgttagagct 60 - 552 
5R 5R 4R 5R 4R 5R 5R 5R 4R 5R aactggctgggaactcacaat    
6F 6F 5F 6F 5F 6F 6F 6F 5F 6F agtggaggccaatggttatg 60 yes 396 
6R 6R 5R 6R 5R 6R 6R 6R 5R 6R gctcactgagttggagtcacc    
7F 7F 6F 7F 6F 7F 7F 7F 6F 7F ctggctttgtgtggtacctg 60 yes 242 
7R 7R 6R 7R 6R 7R 7R 7R 6R 7R gagagggtgggggaggtg    
8F 8F 7F 8F 7F 8F 8F 8F 7F 8/9F acttcccagcctcatccac 60 - 475 
8R 8R 7R 8R 7R 8R 8R 8R 7R 8/9R cggtcctctacaggtcatgc    
9F 9F 8F 9F 8F 9F 9F 9F 8F 8/9F acttcccagcctcatccac 60 - 475 
  
104 
 
9R 9R 8R 9R 8R 9R 9R 9R 8R 8/9R cggtcctctacaggtcatgc    
10F 10F 9F 10F 9F 10F 10F 10F 9F 10F cgtctgctttccactgtcct 60 - 291 
10R 10R 9R 10R 9R 10R 10R 10R 9R 10R ccgatagcttggacataggc    
11F 11F 10F 11F 10F 11F 11F 11F 10F 11F ctggtgatgcacagctcagt 62 - 378 
11R 11R 10R 11R 10R 11R 11R 11R 10R 11R agtggcaccctccctctact    
12F 12F 11F 12F 11F 12F 12F 12F  12F ggcccctaacagacagtcg 60 - 400 
12R 12R 11R 12R 11R 12R 12R 12R  12R gaggcatctgccctcact    
13F 13F 12F 13F 12F 13F 13F 13F  13F gtgggcacaaacacagtcc 60 - 287 
13R 13R 12R 13R 12R 13R 13R 13R  13R tgagcagccgacctgact    
14F 14F 13F 14F 13F 14F 14F 14F  14bF ctccacccacgctcag 60 yes 179 
14R 14R 13R 14R 13R 14R 14R 14R  14R ggcaggtctcttccctcag    
15F 15F 14F 15F 14F 15F 15F 15F  15cF agcccgtctgcact 58 yes 251 
15R 15R 14R 15R 14R 15R 15R 15R  15bR caccatcacccaacagcat    
16F 16F 15F 16F 15F 16F 16F 16F  16F gcaccttcaggaagtgagca 60 - 294 
16R 16R 15R 16R 15R 16R 16R 16R  16R ctcctctgggaagcccatc    
17F 17F 16F 17F 16F 17F 17F 17F  17F ggcaaaagtcctgcataggg 60 - 338 
17R 17R 16R 17R 16R 17R 17R 17R  17R gagggcacagagcagagc    
18F 18F 17F 18F 17F 18F 18F 18F  18bF gactctggtgatttgcaggaa 60 - 384 
18R 18R 17R 18R 17R 18R 18R 18R  18bR ctggtctcccgccaaag    
19F 19F 18F 19F 18F 19F 19F 19F  19F tcacctgagctctgggaact 60 - 394 
19R 19R 18R 19R 18R 19R 19R 19R  19R accaaggatgctccgacac    
20F 20F 19F 20F 19F 20F 20F 20F  20bF tgtgcagctgtgctgag 59 - 220 
20R 20R 19R 20R 19R 20R 20R 20R  20R gagaaaccagggcaggtatg    
21F 21F 20F 21F 20F 21F 21F 21F  21F gtggccagcaggaaccac 62 yes 288 
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21R 21R 20R 21R 20R 21R 21R 21R  21R ctggctgcaggtctgagg    
22F 22F 21F 22F 21F 22F 22F 22F  22F ctctgtgcatggagggtagg 60 - 234 
22R 22R 21R 22R 21R 22R 22R 22R  22R caccccagactttggaagag    
23F 23F 22F 23F 22F 23F 23F 23F  23F gtcctgtgggtggggagt 60 - 238 
23R 23R 22R 23R 22R 23R 23R 23R  23bR gggcttgtggtcatagctg    
24F 24F 23F 24F 23F 24F 24F 24F  24cF accctgagagtcccacagccatga 60 yes 234 
24R 24R 23R 24R 23R 24R 24R 24R  24cR tttccctgaccgcgtgtgaggcact    
25F 25F 24F 25F 24F 25F 25F 25F  25F tgtacggtgcacacacagt 60 - 215 
25R 25R 24R 25R 24R 25R 25R 25R  25R ggagtcctatcattcagaac    
26F 26F 25F 26F 25F 26F 26F 26F  26fB agaaaaggcctcccagaactctgcc 55 yes 332 
26R 26R 25R 26R 25R 26R 26R 26R  26R agagcctcctggccaccgtgaatca    
27F 27F 26F 27F 26F 27F 27F 27F  27bF agccaactcagggttcc 60 - 381 
27R 27R 26R 27R 26R 27R 27R 27R  27R atctagcccaggtccctgac    
28F 28F 27F 28F 27F 28F 28F 28F  28F ctaagcatgttccgtgcaga 60 - 189 
28R 28R 27R 28R 27R 28R 28R 28R  28R ctggcaggcttctccatgt    
29F 29F 28F 29F 28F 29F 29F 29F  29F gagcccacacctcttcctaa TD - 566 
29R 29R 28R 29R 28R 29R 29R 29R  29.2Rb ccgactgttcttggctgtg    
30F 30F 29F 30F 29F 30F 30F 30F  30F gcacctcgcttgctgatatt 60 - 241 
30R 30R 29R 30R 29R 30R 30R 30R  30R ctcacagctcctgtccacct    
31F 31F 30F 31F 30F 31F 31F 31F  31F atgaggtgctggagcagaat 60 yes 299 
31R 31R 30R 31R 30R 31R 31R 31R  31R gtgcctgtggcctcatct    
32F  31F  31F 32F 32F 32F  32F gggcactggggagatgag 60 - 293 
32R  31R  31R 32R 32R 32R  32R ctcctccacgtccttcctg    
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Table 4.2 Primer coverage and PCR conditions for Sanger sequencing of KCNT1. TD touchdown PCR: 950C 5 minutes; 8 cycles of (950C 30 seconds, 
600C 30 seconds, 720C 1 minute); 20 cycles of (950C 30 seconds, 600C 30 seconds [decreasing by 0.50C each cycle], 720C 1 minute); 15 cycles of 
(950C 30 seconds, 500C 30 seconds, 720C 1 minute); 720C 5 minutes  
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To optimize primer PCR conditions (see Chapter 2), I initially trialled primers with control 
DNA at 600C and a standard thermocycling regime of 950C for 5 minutes; 40 cycles of 950C 
for 45 seconds, 600C for 45 seconds 720C for 1 minute; followed by 720C for 5 minutes. 
These conditions were effective for the majority of the primer pairs but some required 
alterations in annealing temperature and/or use of a GC-rich reaction buffer (Table 4.2). 
Touchdown PCR (see Methods 2.3.3) was required for exon 29.  
Following successful PCR amplification, I sequenced PCR products using the primers 
detailed in Table 4.2 and the methods described in Chapter 2.3.5. I analysed sequencing 
data was analysed using Chromas (Technelysium Pty Ltd, Australia) or Sequencher 
(GeneCodes Corporation, USA) software.  
4.2.3 Next generation sequencing panel 
Eight patients from the EIMFS cohort and two patients with EOEE (Table 4.1) were tested 
for KCNT1 mutations by the Great Ormond Street Hospital Regional Genetics laboratory 
using their in-house diagnostic next generation sequencing panel (see Appendix).  
4.2.4 Whole exome sequencing 
Whole exome sequencing was performed in collaboration with Professor Ann Poduri, 
Harvard Medical School, Boston, USA and Dr Erin Heinzen, Duke University, North Carolina, 
USA (see Appendix). I then took a candidate gene approach to interrogate the filtered data 
for mutations in previously reported EIMFS genes (Table 1.2).  
4.2.5 Protein homology modelling 
In order to better understand the effects of mutant KCNT1 on protein structure-function 
properties, protein homology modelling was undertaken by Dr Maya Topf and Dr Sony 
Malhotra from the Institute of Structural and Molecular Biology, Birkbeck College, 
University of London, UK (see Appendix).  
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4.2.6 Electrophysiology in a xenopus oocyte model 
In order to investigate the effects of mutant KCNT1 on potassium channel function, 
electrophysiology experiments were undertaken by Dr Umesh Nair and Dr Steve Petrou, 
Florey Institute of Neuroscience and Mental Health, Melbourne, Australia. Methods are 
described in detail in the Appendix. In brief, variants were introduced into a wild-type 
human KCNT1 expression construct using in situ mutagenesis. Xenopus laevis oocytes were 
transfected with either wild type or mutant cRNA and whole cell patch clamping 
performed, both before and after the application of Quinidine. Of note, KCNT1 subunits 
form either homotetramers, or heterotetramers with KCNT2 in vivo. As xenopus oocytes do 
not have endogenous KCNT1 or KCNT2 expression, it expected that channels formed in this 
over-expression system would be KCNT1 homotetramers.  
4.3 Results 
Of the 30 patients tested, heterozygous KCNT1 mutations were identified in 12.  Five were 
detected through direct Sanger sequencing alone, two on whole exome sequencing and 
five from the Great Ormond Street Hospital diagnostic multiple gene panel. Of note in the 
two patients diagnosed by WES and in one of the panel diagnosed patients, Sanger 
sequencing of the entire KCNT1 gene was also performed (Table 4.1). 
4.3.1 Clinical features of KCNT1-EIMFS 
Clinical features for Patients 1,3 and 6 were briefly described in Chapter 3. Considering the 
KCNT1-positive patients as a group, the median age of seizure onset was 3.5 weeks, with a 
range of one day to six months. The majority of patients, as expected, had seizure 
semiology consistent with EIMFS as discussed in Chapter 3.  Two of the 12 patients (EOEE1 
and EOEE2, Table 4.3) presented with severe, early onset nocturnal frontal lobe epilepsy, 
characterized by asymmetric tonic posturing and later fencing posture. These two patients 
had presented with early onset epilepsy and were referred for testing on the GOSH EIEE 
panel. Similar frontal seizure semiology was also noted in some EIMFS patients (Patients 
1,6,16,17, 21). All patients developed marked axial hypotonia and three patients displayed 
pyramidal motor features. A choreiform movement disorder (onset 14-24 months) was 
seen in four patients (also discussed for Patient 6 in Chapter 3); one developed generalised 
dystonia at 18 months. The onset of the hyperkinetic movement disorder did not appear to 
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be related to medication (including Vigabatrin) or intercurrent illness. All patients had 
normal 12-lead electrocardiograms, but no patients underwent more extensive cardiac 
testing. All patients were extensively investigated for an underlying metabolic or structural 
aetiology for their epilepsy and these tests were unrevealing in most patients. However, 
abnormal muscle respiratory chain enzyme activity for complex I and/or II was detected in 
Patients 6 and 16 of uncertain significance (Table 4.4).  In Patient 6 a routine muscle biopsy 
revealed borderline abnormalities in Complex I and II ratios (as discussed in Chapter 3). The 
muscle biopsy in Patient 16, was taken during an intercurrent illness, revealing Complex I 
deficiency. This was repeated following clinical recovery, with a more borderline result. 
Notably, neither patient had any other systemic, biochemical or radiological indicators of 
mitochondrial disease nor concurrent Sodium Valproate treatment. In general, the majority 
of EIMFS patients had a poor neurodevelopmental outcome. All patients had a trial of at 
least five different medications (Table 4.3), though seizures remained intractable to most 
medical interventions. Eight patients with KCNT1 mutations received the ketogenic diet in 
combination with other anti-epileptic drugs. Three responded with approximately 75% 
seizure reduction. Three patients were treated with quinidine based on early reports of 
therapeutic benefit (Bearden et al. 2014). Patient 15 tolerated 40mg/kg/day without 
adverse events (prior to the in vitro data being available), but no effect on seizure burden 
was noted. Patient 17 was treated with Quinidine at 30mg/kg/day and had a marked 
reduction in seizure frequency. Patient 18 showed some initial reduction in seizure 
frequency at 30mg/kg/day, but this effect was transient. For this patient, the unexpected 
development of a severe proliferative pulmonary and mediastinal vasculopathy resulted in 
life-threatening pulmonary haemorrhage. Investigations failed to identify an underlying 
vasculitis and quinidine was subsequently withdrawn. The patient later died despite initial 
successful pulmonary embolization. 
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EIMFS 
Patient 
Cohort 
No 
Electroclinical 
syndrome 
Age of 
onset 
Initial seizure type Subsequent 
seizure types 
Autonomic 
features 
Movement 
disorder (age 
at onset) 
Additional 
features 
Best 
developmental 
stage attained 
Effective 
anti-
epileptic 
treatments 
1 EIMFS 2 weeks HV, eye jerking, oral 
automatisms, FM upper 
limbs 
Asymmetric tonic 
posturing, My, GTCS 
Facial flushing - - No developmental 
milestones achieved 
None 
3 EIMFS 2 weeks HV, ED, vocalisation TS with adversive 
component 
Facial flushing, 
pupillary 
dilation  
- Gastrointestinal 
dysmotility 
Partial head control, 
smiling 
Nitrazepam at 
5 months 
6 EIMFS 4 weeks HV, ED, fisting of hands Asymmetric tonic 
posturing, ED, oral 
9automatisms 
Facial flushing 
 
Limb dystonia 
and severe 
scoliosis (18 
months) 
Peripheral 
hypertonia  
Babbling, some degree 
of head control 
Steroids and 
KD in 
combination 
at 7-12 
months 
15 EIMFS Day 1 HV, ED and jerking, TS 
upper limbs  
FM seizures of face and 
arm 
- - - No developmental 
milestones achieved 
None 
(including 
quinidine) 
16 EIMFS 7 weeks Exaggerated startle, reflex 
warm water clonic/My, 
evolved to HV and ED, 
tonic posturing upper 
limbs, FM all limbs 
Rapid alternating ED, 
facial grimacing leading 
to airway obstruction  
Drooling, 
salivation, 
apneas 
Hyperkinetic 
movement 
disorder 
affecting upper 
limbs (18 
months) 
Coarse facial 
features, gum 
hypertrophy  
Normal development 
until 10 weeks, then 
regression with loss of 
social smile and head 
control 
None 
17 EIMFS 3 
months 
Behavioural arrest, 
staring, upward eye 
rolling, HV and ED to 
either side, asymmetric 
tonic posturing and 
elevation of limbs  
Flexor spasms involving 
the trunk, clonic 
seizures of limbs, eyelid 
twitching, gelastic 
seizures 
 Hyperkinetic 
movement 
disorder 
involving head 
and all limbs (18 
months) 
Cleft of hard palate Early social smile and 
visual interaction, lost 
after onset of epilepsy 
Ketogenic 
diet with 
Vigabatrin, 
effect later 
lost 
Quinidine- 
effective 
18 EIMFS 2 weeks Brief FM all limbs 
(twitching) 
HV, dystonic posturing 
upper limbs, ED and 
jerking 
Facial flushing, 
noisy 
breathing 
Hyperkinetic 
movements 
perioral muscles, 
Systemic 
proliferative 
vasculopathy of 
No developmental 
milestones achieved 
None (some 
initial 
response to 
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tongue, hand 
and wrists (2 
years) 
pulmonary and 
mediastinal vessels   
quinidine) 
19 EIMFS 5 
months 
HV, TS TS, gelastic seizures - Hyperkinetic 
movement 
disorder (14 
months) 
- Normal until seizure 
onset, (smile and head 
control), regression at 5 
months with no further 
development 
None 
20 EIMFS 3 weeks HV, ED with pupil jerking, 
FM arm and face, oral 
automatisms 
HV, ED12, drooling, TS 
upper limbs, FM upper 
limbs 
Facial flushing - - Smiling, visual 
awareness, some head 
control, rolling 
Stiripentol, 
levetiracetam 
and 
clonazepam 
in 
combination 
21 EIMFS 3 weeks ED with eye flickering, HV, 
TS upper limbs 
FM upper and lower 
limbs with lip smacking, 
hand fisting, HV and ED, 
fencing posture of arm  
 
Facial flushing - - Social smile and 
reaching for objects until 
regression and loss of 
these skills at 5 months   
KD and 
lacosamide in 
combination 
EOEE1 NFLE 6 
months 
Predominantly nocturnal, 
asymmetric tonic 
posturing  
ED, choking noises, 
fencing posture, brief 
generalised TS and 
GTCS 
 
Facial flushing - Right sided neglect, 
increased tone on 
right side, peripheral 
hyperreflexia in 
lower limbs 
Grasps objects and 
standing briefly at 2.5 
years, vocalising and 
babbling  
None resulted 
in seizure 
freedom 
EOEE2 NFLE 8 weeks Focal motor seizures 
hands, ED and jerking, TS 
upper limb and FM 
contralateral lower limb 
Seizures only in sleep 
Stopped at 4-5 months 
From 11 months: GT 
with fist clenching, ED, 
asymmetric tonic 
posturing, mainly from 
sleep 
- - Right sided 
weakness with 
peripheral 
hyperreflexia  
Walking prior to 
regression at 11 months, 
best subsequent stage 
sitting independently 
No sustained 
response 
Table 4.3 Clinical features of patients with KCNT1 mutations ED eye deviation, EIMFS epilepsy of infancy with migrating focal seizures, FM focal motor, 
GTCS generalised tonic-clonic seizures, HV head version, KD ketogenic diet, My myoclonic seizures, NFLE nocturnal frontal lobe epilepsy, TS tonic seizures. 
Adapted from McTague et al Neurology 2018 Jan 2;90(1):e55-e66. 
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 Patient 6 Patient 16 
Muscle Biopsy Normal 2014: slight 
prominence of 
intermyofibrillar 
mitochondria 
2016: Coarse clumps 
of mitochondria 
suggesting 
mitochondrial 
abnormality 
Respiratory 
chain 
enzymes 
Complex I ratio: 0.077 
(normal range 0.104-
0.268) 
Complex II ratio: 0.029 
(normal range 0.040-
0.204) 
2014: Complex I 
68.6nmol/min/UCS 
2016: Complex I 84.5 
nmol/min/UCS 
(normal range>94.17) 
POLG 
sequencing 
Normal Normal 
Mitochondrial 
common 
deletions 
Normal Not done 
Whole 
Mitochondrial 
Genome 
sequencing 
Normal Not done 
Table 4.4 Mitochondrial investigations in Patients 4 and 8. UCS units of citrate synthase. 
Adapted from McTague et al Neurology 2018 Jan 2;90(1):e55-e66. 
4.3.2 EEG findings 
All patients with an EIMFS phenotype had a “migrating” ictal focus with discrete ictal 
involvement of differing cortical areas within the same EEG (Table 4.5) as discussed in 
Chapter 3. Although this was not always evident at initial presentation, it emerged by 7 
months of age in most patients. Periods of EEG suppression or burst suppression were 
noted in 8/10 EIMFS patients with KCNT1 mutations. Of note, six of these had seizure onset 
in the first four weeks of life. Further atypical EEG features included a generalised 
electrodecremental response in five patients and hypsarrhythmia in one case (Figure 4-1).  
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Patient
Cohort 
No 
Age at 
1st EEG 
Features on initial EEG Suppression (age) Further EEG evolution  Atypical EEG features (age) 
Ictal Interictal 
1 4 w MIF Slow background, MF 
Sh/SW 
Inter-ictal suppression 
(6 weeks) 
- Brief ED (4 weeks)  
Atypical hyps (6 months) 
3 3 w L temporal ictal focus 
 
MF Sh/SW and slowing - MIF (4 months) - 
6 2 m L or R temporal ictal foci 
with theta/alpha 
discharges 
 
Independent MF Sh over the 
post-central regions 
Asynchronous BS (7 
months)  
MIF (7 months) ED (7.5 months) 
15 1 m MIF MF Sh/SW Brief periods of 
suppression (1 month) 
- - 
16 5 m Onset left OL but also 
independently within the 
right OL, spreading 
anteriorly/to the CL 
hemisphere 
Frequent bilateral 
independent spike wave 
discharges in posterior 
temporal regions 
Post-ictal suppression 
(6 months) 
MIF at 6 months - 
17 4 m Continuous focal 
epileptiform activity 
(rhythmic theta) arising 
from either hemisphere 
Diffuse background slowing - MIF at 4.5 months ED at 7 months 
Bilateral asymmetric tonic 
posturing with frontal ictal 
theta activity at 15 months  
18 2 m Rhythmic delta left 
parietal 
Slow background, MF 
Sh/SW 
Asynchronous BS (2 
months) 
MIF at 3 months ED at 2 months   
19 5 m Right mid-temporal region 
Sp-SW complexes, 
subsequent seizure arising 
from left temporal region 
Runs of discrete Sp-SW R 
temporo- parietal regions, 
and independently L 
parieto-occipital region  
Brief ictal suppression 
(15 months) 
MIF noted at 14 months - 
20 1 m Initial suppression 
followed by focal seizure 
MF Sp/Sh and SW Ictal suppression (1 
month and 7 months 
MIF (7 months) - 
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with tonic seizure) 
21 1 m No ictal features MF Sp/Sh and SW Inter-ictal suppression 
(from 1 month, still 
seen at 7 months) 
MIF  5 months) ED (2 months) 
EOEE1 6 m Onset right anterior 
quadrant  
Asymmetric right sided 
slowing 
- MF Sh/SW. Left frontal or 
posterior ictal onset (12 
months)  
- 
EOEE2 2 m Information unavailable - - MF anterior independent 
asymmetric Sh 
Ictal focus R mid-temporal 
at 3 years and L mid-
temporal at 11 years  
- 
 
 
 
 
Table 4.5 EEG features in 12 patients with KCNT1 mutations BS burst suppression, ED electrodecrement, hyps hypsarrhythmia, L left, m months, MIF 
migrating ictal focus, MF multifocal w weeks, OL occipital lobe, R right, Sh sharp waves, Sp spikes, SW slow waves. Adapted from McTague et al 
Neurology 2018 Jan 2;90(1):e55-e66. 
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Figure 4-1 Left sided post-ictal suppression at 6 months of age in Patient 16. Suppression 
indicated by red box.  
4.3.3 MRI findings 
Neuroimaging was available in 11/12 patients and was reviewed with Dr Kling Chong, 
consultant neuroradiologist, Great Ormond Street Children’s Hospital. Note Patients 1, 3 
and 6 were also discussed in Chapter 3. The majority developed cerebral atrophy by three 
years of age, with predominantly frontal involvement (Figure 4-2, Table 4.6). Cerebellar 
atrophy was also evident in four patients (Figure 4-2c). An open operculum was evident in 
the first six months of life in Patient 16 (Figure 4-2b). Delayed myelination was evident in 
9/11 patients (including Patients 3 and 6) who had imaging after three months of age. In 
some patients, early brain imaging undertaken under five months of age was normal. 
Magnetic resonance spectroscopy was abnormal with a relatively reduced N-acetylcholine 
peak in 3/4 patients (including Patients 1 and 3 as described in Chapter 3) in whom this 
investigation was undertaken.  
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Figure 4-2 MRI features in KCNT1-related epilepsy  
4-2a: Coronal(left) and axial (right) T2 weighted images in Patient 15 at 10 months of age 
reveal severely delayed myelination (yellow arrowhead), volume loss and frontal 
predominant atrophy(yellow arrows) with plagio/dolichocephaly. 4-2b: Axial T2 weighted 
images in Patient 16 at 5 months of age show abnormally open operculum (black arrows) 
with lack of brain development. 4-2c: Coronal T2 weighted images with cerebellar atrophy 
indicated by prominent cerebellar foliae (green arrows) in Patient EOEE2 at 8 years of age. 
Adapted from McTague et al Neurology 2018 Jan 2;90(1):e55-e66. 
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Patient 
Cohort No 
Age at imaging MRI MRS 
1 31 days WNL - 
4 months Dolicocephaly; DM Relative 
choline 
elevation 
and NAA 
reduction 
3 
 
11 weeks DM Low NAA  
3 years DM and global CA  
6 
 
9 weeks DM - 
4 months DM - 
2 years Very little myelination maturation after 6-8 months 
with decreased white matter volume, volume 
loss/CA 
- 
15 10 weeks DM already apparent, underdeveloped FL, slim CC - 
10 months Plagio and dolicocephaly, severe volume loss/CA, 
fronto-temporal worse than parieto-occipital, thin 
corpus callosum 
 
16 4 months Underdevelopment of frontal and temporal lobes 
and cerebellum 
Normal 
5 months Abnormally open operculum, CA/lack of brain 
development 
- 
17 3 months WNL - 
18 
 
10 weeks WNL - 
10 months DM, CA and cerebellar atrophy  
19 5 months DM - 
20 23 days WNL - 
21 
 
7 weeks WNL Relative 
NAA 
reduction 
5 months WNL - 
6 months Marked CA /volume loss, cerebellar atrophy - 
8 months Worsened CA & DM - 
1 year Further atrophy with left subdural effusion, 
cerebellar atrophy & DM 
- 
EOEE1 5 months WNL - 
 18 months DM 
 
- 
 3 years DM (18/12 stage), CA, cerebellar atrophy - 
EOEE2 2 years WNL - 
 5 years 
 
Global CA and cerebellar atrophy 
 
- 
 8 years Progression of CA, cerebellar atrophy, DM - 
Table 4.6 Radiological features of patients with KCNT1 mutations. CA cerebral atrophy, CC 
corpus callosum, DM delayed myelination, FL frontal lobe, WNL within normal limits. 
Adapted from McTague et al Neurology 2018 Jan 2;90(1):e55-e66. 
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4.3.4 Molecular genetic findings 
12 patients with missense mutations in KCNT1 were identified; eight of these have been 
previously reported and four are novel unreported mutations (McTague et al. 2013; Ishii et 
al. 2013; Ohba et al. 2015; Møller, Heron, et al. 2015; Hildebrand et al. 2016) (Table 4.7). 
8/12 patients had variants located in the carboxy terminus, of which five had the A934T 
variant, reported in multiple cases. Of these five cases, four had an EIMFS presentation and 
one (Patient EOEE2) had a NFLE-like phenotype. In addition, I identified a total of four 
(including two previously unreported) variants around transmembrane (TM) domains 5 and 
6 (V271F, L274I, G288S and F346L).  
In order to determine the potential effect of identified missense variants, I undertook 
pathogenicity predictions using a variety of in silico tools. Polyphen2 scores variants based 
on both phylogenetic, sequence-based and structural features integrating predictions on 
the impact of the variant on protein structure and function (Adzhubei et al. 2010). The 
Sorting Tolerant from Intolerant (SIFT) score uses sequence-based homology data to assess 
pathogenicity based on conservation and the tolerance of that residue to substitution, with 
changes at highly-conserved residues scored as deleterious(Ng & Henikoff 2001). The 
Protein Variant Effect Analyzer (Provean) tool uses multiple protein sequence alignments 
to assess the impact of a change in sequence homology amino acid variation to the query 
sequence(Choi et al. 2012). While each of these tools has advantages, they tend to use a 
single measure such as sequence alteration based on conservation or protein structure and 
are not directly comparable. As a result, tools which integrate multiple annotations of 
variant effects such as the Combined Annotation Dependent Depletion (CADD) tool have 
been developed. CADD enables calculation of a single score for deleteriousness (Kircher et 
al. 2014) by comparing the combined predictions for simulated variants with those of fixed 
or nearly-fixed alleles in humans i.e. those which have survived natural selection. Using a 
combination of these methods, the majority of the KCNT1 variants are predicted to be 
pathogenic (Table 4.7). F346L has a CADD score of 14 and is only predicted to be 
pathogenic on one tool, Provean.  All variants including F346L affect highly conserved 
amino acid residues (Figure 4-3). They are not reported in databases of normal genetic 
variation including 1000 Genomes, the ExAC database, the Exome Variant Server or the 
gnomAD database (see Appendix for websites).  
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For 9/12 cases variants occurred de novo (Patients 3,6,15,16,18,20,21, EOEE1 and EOEE2). 
Parental DNA was not available in Patient 1. For Patient 17, the same KCNT1 variant was 
found in an asymptomatic mother. A lower heterozygous peak was noted on Sanger 
sequencing of both salivary and blood-derived maternal genomic DNA (Figure 4-4). In 
Patient 19, the variant was inherited from an unaffected father with no difference in peak 
size on Sanger sequencing (Figure 4-5). The recurrent A934T variant was identified in five 
patients, four with a EIMFS presentation and one (EOEE2) with a NFLE phenotype.  
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Table 4.7 KCNT1 mutations identified in 12 patients. 1000G 1000 genomes database, B benign, CADD Combined Annotation Dependent Depletion, CDS coding 
sequence, D damaging, Del deleterious, EVS exome variant server, ExAC Exome Aggregation consortium, gnomAD Genome Aggregation database, N neutral, 
Patient 
Cohort 
No 
CDS 
 
Protein 
change 
PP2 SIFT 
(<0.05) 
Provean 
(<-2.5) 
CADD 
(scaled) 
In ExAC, 
1000G, EVS, 
gnomAD 
Inheritance Previous functional 
validation? 
1 c.811G>T  V271F 0.773 PD 0.092 T -3.29 
Del 
23.0 No Unknown (parental DNA not 
available) 
Gain of function 
(McTague et al. 2013; Q.-
Y. Tang et al. 2016)  
 
15 c.820C>A  L274I 0.947 PD 0.002 D -1.76 N 28.7 No De novo No 
EOEE1 c.862G>A  G288S 0.978 
PrD 
0.086 T -5.27 
Del 
24.8 No De novo Gain of function 
(Kim et al. 2014; Ohba et 
al. 2015; Møller, Heron, 
et al. 2015; Rizzo et al. 
2016b; Q.-Y. Tang et al. 
2016; Arai-Ichinoi et al. 
2015) 
16 c.1038C>G  F346L 0.043 B 0.341 T -3.62 
Del 
14.44 No De novo No 
17 c.1504T>G  F502V 0.051 B 0.004 D -6.29 
Del 
23.6 No Maternal inheritance, likely 
somatic mosaicism 
No 
18 c.2687T>A  M896K 0.978 
PrD 
0.001 D -4.82 
Del 
29.2 No De novo No 
7 c.2800G>A A934T 0.602 PD 0.064 T -2.51 
Del 
23.6 No De novo Gain of function 
(Barcia et al. 2012; 
McTague et al. 2013; Kim 
et al. 2014; Ohba et al. 
2015; Milligan et al. 
2014) 
 
3 c.2800G>A A934T 0.602 PD 0.064 T -2.51 
Del 
23.6 No De novo 
20 c.2800G>A A934T 0.602 PD 0.064 T -2.51 
Del 
23.6 No De novo 
EOEE2 c.2800G>A A934T 0.602 PD 0.064 T -2.51 
Del 
23.6 No De novo 
21 c.2800G>A A934T 0.602 PD 0.064 T -2.51 
Del 
23.6 No De novo 
19 c.2849G>A  R950Q 0.941 PD 0.012 D -2.95 
Del 
23.6 No Paternally inherited No 
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NGSP next generation sequencing panel, PD possibly damaging, PP2 Polyphen2, PrD probably damaging, SS sanger sequencing, T tolerated, WES whole exome 
sequencing. Adapted from McTague et al Neurology 2018 Jan 2;90(1):e55-e66. 
 
 
Figure 4-3 Conservation of amino acid residues affected by novel variants. Schematic drawing of the 31 exons of KCNT1 with multiple protein 
alignments from different species (H. sapiens, P. troglydytes, M. mulatta, C. lupus, B. taurus, M. musculus, R. norvegicus, G. gallus, D. rerio, D. 
melanogaster, A. gambiae, C. elegans, X. tropicalis). The residues involved in the five novel mutations (F271 and L274, F346, F502 and M896) are 
highly conserved throughout species. Adapted from McTague et al Neurology 2018 Jan 2;90(1):e55-e66. 
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Figure 4-4 Evidence of possible maternal mosaicism for Patient 17. A lower heterozygous 
peak for variant 1504T>G, F502V is evident in both maternal lymphocytic and salivary DNA. 
Adapted from McTague et al Neurology 2018 Jan 2;90(1):e55-e66. 
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Figure 4-5 Evidence of parental inheritance for Patient 19. The mutation c.2849G>A, 
R950Q in Patient 19 is paternally inherited. Adapted from McTague et al Neurology 2018 
Jan 2;90(1):e55-e66. 
4.3.5 Protein homology modelling 
To further understand how the identified previously unreported missense variants could 
impact on protein structure, homology modelling was performed by Dr Sony Malhotra and 
Dr Maya Topf. Due to availability of homologous sequences, only two of the novel variants 
were amenable to modelling, F346L, located in the ion-channel domain (residues 270-353) 
and F502V, located in the gating region (residues 373-1174. F346 is located on the inner 
helix (Figure 4-6a, b) within the ion channel transmembrane domain (residues 270-353 that 
form the transmembrane pore region) and is part of the hydrophobic cavity, which 
mediates interactions between the inner-membrane helices of two adjacent subunits 
(Figure 4-6c). As in the modeled open conformation, F346 is surrounded by many 
hydrophobic residues of the inner helix of other protomer and hence responsible for 
maintaining the stability of the open conformation. It is observed in the modeled closed 
state conformation that the helix containing F346 and the inner helix from the other 
protomer undergo conformational changes (Figure 4-7). Therefore, mutation to leucine 
(F346L) is likely to destabilize the open state by perturbing the hydrophobic interactions as 
the side chain of leucine is smaller (Figure 4-6c). If the open state is less stable, then the 
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overall dynamics of the channel (i.e. equilibrium between the open and closed) is likely to 
be affected. Also, the packing arrangement in the K+ channels involving the pore and the 
inner helix is known to be critical for the stability of the tetrameric assembly, the ion 
conduction function and also for its selectivity for the cation (Doyle et al. 1998). F346 lies 
on the inner helix and F346L might be detrimental for these functions.  
F502 is in the KCNT1 gating region (373-1174). Within each protomer of the gating region, 
there are two tandem RCK domains (RCK1 and RCK2), which serve as regulators of 
potassium conductance (Figure 4-6e). The two RCK domains form flexible intra- and inter-
subunit (Figure 4-6e). interfaces which facilitate channel assembly into a functional 
tetramer (Yuan et al. 2010). F502 is in RCK1 and predicted to form a pi-pi interaction (a 
non-covalent attractive force) with W476 from αD (Figure 4-6f). F502 is also surrounded by 
several hydrophobic residues (I472, L473, A475, V500 and A503) which may play a role in 
stabilising the overall assembly structure of the gating ring (Figure 4-6f). The amino acid 
substitution F502V is predicted to result in (i) destabilisation of these hydrophobic 
interactions, given the smaller valine side chain (Figure 4-6g) and (ii) abolition of potential 
pi-stacking with resultant disruption of the stable assembly interface. 
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Figure 4-6 Modeling the ion channel and gating apparatus of KCNT1. (a) Side view of the 
homology model of the KCNT1-ion channel (residues 278-346) as a tetramer. F346 is 
present on the edge of the inner helix (gold) and interacts with the inner helix of the 
adjacent subunit. Membrane position is shown in spheres. (b) Top-view of the tetramer 
and location of F346 on the inner helix. (c) F346 is part of the hydrophobic cavity (shown as 
surface), which mediates interactions between the inner-membrane helices of the two 
subunits. F346 (green) and the surrounding hydrophobic residues (red) (d) Upon mutation 
to leucine (F346L, green), hydrophobic interactions between the two subunits are likely to 
be reduced (black circle), as the side chain of leucine is much shorter than phenylalanine. 
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(e) A model of a dimer of the gating ring (residues 372-1044), which is a tetramer, based on 
recent cryo-EM structure at 4.5 Å (PDB ID: 5A6F). Each subunit has two RCK domains; RCK1 
(blue) and RCK2 (gold). F502 (green) is in the RCK1 domain, near the inter-subunit interface 
(assembly interface). The RCK1-RCK2 intra-subunit interface is purple (residues from RCK1) 
and orange (residues from RCK2). The dimer interfaces formed by both RCK-1 and RCK-2 is 
pointed with an arrow. (f): F502 (green) and its neighbouring hydrophobic residues (red), 
including W476, with which it could potentially form a pi-pi interaction. The distance 
between the centroid (indicated as spheres) of the two rings (F502 and W476) is 4.7 Å and 
the angle between the ring planes is 27.3 degrees. (g): F502V could abolish the formation 
of the potential pi-pi interaction with W476 and is likely to reduce the hydrophobic 
interactions (pointed using a black circle), as the side chain of valine is smaller than that of 
phenylalanine. Adapted from McTague et al Neurology 2018 Jan 2;90(1):e55-e66. 
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Figure 4-7 Open-state (in orange) vs. closed state (in pink) model of the ion channel 
domain. F346, which is shown in green, is present at the dimeric interface between two 
inner helices (Io and Ic for open and closed state respectively) (see Figure 4-6) in the open 
state, but the two helices undergo conformational change in the closed state, as pointed 
out using black arrows. Potassium ions (black spheres) are modelled into the tetrameric 
model using structure superposition with the K+-bound open form (PDBID: 3LDC). The 
dimer of the open state is modeled based on the biological assembly of the open state of 
MthK from Methanothermobacter thermautotrophicus (PDBID: 3LDC). The dimer of the 
closed form of the ion channel domain is modeled using the closed form of potassium 
channel from Streptomyces lividans (PDBID: 2A9H). Oc and Oo correspond to outer helices 
in closed and open states and Po and Pc represent the pore helices in closed and open state 
respectively. Adapted from McTague et al Neurology 2018 Jan 2;90(1):e55-e66. 
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Io
Ic
F346Oc
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4.3.6 Electrophysiology 
Electrophysiology experiments were performed by Dr Umesh Nair and Dr Steve Petrou. The 
four previously unreported variants and V271F, which I described previously (McTague et 
al. 2013) and which was recently studied in a xenopus oocyte system (Q.-Y. Tang et al. 
2016), were chosen for evaluation. All variants led to an increase in current magnitude 
compared to wild type (WT) (Figure 4-8a). Notably, for the mutants V271F and F346L, the 
rate of activation was slowed at higher voltages compared to WT, whereas in others 
(M896K, F502V and L274I) activation rates were faster than WT (Figure 4-8a). Assessment 
of the current-voltage relationship showed that mutant channels were either very weakly 
voltage-dependent or, in some cases, there was absence of voltage dependence of steady 
state activation (Figure 4-8b and c). In addition, only residual Goldman–Hodgkin–Katz 
rectification was seen. This refers to the phenomenon where currents flowing across 
permeable membranes are larger when flowing in one direction e.g inward versus 
outward, due to ion flow across membranes as determined by ion concentrations and 
gradients (Goldman 1943). Evaluation of average peak currents at +10mV revealed a highly 
statistically significant difference between both individual mutant channels and summated 
data when compared to WT (Figure 4-8d and e). Therefore, not only did mutant channels 
exhibit increased channel amplitude, but several aspects of channel kinetics were observed 
to be altered in mutant KCNT1 channels. 
Quinidine responsiveness was assessed in the xenopus oocyte system (Figure 4-9). Four of 
the five novel mutations showed some degree of reduction in channel current amplitude 
with quinidine application. This was variable and only reached statistical significance for 
M896K and F502V (Figure 4-9c). There was no effect of quinidine on channel amplitude in 
F346L.  Correlation with clinical response to quinidine will be discussed in section 4.4. 
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Figure 4-8 Functional investigation of KCNT1 mutations in a xenopus oocyte model. a: Representative current traces from oocytes expressing WT 
or EIMFS mutants (M896K, F502V, V271F, F346L and L274I). Oocytes held at -90mV and stepped from -80mV to 80mV for 600 ms every 5 s. Scale 
bars apply to all traces. b Current–voltage (IV) relationships WT (n = 32), M896K (n = 15), F502V (n = 13), V271F (n = 9), F346L (n = 11) and L274I (n 
= 12). Currents averaged, then normalized to the value at test potential of +80mV (Imax). c Comparison of IV relationships between WT (solid 
circles, n = 32) and EIMFS mutations [M896K (squares, n = 15), F502V (triangles, n = 13), V271F (hexagons, n = 9), F346L (diamonds, n = 11) and 
L274I (inverted triangles, n = 12)]. d Average peak currents at +10mV for WT (n = 44), M896K (n = 19), F502V (n = 16), V271F (n = 10), F346L (n = 
11), L274I (n = 12), channels. Peak currents for mutant channel at +10mV compared to the peak currents for the WT channel at +10mV. ***p < 
0.001, ****p < 0.0001. e Comparison of pooled WT (n = 44) and EIMFS (n = 68) currents at +10mV. ****p < 0.0001. Adapted from McTague et al 
Neurology 2018 Jan 2;90(1):e55-e66.
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Figure 4-9 Effect of quinidine on Xenopus oocytes expressing hKCNT1 channels. 4.9a Representative current traces obtained from oocytes 
expressing WT and EIMFS mutants (M896K and F346L) with application of vehicle (ND96) and 300 µM quinidine. Oocytes were held at -90mV and 
stepped from -80mV to +80mV for 600 milliseconds every 5 seconds. Scale bars apply to all traces. 4.9b Current–voltage relationships for WT (n = 
32), M896K (n = 15), F502V (n = 13), V271F (n = 9), F346L (n = 11) and L274I (n = 12) hKCNT1 channels in the presence of vehicle (ND96) and 300 
µM quinidine. Currents were averaged, then normalized to the value at a test potential of +80mV (Imax). 4.9c Average percent inhibition at +80mV 
of WT (n = 31) and EIMFS (M896K, n = 15; F502V, n = 13; V271F, n = 9; F346L, n = 11;L274I, n = 12) hKCNT1 channels by quinidine (300 µM) 
depicting the variable degree of block by 300 µM quinidine (One-way ANOVA followed by Bonferroni post hoc analysis). *p < 0. Arrows indicate 
4-9a 
4-9b 4-9c 
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patients treated with quinidine and clinical response: orange arrow indicated minimal response, green arrow indicates good response, grey arrow 
indicates no response – see section 4.4. Adapted from McTague et al Neurology 2018 Jan 2;90(1):e55-e66. 
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4.4 Discussion 
KCNT1 encodes the sodium-activated potassium channel KCa4.1 (SLACK: sequence like a 
calcium-dependent potassium channel, Slo2.2). KCNT1 is broadly expressed throughout the 
brain, as well as in the dorsal root ganglia and kidney. Activation of KCNT1 channels 
following bursts of action potentials results in slow hyperpolarization (Kaczmarek 2013; 
Brown et al. 2008). KCNT1 also has direct interactions with Fragile X related protein (FMRP) 
(Kim & Kaczmarek 2014). In contrast to other potassium channels, KCNT1 is involved in a 
wide protein network, which may indicate an important role, not only in neuronal 
excitability but also in cognitive developmental processes (Kim et al. 2014; Barcia et al. 
2012; Kim & Kaczmarek 2014; Kaczmarek 2013).   
KCNT1-related disease includes a range of heterogeneous and typically severe epilepsies 
associated with severe neurodevelopmental delay and cognitive difficulties. KCNT1 
mutations have been reported in Ohtahara syndrome, West syndrome/infantile spasms, 
ADNFLE, non-specific early onset epileptic encephalopathy (EOEE) and hypomyelinating 
leucoencephalopathies (Table 4.8) (Barcia et al., 2012b; Heron et al., 2012; Allen et al., 
2013, 2015; McTague et al., 2013b; Ishii et al., 2013b; Kim et al., 2014; Martin et al., 2014; 
Vanderver et al., 2014; Bearden et al., 2014a; Mikati et al., 2015; Møller et al., 2015; Ohba 
et al., 2015; Arai-Ichinoi et al., 2015; Rizzo et al., 2016; Chong et al., 2016; Hildebrand et al., 
2016; Fukuoka et al., 2017). Recently, two siblings with childhood onset learning difficulties 
with ensuing adult onset epilepsy with hippocampal sclerosis and cerebellar ataxia were 
reported (Hansen et al. 2017). In addition, a patient with Brugada syndrome and seizures 
has been described (Juang et al. 2014). Notably, an ADNFLE patient was found to have a 
concurrent cardiac  arrhythmia , similar to Brugada syndrome, and a member of the same 
family who harboured an identical mutation died from SUDEP (Møller et al. 2015).  
Given case acertainment bias, the majority of patients with KCNT1 mutations in my cohort 
had electroclinical EIFMS. A broader phenotypic range may be seen in a larger multi-centre 
study. Indeed, two of the five KCNT1 positive patients identified by the NGS panel from a 
larger pool of 800 patients with EOEE/developmental delay referred for panel testing had a 
NFLE-like presentation. Several atypical EEG features are evident in these patients. 
Generalised electrodecrement and hypsarrhythmia, more classically associated with 
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infantile spasms, have been previously described in EIMFS (Fukuoka et al. 2017; McTague 
et al. 2013; Ohba et al. 2015; Møller, Heron, et al. 2015; Allen et al. 2015). While EEG 
suppression, classically seen in Ohtahara syndrome (Ohtahara 1977), has been described in 
EIMFS before (McTague et al. 2013; Ohba et al. 2015), it was found in most the KCNT1-
EIMFS patients and it seemed to be associated with earlier seizure onset.  These findings 
may reflect the age-dependent expression of KCNT1 dysfunction.  
Extensive diagnostic investigations performed in KCNT1 patients prior to diagnosis were 
mainly uninformative, other than abnormal muscle respiratory chain enzyme analysis of 
muscle tissue in two patients. As in other severe epilepsies, this may be evidence of 
secondary mitochondrial dysfunction in KCNT1-epilepsy (Folbergrová & Kunz 2012). Other 
genetic and environmental influences on mitochondrial function may also play a role. 
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Genomic 
mutation  
Effect on 
protein  
Age of 
seizure 
onset 
Phenotype Additional features  Inheritanc
e 
Functional 
validation 
(references 
Seizure 
types 
EEG  MRI  Pyramidal 
features 
Movement 
disorder 
Psychiatric  Other  
c.769C>G H257D 2 weeks EIMFS - -  - - - - De novo No 
(Møller et al. 
2015) 
c.785G>A R262Q 8 weeks EIMFS - -  - - - - De novo No 
 (Møller et al. 
2015) 
c.808C>G Q270E 2 days EIMFS - Brief EEG 
suppression 
 
 Spasticity - - - De novo No 
(Ohba et al. 
2015) 
c.811G>T V271F 2 weeks EIMFS - Subtle BS (6 
weeks) 
Hyps (6 
months) 
 - - - - Unknown 
(donor egg 
IVF) 
Gain of 
function 
(McTague et 
al. 2013; 
Tang et al. 
2016) 
c.862G>A  G288S 2 months EIMFS - -  - - - - De novo Gain of 
function 
(Møller et al. 
2015; Ohba 
et al. 2015; 
Tang et al. 
2016; Ishii et 
al. 2013; Kim 
et al. 2014; 
Arai-Ichinoi 
et al. 2015; 
Rizzo et al. 
c.862G>A  G288S 2 months EIMFS - -  - - - - De novo 
c.862G>A G288S 3 years ADNFLE - -  - - - - Unknown 
c.862G>A G288S 4 months EIMFS - -  Spasticity Chorea (left 
finger) 
 
- - De novo 
c.862G>A G288S 2 months EIMFS      - - De novo 
c.862G>A G288S 3 months EIMFS Spasms 
 
-  - Choreiform 
movements 
- - Unknown 
c.862G>A G288S 5 weeks EIMFS - -  - - - - Unknown 
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c.862G>A G288S 3 months EOEE - - Severe 
DM 
(HL) 
- - - - Unknown 2016a) 
 
 
c.862G>A G288S 2 months EIMFS - - - - - - - De novo 
c.1018G>A V340M 3 years Multifocal 
epilepsy 
- - - - Limbic 
encephalitis 
- - De novo No 
(Møller et al. 
2015) 
c.1193G>A R398Q Median 
5.5 years 
(range 5–
18) 
ADNFLE - - - - Psychiatric/ 
behavioural 
problems in 
2/4 
No ID 
 - Familial 
(AD) 
Gain of 
function 
(Mølleet al. 
2015; Kim et 
al. 2014; 
Allen et al. 
2015; 
Milligan et 
al. 2014; 
Heron et al. 
2012) 
c.1193G>A R398Q ADNFLE - - - - - - 
c.1193G>A R398Q ADNFLE - - - - - - 
c.1193G>A R398Q ADNFLE - - - - - - 
c.1193G>A R398Q 10 days EIMFS - - - - - - - Unknown 
c
.
1
1
9
-
3
—
G
-
>
A
c
.
1
1
9
3
G
R398Q Unknow
n 
Likely 
ADNFLE 
- - - - - - - Familial 
(AD) 
R398Q 8-14 
months 
ADNFLE - - - - - - - 
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>
A 
c.1193G>A R398Q 3 months EIMFS - - - - - - - 
c.1193G>A R398Q 6 months Focal 
epilepsy 
- - - - - - - 
c.1193G>A R398Q 5 months EIMFS - - - - - - - 
c.1193G>A R398Q 10 weeks EIFMS - - - - - - - De novo  
c.1225C>T P409S 2 months EIMFS - - - - - - - De novo No 
(Ohba et al. 
2015) 
c.1283G>A R428Q 2 months EIMFS - - - - - - - De novo Gain of 
function 
(Møller et al. 
2015; Ohba 
et al. 2015; 
Barcia et al. 
2012; 
Bearden et 
al. 2014) 
c.1283G>A R428Q 17 hours EIMFS - - - - - - - De novo 
c.1283G>A R428Q 2 hours EIMFS - - - - - -  De novo 
c.1283G>A  R428Q 10 weeks EIMFS Apnoea
with 
seizure
(2 
years) 
- - - - - - Unknown 
c.1283G>A R428Q 1 month EOEE - Brief period 
of EEG 
suppression 
- - - - - De novo 
c.1283G>A R428Q 3 weeks EIMFS Spasms - - - - - - Unknown 
c.1420C>T R474C Day 1 EIMFS  Hyps-like 
when awake 
BS in sleep 
 Spasticity Tremor - - De novo No 
(Ohba et al. 
2015) 
c.1421G>A R474H 2 weeks EIMFS -  - - - - - De novo Gain of 
function 
(Ohba et al. 
2015; Tang 
et al. 2016; 
Barcia et al. 
2012) 
c.1421G>A R474H 4 days EIMFS - - - - - - - De novo 
c.1421G>A R474H 15 days EIMFS - - - - - - - De novo 
c.1421G>A R474H 2 months WS Spasms - - - - - - De novo 
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c.1429G>A A477T 1-2 
weeks 
EIMFS - - - - - - - De novo No 
(Ohba et al. 
2015) 
c.1546A>G M516V Day 2 EIFMS - - - - - - - De novo Gain of 
function 
(Rizzo et al. 
2016a) 
c.1694G>A 
 
R565H 18 years MTLE - - Enlarge
d 
amygd
ala and 
HS 
- Cerebellar 
ataxia 
Nystagmus 
 
Learning 
difficulties 
from 
childhood 
 
- Maternally 
inherited 
No 
(Hansen et 
al. 2017) 
c.1694G>A 
 
R565H 25 years MTLE - - - - 
c.1887G>C K629N 4 months EIMFS - - - - - - - De novo Gain of 
function 
(Mikati et al. 
2015) 
c.1955G>T G652V 
 
5 months West 
syndrome 
Spasms - - - - - - Unknown No 
(Fukuoka et 
al. 2017) 
c.2280C>G I760M 3 days EIMFS - - - - - - - De novo Gain of 
function 
(Barcia et al. 
2012) 
c.2386T>C Y796H Median 
5.5 years 
(range 3–
8) 
ADNFLE - - - - - Psychiatric 
and  
behav 
problems 
in 2/4 
- Familial AD Gain of 
function 
(Tang et al. 
2016; 
Milligan et 
al. 2014; 
Heron et al. 
2012; Mikati 
c.2386T>C Y796H ADNFLE - - - - - 
c.2386T>C Y796H ADNFLE - - - - - 
c.2386T>C Y796H ADNFLE - - - - - 
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et al. 2015) 
c.2386T>C Y796H 18 
months 
Sporadic 
NFLE 
- - - - - - -- De novo Gain of 
function 
(Mikati et al. 
2015) 
c.2688G>A M896I 9 years Sporadic 
FLE 
- - - - - No ID -- De novo Gain of 
function 
(Kim et al. 
2014; 
Milligan et 
al. 2014; 
Heron et al. 
2012) 
c.2718G>T 
 
Q906H 3 months EOEE  - - Severe 
DM 
(HL) 
- - - - De novo No 
(Arai-Ichinoi 
et al. 2015) 
c.2771C>T P924L 1 month EIMFS  Spasms - - - - - - De novo Gain of 
function 
(Ohba et al. 
2015; Allen 
et al. 2015; 
Milligan et 
al. 2014) 
c.2771C>T P924L 1.5 
months 
EIMFS - - - - - - - Inherited 
(maternal 
somatic 
mosaicism) 
c.2782C>T R928C Median 2 
years 
(range 1-
15) 
ADNFLE - - - - - Psychiatric
and behav 
problems 
in 5/6 
 Familial AD Gain of 
function 
(Møller et al. 
2015; Tang 
et al. 2016; 
Kim et al. 
2014; 
Milligan et 
c.2782C>T R928C ADNFLE - - - - - - 
c.2782C>T R928C ADNFLE - - - - - - 
c.2782C>T R928C ADNFLE - - - - - - 
c.2782C>T R928C ADNFLE - - - - - - 
c.2782C>T R928C ADNFLE - - - - - - 
c.2782C>T R928C - Unaffected - - - - -  - Familial 
(AD)- 
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reduced 
penetranc
e 
al. 2014; 
Heron et al. 
2012) 
c.2782C>T R928C 1 year ADNFLE - - - - - - - Familial 
(AD) 
c.2782C>T R928C 12 years  ADNFLE - - - - - - - Familial 
(AD) 
c.2782C>T R928C 15 years ADNFLE - - - - - - Familial 
(AD) 
c.2782C>T R928C 7 years ADNFLE - - - - - - Familial 
(AD) 
c.2782C>T R928C 6 years ADNFLE - - - - - - Familial 
(AD) 
c.2782C>T
  
R928C 5 years NFLE - - - - - - - Unknown 
c.2794T>A  F923I 1 month EOEE with 
myoclonic 
seizures 
- - Severe 
DM 
and HL 
- Choreo-
athetosis (2 
years).  
- - De novo Gain of 
function 
(Tang et al. 
2016; 
Vanderver et 
al. 2014) 
c.2800G>A  A934T 2 weeks EIMFS - - - - - - - De novo Gain of 
function 
(Ohba et al. 
2015; 
McTague et 
al. 2013; 
Tang et al. 
2016; Ishii et 
al. 2013; Kim 
et al. 2014; 
Barcia et al. 
c.2800G>A A934T 1 month EIMFS - - - - - - - De novo 
c.2800G>A  A934T 2.5 
months 
EIMFS - - - - - - - Unknown 
c.2800G>A A934T 1 month EIMFS - - - Spasticity - - - De novo 
c.2800G>A A934T 8 weeks EIMFS - - - Spasticity, 
hyper-
reflexia 
- - - Inherited 
(maternal 
somatic 
mosaicism) 
c.2800G>A A934T 2 months EIMFS - - - - - - - De novo 
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2012) 
c.2849G>A R950Q 5 months EIMFS - - - Hyper-
reflexia 
- Autistic 
traits 
 De novo No 
(Ohba et al. 
2015) 
c.2849G>A R950Q 3 years NFLE - - - - - Psychosis, 
depression 
- De novo Gain of 
function 
(Hildebrand 
et al. 2016) 
c.G2896G>
A 
A966T Day 1 Ohtahara 
syndrome 
- BS - - - - - Paternal 
isodisomy 
(autosoma
l recessive 
mutation) 
Marked gain 
of function 
(Martin et al. 
2014) 
 
Table 4.8 Published mutations in KCNT1 leading to epilepsy and other neurodevelopmental disorders. Recurrent mutations are shaded in blue or grey. AD 
autosomal dominant, ADNFLE autosomal dominant frontal lobe epilepsy, behave behavioural, BS burst suppression, DM delayed myelination, EIMFS 
epilepsy of infancy with migrating focal seizures, EOEE early onset epileptic encephalopathy, FLE frontal lobe epilepsy, GI gastrointestinal, HL 
hypomyelinating leucoencephalopathy, hyps hypsarrythmia, ID intellectual disability, MTLE mesial temporal lobe epilepsy, NFLE nocturnal frontal lobe 
epilepsy, SUDEP sudden unexplained death in epilepsy, WS West syndrome. Adapted from McTague et al Neurology 2018 Jan 2;90(1):e55-e66. 
 
  141 
 
 In this study I identified patients with identical mutations associated with different 
electroclinical phenotypes (Table 4.4 and Table 4.8). Such phenotypic pleiotropy (see 
Chapter 1) is a recurrent theme in the early onset genetic epilepsies, and it is postulated 
that other genetic/epigenetic for environmental factors may play a role (Zuberi et al. 2011; 
Lim et al. 2016). Variation of the phenotype caused by KCNT1 mutations has been reported 
even within single families, where different individuals may present with either ADNFLE or 
EIMFS (Møller, Heron, et al. 2015) resulting from the same mutation. This intrafamilial 
phenotypic variability is also described in SCN1A-kindreds, where Dravet syndrome, febrile 
seizures and a variety of other generalized epilepsies may be reported within the same 
family (Scheffer et al. 2009). While most of the mutations in this cohort occurred de novo, 
two patients inherited mutations from an unaffected parent. Parental inheritance of 
disease-associated variants has significant implications for future genetic counselling.  
How can an unaffected parent transmit a dominant disease-causing mutation to their 
offspring? Two possibilities are reduced penetrance and somatic mosaicism.  Penetrance 
refers to the proportion of individuals in a population harbouring a mutation who manifest 
the disease associated with that mutation (Cooper et al. 2013). If the mutation is present in 
unaffected individuals within this population, the mutation shows reduced penetrance.  
This differs from variable expressivity which describes differing phenotypes in affected 
individuals with the same mutation. Apparent reduced penetrance in KCNT1-related 
epilepsy has been reported previously in a single individual from a family with multiple 
members affected with ADNFLE due to the R298C mutation (Table 4.9) (Møller, Heron, et 
al. 2015).  In addition, the healthy father of a patient with Ohtahara syndrome, thought to 
be due to a homozygous KCNT1 mutation (but due to paternal isodisomy for chromosome 
9) was found to be heterozygous for the A966T mutation (Martin et al. 2014). Most 
recently, two siblings with adult-onset mesial temporal lobe epilepsy were found to have a 
novel mutation that was maternally inherited, although this variant has not yet been 
functionally validated (Hansen et al. 2017). Reduced penetrance is also well documented in 
other autosomal dominant focal epilepsies, for example those caused by mutations of 
CHRNA4 or DEPDC5 (Lal et al. 2014; Leniger et al. 2003) . Possible mechanisms for reduced 
penetrance identified in other disorders such as cystic fibrosis include a mutation-specific 
effect, where certain mutations are highly penetrant but others less so (Cooper et al. 
2013).  This seems not to be the case for KCNT1, as penetrance appears to vary for the 
same mutation between different individuals.  Other possible mechanisms include altered 
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effects on protein function in low penetrance mutations. Again, this does not seem 
pertinent to KCNT1, as the mutations identified with lower penetrance have similar gain of 
function identified in functional studies, albeit in over-expression systems.  However, 
factors which have not yet been explored for KCNT1 penetrance include modifying effects 
of polymorphisms within the same gene, or within different genes, which may rescue the 
phenotype in unaffected individuals. In addition, alterations in gene expression and 
epigenetic differences between individuals or environmental factors may play a role.  
As discussed in Chapter 1, somatic mosaicism has been reported in other genetic early 
onset epilepsies such as Dravet syndrome, resulting in transmission by an apparently 
unaffected parent (Depienne et al. 2010). Parental mosaicism has also been previously 
reported in two cases of KCNT1-related epilepsy (Møller, Heron, et al. 2015; Ohba et al. 
2015). It is possible that mosaicism may also contribute more widely to variable expression 
of phenotypes and the difficulties in correlating phenotype with genotype. 
Differential expression of alternative KCNT1 transcripts may also play a role in phenotypic 
variability. In rodents it has been shown that there are several differing amino-terminus 
SLACK isoforms under the control of differing promoters (Brown et al. 2008). The original 
SLACK sequence is denoted as SLACK-B and other transcripts with an alternate exon 1 are 
termed SLACK-A. In addition, a further transcript was denoted as SLACK-M. All transcripts 
are highly expressed throughout the brainstem and olfactory bulb and more variably in the 
cerebral cortex and hippocampus. Interestingly, cortical expression of SLACK-B is restricted 
to the frontal cortex (Bhattacharjee et al. 2002). Channels derived from SLACK-B versus  
SLACK-A transcripts have different electrical properties when studied in vitro with slow 
activation in B and rapid activation in SLACK-A (Brown et al. 2008). Therefore conceivably 
the functional impact of a mutation may be mediated by which isoform is predominantly 
affected. Lim et al discuss that seizures in ADNFLE may be a result of mutations more 
affecting SLACK-B isoforms with predominant expression in frontal cortex, whereas 
disruption of SLACK-A function could result in EIMFS or ADNFLE (Lim et al. 2016). However, 
although sequences orthologous to the SLACK-A and B isoforms are present within the 
human KCNT1 gene, the relative expression and significance of these transcripts has not 
been shown in humans. To date, all KCNT1 disease-causing mutations described appear to 
affect the latter transmembrane domains and carboxy terminus of KCNT1 (Figure 4-10), 
which theoretically should equally impact on all isoforms.   
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A further layer of functional complexity is the influence of different isoforms on heteromer 
formation with SLICK (KCNT2) channels. Only the SLACK-B isoform is able to form 
heterotetramers with SLICK and these channels have markedly different electrical 
properties and response to protein kinase C (PKC) regulation compared to homomeric 
SLICK or SLACK channels (Chen et al. 2009; Kaczmarek 2013). The effect of a mutation on 
channel function may therefore also be mediated by the impact on heteromeric or 
homomeric channel formation. Again, this is speculative, as although co-expression of 
SLICK/SLACK channels has been shown with co-immunoprecipitation and co-staining on 
immunocytochemistry (Chen et al. 2009), this has not been demonstrated in humans. 
Functional studies of KCNT1 function have largely taken place in oocyte systems where 
KCNT2 is not expressed and therefore have studied KCNT1 homomers. In addition, the 
extent to which mutant and wild-type subunits form tetramers may also influence the 
functional impact of mutations. In one study, co-transfection of mutant KCNT1 constructs 
revealed a more marked gain of function than mutant-WT co-transfection, albeit in a 
heterologous, over-expression cell model system (Rizzo et al. 2016a). Further study in a 
patient-derived or animal neuronal model could evaluate the effect on tetramer function 
which might contribute to genotype: phenotype correlation.   
KCNT1 tetramers form a transmembrane (TM) sodium-activated potassium channel. Each 
subunit consists of six TM domains with an extended cytoplasmic carboxy (C-) terminus 
(Figure 4-10). Most reported mutations (Table 4.8), as seen in this study, are in the C-
terminus with clustering around the RCK (regulators of potassium conductance) and 
nicotinamide adenine dinucleotide (NAD) binding domains (Figure 4-10). More recently, 
several mutations have been identified within TM domain 5 and in the pore forming 
regions between TM domains 4 and 5 (Table 4.8), (McTague et al. 2013; Ishii et al. 2013; 
Kim et al. 2014; Møller, Heron, et al. 2015). This study further demonstrates epilepsy-
associated mutations in transmembrane domains.  
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Figure 4-10 Schematic diagram of mutations in KCNT1 in this and previously published studies. 6 transmembrane domains with a pore-forming 
region, RCK (regulator of potassium conductance) and NAD-binding domains are shown. EIMFS phenotypes (purple), ADNFLE/NFLE (pink), others 
[Ohtahara syndrome, leucoencephalopathy, focal epilepsy, EOEE, West syndrome, unaffected] (orange). Mutations giving rise to more than one 
phenotype are shaded with a combination of the corresponding colours. Novel mutations identified in this study are outlined in green, those 
identified in previous studies in turquoise. Adapted from McTague et al Neurology 2018 Jan 2;90(1):e55-e66. 
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Although there does not appear to be a clear genotype: phenotype correlation in terms of 
mutation location, there is clustering of 90% of reported mutations around functional 
domains (Figure 4-10, Table 4.8), namely the pore-forming transmembrane domains (20%), 
the RCK1 domain (30%), the RCK2 and nicotinamide acid (NAD+) sensing domains (10%) and 
the distal carboxy terminus (30%). For example, as discussed in Milligan et al, NAD+ 
regulates KCNT1 channels and shows circadian oscillation, which may be associated with 
the nocturnal occurrence of seizures in some ADNFLE-associated KCNT1 mutations 
(Milligan et al. 2014).  
Therefore, due to the inter-individual and intra-familial phenotypic variability seen in 
KCNT1 disease, genotype: phenotype correlation or prediction of the resultant phenotype 
based on the mutation is complex. For clinicians making this diagnosis in a patient with 
EIMFS, it is worth observing that the initial age of presentation, disease course, response to 
medication, MR brain imaging and EEG findings were similar for both KCNT1 mutation-
positive and negative patients from the EIMFS cohort. However, 5/10 mutation-positive 
patients with EIFMS presented with a severe movement disorder, as opposed to 2/18 
KCNT1 negative cases. Although movement disorders are increasingly reported in other 
severe early onset genetic epilepsies (Chapter 1), they have only previously been described 
in three patients with KCNT1-epilepsy (Ohba et al. 2015; Møller, Heron, et al. 2015; 
Vanderver et al. 2014). As in our study, the movement disorder was described as 
“choreiform”. Further details are limited but both generalised and finger chorea are 
described. While mechanisms are unclear, it is notable that particularly strong 
immunoreactvity for SLACK was seen in the substantia nigra, globus pallidus and cerbellar 
cortex of mouse brain, possibly indicating a role for KCNT1 in motor control (Rizzi et al. 
2016).   
Do functional studies of KCNT1 mutations enable us to better correlate genotype with 
phenotype? A variety of different model systems have been utilised to determine the 
functional impact of KCNT1 mutations (Martin et al. 2014; Ishii et al. 2013; Bearden et al. 
2014; Møller, Heron, et al. 2015; Rizzo et al. 2016b; Milligan et al. 2014; Q.-Y. Tang et al. 
2016; Evely et al. 2017). Most functional assessments have been performed in the xenopus 
oocyte system, although several authors have used mammalian cell systems, namely CHO 
cells (Evely et al. 2017; Rizzo et al. 2016b) as discussed below. The Kcnt1 null mouse 
displays altered cognitive function but no epileptic seizures; a knock-in model is not 
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currently available (Bausch et al. 2015).  Most recently, a drosophila model of two 
recurrent KCNT1 variants has been generated (Ehaideb et al. 2017). 
In this study I used data from both protein homology modelling and electrophysiology to 
evaluate the functional impact of novel KCNT1 variants. This approach is useful in the 
assessment of novel variants such as F346L where the CADD score was not significant and 
further evidence of pathogenicity is crucial. The American College of Medical Genetics and 
Genomics guidelines for variant classification also use this integrative approach combining 
evidence from variant segregation, effect on protein, functional studies and presence in 
control databases to come to a final classification of pathogenic, likely pathogenic, benign 
or uncertain significance (Richards et al. 2015). For example, F346L is a de novo variant 
which is PS2 or strong evidence of pathogenicity. There is also moderate evidence of 
pathogenicity (PM2) as F346L does not feature in Exome Sequencing Project (EVS), the 
1000 Genomes Project, or ExAc (Table 4.7). However, without the electrophysiology 
studies, this variant would not qualify for final classification as pathogenic by ACMG 
standards.  
The structural modelling performed by Dr Topf and Dr Malhotra suggests anomalous gating 
or protein instability within the pore-forming region as possible disease mechanisms for 
the novel mutations F346L and F502V. This information has been particularly useful in 
understanding the differential response of the F346L variant to quinidine (see below). In 
silico modelling of G288S, suggests a similar functional effect to F502V (Ishii et al. 2013) 
whilst Y775H is projected to influence sodium sensitivity of the channel (Q.-Y. Tang et al. 
2016). KCNT1 mutations may therefore change protein structure, possibly leading to 
altered channel function. As reported previously (Martin et al. 2014; Rizzo et al. 2016b; 
Barcia et al. 2012; Milligan et al. 2014; Q.-Y. Tang et al. 2016)(Table 4.8), the Xenopus 
oocyte model showed that all novel KCNT1 mutations identified in this study display a gain-
of-function effect, with increased current amplitude (Figure 4-8). Initially several studies 
correlated disease severity with the fold-change increase in channel amplitude of gain-of-
function (Martin et al. 2014; Milligan et al. 2014). However, in keeping with more recent 
studies (Kim et al. 2014), such genotype-phenotype correlation was not evident in our 
study, albeit with smaller numbers of mutations studied. A finding that is common to 
several studies is that KCNT1 mutations result in an increased Po (probability of the channel 
being open), which may be due to increased mutant channel cooperativity or altered 
sodium sensitivity (Kim et al. 2014; Q.-Y. Tang et al. 2016). Indeed, in this study, altered 
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voltage sensitivity of mutant channels was seen, with the rate of activation slowed at 
higher voltages compared to WT in F346L and V271F. V271F could not be modelled, but 
the abnormal gating revealed by modelling of F346L may indicate that altered channel 
dynamics influence the ability of the mutant channel to respond to voltage changes in the 
same way. Assessment of the effect of sodium removal from the pipette solution revealed 
a less negative impact on G288S channel amplitude than WT, suggesting altered sodium 
sensitivity in the mutant (Rizzo et al. 2016b). Recently functional assessment of F932I, a 
mutation identified in a patient with an epileptic encephalopathy, generalised seizures and 
severely delayed myelination (Table 4.8) was undertaken (Vanderver et al. 2014). 
Surprisingly, using a CHO model system, a loss of function was noted with reduced channel 
amplitude and reduced cell surface expression of the mutant construct (Evely et al. 2017). 
Co-expression of wild-type and mutant constructs indicate a possible dominant negative 
effect of the mutation. The reasons for this difference from a previous study of this 
mutation in a xenopus oocyte model (which found a gain of function, altered sodium 
sensitivity and similar surface expression to WT, although measured by a different method) 
are unclear (Tang et al. 2016). The authors postulate that these differences may be 
attributed to their use of a mammalian heterologous expression system, rather than the 
xenopus oocytes used in ours and many previous studies. Study of a different mutation 
(G288S) found a similar gain-of-function between CHO cells and xenopus oocytes (Rizzo et 
al. 2016b; Tang et al. 2016; Kim et al. 2014). The carboxy terminus of KCNT1 has recently 
been identified as a site of p38 Mitogen-Activated Protein Kinase (MAPK) phosphorylation 
which regulates trafficking of KCNT1 to the cell surface (Gururaj et al. 2016) . However, 
previous studies in a CHO cell system, (albeit of non-C terminus variants G288S and 
M516V), and in a xenopus system (studying several carboxy terminus variants) did not 
reveal any differences in mutant KCNT1 cell surface expression (Rizzo et al. 2016b; Kim et 
al. 2014). Further evidence for a gain of function mechanism in KCNT1-epilepsy can be 
derived from a study of human induced pluripotent stem cell (iPSC) derived neurons where 
the P924L mutation was engineered using nuclease technologies in a control line (Mangan 
et al. 2015). Details are limited but a gain of function with increased channel bursting was 
reported. Most recently, a drosophila model which over-expressed two recurrent KCNT1 
variants (G288S and R928C) also showed a gain of function with an increase in potassium 
conductance (Ehaideb et al. 2017). Finally, the phenotype related to the F932I mutation is 
somewhat “atypical” with generalised myoclonic rather than focal seizures and severely 
abnormal myelination (Table 4.8). This could indicate that LOF variants may be associated 
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with a slightly different phenotype to EIFMS but that both LOF and gain-of-function results 
in overall brain neuronal hyperexcitability. To date, no patients with deletions or stop-gain 
mutations have been identified and many healthy individuals with LOF variants of KCNT1 
are represented in the ExAC and gnomAD databases, but it remains to be seen whether 
further patients with atypical phenotypes and loss of function mutations are identified. In 
addition, the complete knock-out mouse does not have an epilepsy phenotype(Bausch et 
al. 2015). 
Overall, this work shows that in patients with severe early onset epilepsy, mutations in 
KCNT1 lead to both an increase in in vivo channel amplitude and alterations in channel 
dynamics as revealed by electrophysiology and modelling studies. This study is in keeping 
with the overwhelming evidence of KCNT1 mutations leading to a gain of channel function, 
albeit in non-neuronal, artificial in vitro over-expression models.  
A significant remaining question is how KCNT1 gain-of-function mutations (which would be 
presumed to lead to neuronal hyperpolarisation) result in epilepsy (Kaczmarek 2013). The 
altered voltage sensitivity as demonstrated in this study may result in KCNT1 channels 
opening at more depolarised potentials allowing for a persistent hyperpolarising current. If 
this predominantly affected inhibitory interneurons, which are richly expressed in the 
frontal lobes, this could result in interneuronal disinhibition, analogous to the proposed 
disease mechanism in SCN1A-related epilepsy (Bhattacharjee et al. 2002; Yu et al. 2006; 
Tang et al. 2016). Conversely, more rapid repolarisation in excitatory neurons permitting 
more frequent and fast action potentials may be a factor in disease pathogenesis (Tang et 
al. 2016; Lim et al. 2016). These hypotheses were recently further explored in a drosophila 
model where the R298C variant, previously characterised in xenopus oocytes as gain of 
function, was over-expressed using a conditional knock-in system in GABAergic inhibitory 
neurons, leading to increased seizure susceptibility compared to control flies and flies over-
expressing wild type KCNT1.  Therefore, silencing of inhibitory interneurons due to gain of 
function KCNT1 mutations could lead to neuronal excitability and epilepsy. In the same 
study, high levels of mutant KCNT1 expression in motor neurons was lethal. However low 
levels (or adult expression) of mutant KCNT1 in motor neurons did not lead to silencing, but 
spontaneous synaptic potentials which could be blocked by the calcium channel blocker 
cadmium. In addition, there was a compensatory increase in the expression of Shaker (a 
homologue of human KCNA3). Therefore, this study shows that there are differential 
effects of KCNT1 variants on differing neuronal subtypes and that these compensatory 
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mechanisms may negatively or positively contribute to the phenotype. A further interesting 
finding of this study was that over-expression of mutant KCNT1 variants in motor neurons 
led to uncoordinated ventral ganglion firing resulting in abnormal larval movement. This 
may bear some relevance to the movement disorder seen in the patients in this study. 
Overall, a number of mutation-dependent complex disease mechanisms might be 
implicated in KCNT1-epilepsy.  
Recently, quinidine has been identified as a novel therapeutic option for patients with 
KCNT1-related epilepsy. In vitro models have shown that quinidine reduced the abnormal 
increase in mutant KCNT1 channel amplitude (Milligan et al. 2014). In a EIMFS patient 
harbouring the KCNT1 mutation R428Q, in vitro testing showed a significant threefold gain 
of function and quinidine sensitivity. Quinidine therapy led to a marked improvement in 
seizure control with neurodevelopmental gains (Barcia et al. 2012; Bearden et al. 2014). 
However, in more recent studies patient response has varied and is not always as 
anticipated by the in vitro data (Mikati et al. 2015).  Another patient with the R428Q 
mutation, but with unclassified EOEE rather than EIMFS, did not respond to quinidine 
therapy. This patient started treatment at a later stage in the disease course (Chong et al. 
2016) which may have impacted upon the therapeutic response. Most recently, a patient 
with West syndrome had a positive response with reduced seizure frequency and 
improvement in developmental progress but only at a higher dose of 60mg/kg/day 
(Fukuoka et al. 2017). Although the therapeutic effect may possibly be determined by the 
specific KCNT1 mutation, other genetic factors, epilepsy phenotype and drug timing within 
a “therapeutic window” may also play a role.  Indeed, a further study of three more 
patients recently confirmed that of the eight published patients, the four patients treated 
at less than 4 years of age responded and those treated after four years of age did not 
(Abdelnour et al. 2018). Further, in a blinded randomised controlled study of adult patients 
with ADNFLE, quinidine was not effective and dosages were limited by cardiac toxicity 
(Mullen et al. 2017).  A further explanation for the variability in response is that the 
xenopus oocyte model where a single channel is studied in isolation, does not adequately 
recapitulate the situation in vivo and therefore may falsely represent the effects of 
quinidine.  In this study, Patient 15 (L274I), Patient 17(F502V) and Patient 18 (M896K) were 
treated with quinidine (up to 40mg/kg/day) at ages of 2 years, 5 years and 2 years 
respectively. Only Patient 17 showed a significant response, which correlated with the in 
vitro studies (Figure 4-9). The L274I mutation did not show a statistically significant 
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response to quinidine in vitro, which also appears to reflect the clinical response (the 
patient in this case was treated prior to availability of in vitro data). In contrast, the M896K 
mutation showed the most marked in vitro response to Quinidine and there was indeed 
felt to be some initial clinical benefit in the patient harbouring this mutation. However, a 
severe pulmonary vasculopathy resulting in pulmonary haemorrhage emerged. Systemic 
vasculitis has been previously reported with quinidine treatment (Lipsker, D, Walther, S, 
Schulz, R, Nave, S, Cribier 1998). Initially there was concern that this might represent an 
adverse response to quinidine, but recently three further patients with different KCNT1 
mutations, who have not been treated with quinidine, presented with severe pulmonary 
haemorrhage secondary to massive systemic to pulmonary collateral arteries(Kawasaki et 
al. 2017). Although KCNT1 mutations have been associated with Brugada, the expression of 
KCNT1 in cardiac and vascular tissue is not understood and the mechanisms remains 
unclear. The patient harbouring the other mutation which showed blockade by quinidine, 
V271F, was not treated with Quinidine. Interestingly, the F346L mutation showed no 
quinidine response at all and this patient was also not treated with quinidine. Although 
quinidine is a direct KCNT1 blocker, the precise mechanism of blockade is unclear (Yang et 
al. 2006). It is possible that the disease mechanism for the F346L mutation, perhaps 
involving abnormal channel opening dynamics as suggested by the homology modelling 
data, is not modifiable by quinidine.  
Overall, the data from this study supports the consideration of a trial of quinidine therapy 
for patients with KCNT1 mutations and early onset epilepsy where in vitro data have shown 
a gain of function and blockade by quinidine. However, it should be used with care and in 
consultation with cardiology colleagues, including a baseline cardiac evaluation, 
consideration of concurrent medications which affect QT interval and meticulous 
monitoring during treatment. Larger multi-centre evaluation of clinical utility, patient 
selection, optimum age of administration and dosing may be helpful in guiding patient 
management and an international effort would be required to gather sufficient patient 
numbers in this rare disorder. There are other KCNT1 blockers such as bepridil (Kaczmarek 
2013), which reversibly blocks mutant KCNT1 channels in vitro at a lower concentration 
than wild type channels (Rizzo et al. 2016b).  However, similar to quinidine, potential 
cardiac effects and lack of specificity may limit usage in patients and it is not currently 
available. For true “precision medicine” to be achieved, what is really needed is 
identification of specific KCNT1 blockers which lack the non-specific actions of quinidine on 
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other potassium channels, particularly on channels expressed in the myocardium. This 
could be investigated in a high-throughput assay using available drug libraries in a xenopus 
oocyte system. Alternatively, a drosophila model as described above could be used in a 
high throughput assay, with conditional expression systems allowing the study of effects of 
drugs in both excitatory and inhibitory neurons. Another model to consider would be a 
human-derived neuronal model using induced pluripotent stem cells derived from 
fibroblasts to generate cortical neurons. In addition to shedding light on disease 
mechanisms (see below), this would also be suited to a high throughput approach, for 
example using multi-electrode arrays to assess the impact of compounds on channel 
bursting.  Identification of test compounds from a high-throughput system could then be 
further studied in a knock-in mouse model.  
In conclusion, I have shown that heterozygous mutations in KCNT1 cause a severe early 
onset epilepsy typically associated with severe neurodevelopmental impact and significant 
disease burden. Ten of 34 EIMFS patients in this cohort were identified to have KCNT1 
mutations, confirming that it is a major disease gene in this syndrome. Movement 
disorders appear to be more frequent in KCNT1-EIMFS than in EIMFS in general. Otherwise 
KCNT1-EIMFS does not seem to have specific features which distinguish it from the EIMFS 
electroclinical syndrome in general. However, the reports of massive systemic to 
pulmonary collateral artery formation in three published cases and one case from this 
cohort are concerning and should be borne in mind in any KCNT1 patient with respiratory 
deterioration or haemoptysis. While the majority of mutations occur de novo, inheritance 
from an unaffected parent is possible due to somatic mosaicism as demonstrated in this 
study, or reduced penetrance which requires further investigation. This has significant 
implications for genetic counselling. Importantly, clinicians should not exclude either novel 
or previously reported variants which are also found in healthy parents. These issues 
highlight the importance of functional validation of novel variants. As demonstrated, both 
protein homology modelling and in vitro model systems may be used in a complementary 
approach to investigate variant pathogenicity. Many KCNT1 mutations including the 
recurrent mutations have now been validated in over-expression model systems and have 
indicated, in general, a gain of channel function with increased channel amplitude. One of 
the challenges following initial gene discovery in rare disorders is whether and how further 
novel variants in a rare gene continue to be functionally validated without research-based 
testing pipelines. It could be argued that for a patient with a typical EIMFS phenotype who 
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is identified to have a heterozygous KCNT1 mutation located in the pore-forming region or 
carboxy terminus and predicted to be pathogenic using in silico tools, this is very likely to 
be the disease-causing variant. Functional validation using a xenopus oocyte system would 
afford the opportunity to assess blockade by quinidine. As in the example of the L274I 
variant, lack of in vitro response may predict lack of clinical response and allow the patient 
to avoid a trial of a drug with potentially serious side effects. Unfortunately, the converse is 
not true, as in vitro blockade may not predict clinical response. This likely reflects the 
limitations of the model, and the research community should now focus its efforts on 
creating useful models to investigate KCNT1 variants, as this carries the highest likelihood 
of identifying better treatments. Several complementary approaches are possible. Firstly, 
generation of knock-in mouse models of the recurrent KCNT1 variants would enable a 
systems-level assessment of mutant KCNT1 expression with the opportunity to investigate 
cardiac and vascular tissue in addition to phenotypic evaluation and the opportunity of 
testing novel compounds. However, an approach which allows the possibility of a human-
derived neuronal model would be achieved with iPSC-derived cortical neurons. This would 
allow investigation of the impact of KCNT1 mutations in both inhibitory interneurons and 
excitatory neurons, which would help delineate disease mechanisms, as has already been 
achieved in Dravet syndrome using an iPSC model (Sun et al. 2016), and provide a platform 
for high throughput testing of novel compounds as discussed above. Further research is 
now essential to allow the pursuit of new therapies for this devastating pharmacoresistant 
group of epilepsies.  
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Chapter 5 Identification of a novel gene for Epilepsy of Infancy with 
Migrating Focal Seizures 
5.1 Introduction 
Over the course of my PhD, I recruited a consanguineous family of Pakistani origin with two 
affected children to my cohort of EIMFS patients. Although heterozygous de novo gene 
mutations are more commonly reported in the early onset epileptic encephalopathies (see 
Chapter 1), recessive disease inheritance has been described, often in consanguineous 
families with multiple affected children (McTague et al. 2015). Indeed, EIMFS due to 
biallelic mutations in SLC25A22, PLCB1, ALG1, ALG3, RFT1, QARS, and TBC1D24 have been 
reported ( see Conclusion, Chapter 6) (Barba et al. 2016; Poduri, Chopra, et al. 2012; 
Annapurna Poduri et al. 2013; Milh et al. 2013; Zhang et al. 2014). I therefore hypothesised 
that these children I had recruited could be affected by a disease gene with an autosomal 
recessive inheritance pattern and prioritised them for further genetic investigation, using 
an autozygosity mapping strategy.  
Consanguinity is defined as a union between two individuals who are second cousins or 
more closely related, indicated by a co-efficient of inbreeding of ≥0.0156 (Hamamy 2012). 
The number of genes shared by two individuals, or the coefficient of relationship, R, for 
those two individuals, can be established by detailed pedigree evaluation. The co-efficient 
of inbreeding (F) for offspring resulting from that relationship can then be calculated (Table 
5.1) This represents the probability that two copies of an allele at a locus are homozygous 
by descent (Spence & Hodge 2000). Consanguineous relationships occur worldwide, with 
one billion of the global population estimated to live in communities where this is a 
widespread practice (Hamamy 2012). In the United Kingdom, certain communities have 
increased rates of consanguineous relationships, such as the UK Pakistani community 
where 37.5% of Pakistani mothers are married to first cousins in one survey (Sheridan et al. 
2013). In addition, complex relationships with multiple loops of consanguinity may exist 
and marriages restricted to culturally specified groups may contribute (Corry 2014). It is 
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well established that consanguinity within UK ethnic populations significantly increases the 
risk of a congenital disorder (Sheridan et al. 2013).  
Relationship Proportion of genes 
shared  
Coefficient of 
inbreeding (F) 
Risk to offspring 
of autosomal 
recessive disease*  
Siblings or parent-child 1/2 1/4 1/8 
Aunt-nephew/Uncle-
niece  
1/4 1/8 1/16 
Double first cousins 1/4 1/8 1/16 
First cousins 1/8 1/16 1/32 
First cousins once 
removed 
1/16 1/32 1/64 
Second cousins 1/32 1/64 1/128 
Table 5.1 Coefficient of inbreeding in consanguineous relationships. Adapted from 
(Bennett et al. 2002) and (Spence & Hodge 2000). *this is a general risk, recurrence risk for 
specific genes may vary depending on a number of factors including parental carrier status. 
Individuals within consanguineous kindreds share many genomic regions of homozygosity 
due to their descent from a common ancestor. A recessive condition will therefore often be 
the result of inheriting two disease alleles (one from each parent) which are derived from a 
mutually common ancestor. Both alleles will be surrounded by regions of homozygosity 
(Lander & Botstein 1987) (Figure 5-1).  Lander and Botstein were the first to describe the 
mathematical model showing that the probability of “homozygosity by descent” at a given 
locus in a child of a consanguineous relationship is high for rare alleles (Lander & Botstein 
1987). This paved the way for autozygosity mapping strategies in consanguineous families 
as a powerful way to identify disease-causing recessive genes in many conditions, including 
the early onset epileptic encephalopathies (e.g. CACNA2D2 and NECPA1) (Alazami et al. 
2014; Pippucci et al. 2013). Originally, genome-wide microsatellite markers or restriction 
fragment length polymorphisms (RFLPs) were used to define regions of genomic 
homozygosity and potential disease loci. However, the advent of microarray technology 
has allowed a much denser interrogation of the genome, allowing genotyping of hundreds 
of thousands of single nucleotide polymorphisms (SNPs) per individual (Lander & Botstein 
1987; Woods et al. 2004). SNP data can then be used to define homozygous regions which, 
if shared by affected family members (and different to unaffected family members), can be 
prioritised. Such potential disease loci can then be further interrogated for disease-causing 
variants either by direct sequencing of genes contained within the homozygous region or 
using whole exome sequencing data.  
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I thus utilised an autozygosity mapping approach to identify potential disease loci in the 
consanguineous family I had recruited for research. During this process, my supervisor was 
contacted by Dr Anna Wedell from the Karolinska Institute, Sweden. They had investigated 
a family with two children affected by EIMFS and had found mutations in a novel gene 
located within one of the homozygous regions that I had identified in our UK family. A 
research collaboration was formed and I will present data from all four affected children in 
the following chapters. 
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Figure 5-1 The principle of autozygosity mapping. A homozygous region (turquoise) 
containing a gene of interest (turquoise circle) is inherited from a common ancestor and 
becomes smaller through successive generations as a result of crossing over 
(recombination) during meiosis. As a result of a consanguineous marriage (indicated by 
double horizontal lines), several affected children may inherit two disease alleles by 
descent.  
Affected Affected Unaffected	
non-carrier
Unaffected	
carrier
Common	ancestor
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5.2 Methods 
5.2.1 Autozygosity mapping.  
In order to identify disease loci, autozygosity mapping, using the Illumina CytoSNP12 array 
was undertaken (see Methods 2.4). Overall, the array genotyped 294,975 single nucleotide 
polymorphisms across the genome. I manually analysed the data in an excel table and 
identified regions of homozygosity using colour coding for the genotypes AA, AB and BB. I 
sorted regions by chromosome and physical position to allow assessment of the size of the 
homozygous regions. In addition, the UCL Genomics Service used BedTools to analyse the 
data, confirming the same homozygous regions as the manual method described above.  
5.2.2 Whole exome sequencing 
Whole exome sequencing was performed for Family 1 by UCL Institute of Neurology Next 
Generation Sequencing Service using an Illumina platform (see Methods 2.5).  Data were 
provided as csv files which I converted to Excel and analysed as described below.  The 
whole exome sequencing methods for Family 2 are described in the Appendix.  
5.2.3 Genetic screening of UK EIMFS cohort and other EIMFS/EOEE cases 
Throughout this chapter, SLC12A5 will be used to refer to the gene and KCC2 will be used 
to refer to the protein, as this is the convention in the literature. I undertook Sanger 
sequencing in UK patients from the UK EIMFS cohort. Annotations are as described in the 
NCBI GRCh37.p13 build. The DNA template for the longest protein-coding transcript of 
SLC12A5 (ENST00000454036.2) located at Chromosome 20: 44,650,356-44,686,341 was 
obtained from the Ensembl genome browser. I used Primer3 
(http://fokker.wi.mit.edu/primer3/input.html) to design primers (as described in Chapter 
2.3.3) to cover all 26 exons and exon-intron boundaries of SLC12A5, with coverage across 
all four protein-coding transcripts (Table 5.2). The standard thermocycling regime of 950C 
for 5 minutes; 40 cycles of 950C for 45 seconds, 600C for 45 seconds 720C for 1 minute; 
followed by 720C for 5 minutes was successful for the majority of exons. Exon 1 required a 
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longer annealing time of 1 minute and exons 6, 18 and 21 required different annealing 
temperatures (Table 5.2). The same primers were used for sequencing the PCR products 
(Methods 2.3.5). 
A further 17 patients who were KCNT1-negative from the EIMFS cohort (n=34) were 
prioritised for SLC12A5 screening (Table 5.3). As described in Chapter 4, for five patients 
either DNA was not available or parents did not wish further investigation. A variety of 
approaches were used (Table 5.3) including Sanger sequencing and whole exome 
sequencing (see Methods 4.2.3). In addition, several patients were investigated using the 
GOSH EIEE next generation sequencing panel which includes SLC12A5 (see Methods 4.2.2) 
and some patients had diagnostic microarray studies as detailed in Table 5.3.  
In addition, through the collaborations formed for this project, 12 unrelated Swedish 
patients with EOEE (including 1 patient with EIMFS) were sequenced by whole exome 
sequencing at the Karolinska Institute. Exome sequencing data (undertaken at Duke 
University, USA) for a further 19 patients from separate Australian and American EIMFS 
cohorts were evaluated by collaborators for putative pathogenic variants in SLC12A5.  
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SLC12A5 Transcript number Primer Primer Sequence Annealing 
temperature 
0C 
GC rich 
solution 
003 002 001 004 
1F    1F aagtggccagattcaggaac 60 yes 
1R    1R ctgcccccttcaacagac   
 1bF 1bF 1bF 1bF atacgggatgaggtgagcag 60  
 1bR 1bR 1bR 1bR cccagcctcctctctgaag   
2F 2F 2F 2F 2F acaccactgtatgcccaggt 60  
2R 2R 2R 2R 2R agggagagagcagctgatga   
3F 3F 3F 3F 3F tgtccccatctcttcctctg 60  
3R 3R 3R 3R 3R attttcctcccccatcctc   
4F 4F 4F 4F 4F acctggggtgttcgtaatga 60  
4R 4R 4R 4R 4R ggtctcatgcttccatcctc   
5F 5F 5F 5F 5F ggtttggctggtgtttatgg 60  
5R 5R 5R 5R 5R tctctcttgggccttgatgt   
6F 6F 6F 6F 6F cttacggcagcccagtgc 62  
6R 6R 6R 6R 6R cagggagcactgattaactga   
7F 7F 7F  7F tttttcctaaagcgctgcat 60  
7R 7R 7R  7R ggggagtttggcagagact   
8F 8F   8F gcgtccgtgtgtttaaaagg 60  
8R 8R   8R cccttaatcctgaccgctta   
9F 9F   9F agagctctggtccccttatg 60  
9R 9R   9R ctctcttccccatccactca   
10F 10F   10/11F catctgtctggtctcctgtgg 60  
10R 10R   10/11R cacctcctgatgggtctgtt   
11F 11F   10/11F catctgtctggtctcctgtgg 60  
11R 11R   10/11R cacctcctgatgggtctgtt   
12F 12F   12F tggaaatccaggcagcact 60  
12R 12R   12R tcactgtgtggtctctctgg   
13F 13F  7F 13F ggagagggctgagaaatcct 60  
13R 13R  7R 13R acggctgcaggattcagata   
14F 14F   14F tctgtttctgcctccctttg 60  
14R 14R   14R gaggggatggactggagtaag   
15F 15F   15F agtcccagcttcagcaacag 60  
15R 15R   15R ctccttcccaccacccttc   
16F 16F   16F agctggtgcagtgtagatgg 60  
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16R 16R   16R gtctcctgagccttgcactc   
17F 17F   17F tatggtgtgtggatggttgg 60  
17R 17R   17R gagactgtcttcctaagtgtcctg   
18F 18F   18F agggaaggaggctacaatgg 58 yes 
18R 18R   18R aaaggagcggaaatccagtt   
19F 19F   19F ggtgttgggagaaccagagt 60  
19R 19R   19R agagcccctgagtctgacct   
20F 20F   20F ccctggatctcctcatcaca 60  
20R 20R   20R ggggccaagaggaaagag   
21F 21F   21F ctcatgctttcctccgtgtt 58 yes 
21R 21R   21R cctgaggcatcctaaacctg   
22F 22F   22F agggcatgggtggtgact 60  
22R 22R   22R ggcagttgagtcctttggag   
23F 23F   23F gtgcagcttgggtggttt 60  
23R 23R   23R ggatgccttctgctctcttg   
24F 24F   24F ctggcagagcaggactcag 60  
24R 24R   24R tcagagatcccagaggtcgt   
25F 25F   25F cgactggctccaatcttctc 60  
25R 25R   25R acagctcagctcttccatcc   
26F 26F   26F  aggtggacgtcagggaatct 60  
26R 26R   26R ACGGGCACAGGGTCTGTA   
Table 5.2 SLC12A5 primer sequences and PCR conditions 
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 Screening Method Diagnostic chromosomal 
microarray* 
Karyotype* 
Patient 
Cohort 
Number  
Sanger 
sequencing 
in research 
laboratory 
NGS 
Diagnostic 
Panel*  
WES# 
7 - - + N - 
8 + - - N - 
9 - - + N - 
11 + - - N - 
12 + - - - N 
13 - - + N - 
22 + - - N - 
23 + - - N - 
24 + - - N - 
25 + - - N - 
26 + - - N - 
27 + - - N - 
28 + + - 11.8 Mb heterozygous 
deletion  
Chr 20q11 copy number 
variant of uncertain 
significance 
- 
29 - + - N - 
30 - + - N - 
31 - + - N  
34 + - + N - 
Table 5.3 SLC12A5 screening of KCNT1-negative EIMFS cohort patients. + test performed, - 
test not done, N normal. *by GOSH regional or local genetic laboratory # sequenced at 
Duke University, USA, analysis by Dr McTague 
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5.2.4 Protein homology modelling- see Appendix 
In order to determine structure-function properties of SLC12A5 mutants, protein homology 
modelling was undertaken by Dr Maya Topf (Birkbeck) (see Appendix for methods). 
5.2.4.1 In situ mutagenesis to investigate mutant SLC12A5 in an over-expression model  
I obtained an expression vector (pCMV6-XL5) containing the full-length human SLC12A5 
cDNA from Origene, USA and validated the sequence by Sanger DNA sequencing. I 
performed in situ mutagenesis was performed using the QuikChange site-directed 
mutagenesis kit (Agilent, Santa Clara, USA) to generate the three mutations (L311H, L426P, 
G551D) identified in EIMFS patients (see Methods 2.6) using custom-designed mutagenesis 
primers (Table 5.4). I performed PCR-based cloning into a pRK5 expression vector (courtesy 
of Professor R. Harvey) using custom-designed cloning primers (Table 5.5). This was 
successful for the wild type (WT) DNA and for L311H (see Methods 2.7).  
For the remaining two mutations, I used custom-designed mutagenesis primers (Table 5.4) 
and a QuikChange II site-directed mutagenesis kit (Agilent Technologies, USA) to 
mutagenise the wild-type KCC2 in the pRK5 expression vector. In this way I successfully 
generated plasmids containing each of the three mutations. I performed Sanger sequencing 
to ensure only the desired mutations had been introduced using cDNA primers (Table 5.6). 
I transiently co-transfected HEK293 cells (Fugene) with plasmids encoding pRK5-GFP, the 
human GlyR α2 subunit in a pRK5 expression vector and equal amounts of WT, L311H, 
L426P or G551D pRK5-KCC2 (Methods 2.9.2, Figure 5-2).
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Mutation Forward primer Reverse primer 
SLC12A5-L311H ttcccgatctgccacctgggtaaccgc gcggttacccaggtggcagatcgggaa 
SLC12A5-L426P tcctacttcaccctgccggttggcatctacttc gaagtagatgccaaccggcagggtgaagtagga 
SLC12A5-G551D caggtctttggccatgacaaggccaatggagag ctctccattggccttgtcatggccaaagacctg 
Table 5.4 Mutagenesis primers for the three SLC12A5 mutations detected in EIMFS 
patients. 
Cloning primer Primer Sequence 
SLC12A5-EcoRI    
 
5'-ggcgaattcgccaccatgctaaacaacctgacggac-3’ 
SLC12A5-SalI     5'-tccgtcgactcaggagtagatggtgatgac-3' 
 
Table 5.5 Cloning primers for PCR-based cloning of SLC12A5 from pCMV6 topRK5 vector. 
The recognition sequence for the respective restriction endonuclease is underlined.  
cDNA primer Primer sequence 
SLC12A5-c1F ACCATGCTAAACAACCTGAC 
SLC12A5-c1R CTCCTACTACATGATTTCCAG 
SLC12A5-c2F CATCTCCATGAGTGCAATTGCAA 
SLC12A5-c2R AAACAATGTCACAGAGATCCAGG 
SLC12A5-c3F AAATGAGACGGTGACCACACGGCTA 
SLC12A5-c3R TGGCCTGGCCATCTCATGGGTAATT 
SLC12A5-c4F GTCTACATCAGCTCCGTTGTTCTG 
SLC12A5-c4R TCTCACTGACCTCCCAGCTGAA 
SLC12A5-c5F ACACACCAAGAACTGGAGGCCACAG 
SLC12A5-c5R CCAGATGGATGACAATAGCATCCAG 
SLC12A5-c6F CATGCTCATGCTGCTGCCCTT 
SLC12A5-c6R TCACCTGGACCAAGGACAAGT 
SLC12A5-c7F AGCTGATCCACGATCAGAGTGCT 
SLC12A5-c7R CTGTCACCGTTTACATACAGACCC 
SLC12A5-c8F ACCATCTACTCCTGAGAACCAGGA 
SLC12A5-c8R ACATAGTGTACAGGAGACATCGCGT 
Table 5.6 cDNA primers for sequencing of the SLC12A5 insert. Eight pairs of over-lapping 
primers were designed to provide full coverage of the cDNA sequence of the gene.  
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5.2.5 Immunoblotting, surface biotinylation and immunocytochemistry studies in an 
overexpression model 
For detailed methods, see Appendix. In brief, a myc-tagged construct was created from a 
pCMV6-KCC2 clone (Origene, Rockville, USA). Full-length human KCC2 was cloned into the 
myc-tagged construct using similar methods to those described in Methods 2.7. This was 
undertaken by Dr Esther Meyer from the Kurian laboratory. An anti-myc antibody was then 
used for immunoblotting, undertaken by Dr Juan Zhen from the Reith laboratory, New 
York.  
Biotinylation exploits the strong interaction between avidin and biotin, allowing extraction 
of biotin-labelled proteins (Elia 2008). Surface biotinylation uses a hydrophilic reagent 
which cannot cross the hydrophobic plasma membrane, ensuring only cell surface proteins 
are biotinylated. Streptavidin coated beads can then be used to capture the biotinylated 
proteins, which are eluted and separated by gel electrophoresis, before immunoblotting to 
identify the protein of interest, in this case myc-tagged KCC2. Total cell lysate was also 
analysed by immunoblotting to establish total KCC2 expression.  
For confocal microscopy, a pCAGG-KCC2 construct with a FLAG-tagged extracellular epitope 
was kindly donated by the Levi laboratory, Institut National de la Santé et de la Recherche 
Médicale, Paris. My collaborator Dr Philip Long (Harvey laboratory, UCL School of 
Pharmacy) performed in situ mutagenesis (see Methods and Appendix) to create the three 
mutant constructs of interest. Non-permeabilised HEK293 cells were transfected with 
either WT or mutant constructs, then subsequent immunoblotting (anti-FLAG antibody) 
allowed assessment of KCC2 cell surface expression. This experiment was repeated with 
permeabilised HEK293 cells for quantification of total KCC2 expression.  
5.2.6 Electrophysiology 
For detailed methods, see Methods 2.10. In brief, a cell-based system was designed in 
collaboration with Dr Arnaud Ruiz and Professor Robert Harvey, UCL School of Pharmacy. 
HEK293 cells were transfected with green fluorescent protein (GFP), the a2 subunit of the 
glycine receptor and either pRK5 alone, pRK5-WT KCC2 or pRK5-mutant KCC2. The glycine 
receptor is essentially a ligand-gated chloride channel and therefore assessment of glycine-
induced chloride currents can be used to calculate the reversal potential of chloride (ECl-), a 
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read-out of KCC2 transporter function. The a2 subunit of the glycine receptor was chosen 
as it forms homopentameric glycine-gated chloride channels (Hoch et al. 1989) unlike the 
GABAA receptor which requires co-transfection of several different subunits to form a 
functional receptor.  
 
Figure 5-2 Cell system set up for electrophysiology experiments 
5.2.7 Zebrafish knockout model 
To assess the effects of mutant KCC2 at a whole organism level, a collaboration was formed 
with Professor Hiromi Hirata (Aoyama Gakuin University, Japan) and Dr Atsuo Kawahara 
(University of Yamanashi, Japan). Zebrafish experiments were undertaken by Professor 
Hirata and Dr Kawahara (see Appendix for detailed methods). 
Glycine
HEK293
Cl-
KCC2
Cl- extrusion
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5.3 Results 
5.3.1 Clinical features of patients with SLC12A5 mutations 
In Family 1, the proband (1-II:4) was born following a normal pregnancy and delivery. He is 
the second child of first cousin Pakistani parents and had an affected older brother (whose 
history and clinical presentation was re-examined in light of his younger brother’s similar 
presentation) and two unaffected brothers (Figure 5-3). He presented at 10 weeks with 
migrating focal seizures consisting of facial and limb twitching with excessive salivation. 
Seizures were short-lasting, approximately 20 seconds, and frequent, up to 70 times per 
day. Prior to seizure onset, developmental attainment was satisfactory, but there was 
neurological regression after seizure onset. Neurological examination revealed a head 
circumference of 38 cm (0.4th percentile) with weight on the 10th percentile, global 
hypotonia, and normal antigravity movements. Phenobarbitone was commenced initially 
with some reduction in seizure frequency but this was not sustained. Trials of pyridoxine 
and folinic acid were ineffective, as were levetiracetam and sodium valproate. The addition 
of topiramate to phenobarbitone led to a period of relative stability, but clusters of focal 
seizures continued particularly during febrile illnesses. He continues to have short-lived 
focal seizures characterised by eyelid, facial or arm twitching, which becomes more 
prolonged and evolves to generalised seizures during intercurrent illnesses. At the last 
assessment at 17 months, he is significantly developmentally delayed but can fixate 
visually. There is evidence of ongoing regression with the gradual loss of swallowing skills 
over recent months. Examination reveals pyramidal signs on the left with microcephaly 
(head circumference 42 cm at 14 months, below 0.4th percentile).  
          II:1 II:2 II:3 II:4 
I:1       I:2 
    
I
II 
II:1 II:2 
I:1       I:2 
    
Figure 5-3 Family tree of both families with multiple affected children with EIMFS. Family 1 
(Pakistani, left) and Family 2 (Swedish European, right). Squares represent males. Circles 
represent females. Affected individuals are represented by black shading. Double parallel 
horizontal bars indicate consanguinity. 
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The proband’s oldest brother (1-II:1) had a similar clinical presentation at 6 weeks of age. 
After a period of early normal development, frequent, migratory focal seizures of the face 
and limbs occurring in clusters with intermittent evolution to bilateral convulsions were 
noted. Twitching of the tongue, apnea and drooling were prominent ictal features. Seizures 
were refractory to multiple antiepileptic drugs and there was no response to pyridoxine. 
Head circumference at birth was 36 cm (50th percentile) but by 6 months was 40.5cm 
(below the 0.4th percentile). He died at 2.5 years following a chest infection, increased 
seizures and cardiac arrest. 
In Family 2, two children with EIMFS were born to non-consanguineous Caucasian parents. 
The following data was derived from clinical information provided by local clinicians. The 
older male child (2-II:1) was born without complications following an uneventful pregnancy 
and neonatal period. His early developmental progress was within normal limits. Seizure 
onset was at 12 weeks of age during an intercurrent illness with fever. The seizure 
semiology consisted of brief behavioural arrest and eye deviation, followed by afebrile 
hemiclonic seizures. By 15 weeks of age, numerous and repeated focal seizures emerged, 
characterised by behavioural arrest, hemiclonic twitching, tonic and atonic features, and 
eye deviation with clinically migratory seizures. He was admitted to hospital from five to 
ten months of age due to refractory status epilepticus. During this period there was loss of 
developmental skills and cognitive decline. 
Seizures were resistant to all anticonvulsants. Treatment with intravenous 
methylprednisolone followed by oral prednisolone at 8 months of age resulted in a 
noticeable reduction in seizure frequency, with electroencephalographic improvement. He 
remained on alternate day therapy with oral prednisolone for the next few years, although 
he continued to have 1-79 seizures per month occurring approximately once per week in 
clusters. Introduction of the ketogenic diet, at 5 years led to a reduction in seizures to one 
nocturnal seizure. Here was also an increase in alertness on the diet. Current treatment 
includes sodium valproate and clobazam. Weaning of the ketogenic diet led to an increase 
in seizure frequency. Patient 2-II:1 made slow developmental gains. He crawled at 1.8 years 
of age,and walked independently from the age of 2.8 years. He was able to grasp for 
objects. He had no dysmorphic features apart from acquired microcephaly (birth head 
circumference 2.5th percentile, current head circumference 0.1st percentile). He had normal 
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tendon reflexes but general hypotonia hyperkinetic and dystonic movements. He smiled 
responsively and made eye contact but was non-verbal. 
The younger sister, Patient 2-II:2, currently aged 7.9 years, had onset of focal seizures at 4 
months. Hospital admission for 3 months was required due to migrating focal seizures 
refractory to medication. Treatment with a variety of corticosteroids (IV 
methylprednisolone, oral prednisolone and ACTH) was not beneficial. At 7 months she 
commenced the ketogenic diet, with some response. She is globally developmentally 
delayed with more motor delay than her brother; she is not able to walk or reach for 
objects and the best motor milestone achieved is sitting with support. 
5.3.2 EEG features 
Inter-ictal EEG at 4 weeks in patient 1-II:4 revealed slowing with multifocal spikes. Ictal EEG 
recorded consecutive seizures with central/vertex onset followed by left hemisphere onset 
associated with facial twitching (Figure 5-4a). An EEG at 10 weeks in patient 1-II:1 captured 
two seizures with eye deviation to the right, chewing automatisms, and right eyelid 
twitching followed by unresponsiveness with loss of tone. Epileptiform activity over the left 
temporal region was captured, and other EEGs captured similar seizures with ictal activity 
in other foci. In Patient 2-II:1, two consecutive EEGs at presentation were normal. 
Subsequent EEGs revealed status epilepticus with migrating foci, some without clinical 
correlate. Ictal migration within seizures and between hemispheres was evident (Figure 5-
4b). Interictal background showed diffuse slowing and multifocal spikes. The EEG in Patient 
2-II:2 also showed multifocal spikes with background slowing and ictal migration.
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Figure 5-4 Ictal EEG in Patient 1-II:4 (a) and Patient 2-II:1(b). Figure 5-4a: In Patient 1-II:4 the upper (compressed) and lower EEG recording reveal 
central/vertex and right parietal epileptiform activity (purple/red and boxed in red, upper right figure) that wanes with a return to the interictal 
state before onset of left centro-temporal ictal activity associated with facial twitching (blue and boxed in red, lower figure). Figure 5-4b: The 
upper two boxes are consecutive EEG segments each 1 minute long. Seizure activity is boxed in black with rhythmic spike-waves evident initially on 
the left hemisphere (red), then fading and seizure activity starting up in the right (blue) temporal area. Expanded segments below (10 sec) show 
the spike-wave activity in more detail. Montage: Longitudinal bipolar according to the 10-20 system. Only lateral channels shown. Adapted from 
McTague et al Nat Commun. 2015 Sep 3;6:803. 
1"sec"
200"uV"
a b 
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5.3.3 MRI features 
I analysed MRI imaging in the context of clinical data, together with Dr Kling Chong, 
Consultant Neuroradiologist, Great Ormond Street Hospital. MRI of the brain at eight 
months in Patient 1-II:4 showed marked delay of myelination and an increase in white 
matter signal (Figure 5-5a). Magnetic resonance spectroscopy (MRS) revealed a relatively 
reduced N-acetyl aspartate (NAA) peak (Figure 5-5a). In Patient 1-II:1 CT brain at 10 weeks 
showed progressive generalized atrophy compared to CT at 6 weeks. MRI brain at 10 weeks 
revealed prominent extra-axial CSF spaces with evidence of thin subdural collections 
(hygromas) bilaterally, the right slightly larger than the left. There were no structural 
abnormalities. In Patient 2-II:1 MRI brain at 4 months showed delayed myelination and at 
29 months, global cerebral atrophy (Figure 5-5b). 
5.3.4 Autozygosity mapping (Family 1) 
Manual SNP array analysis revealed 7 common regions of homozygosity (6-43 Mb in size) in 
the affected children (Figure 5-6 and Table 5.7). Filtering for rare homozygous, potentially 
pathogenic variants within these homozygous regions identified 4 genes, which are 
detailed in Table 5.7. 
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Figure 5-5 Global cerebral atrophy and delayed myelination on MR imaging and 
spectroscopy in KCC2-EIMFS. Figure 5-5a: selected images from Patient 1-II:4 at 8 months 
(A-D) with normal age-matched control (E-H). Axial T2 sequences (A&E) reveal reduced 
myelination in the posterior limb of the internal capsule (arrowhead) compared to the 
normal with lack of myelination in the posterior fornices heading towards the splenium of 
the corpus callosum (arrows). Axial T1 (B&F) also demonstrates delayed myelination in the 
frontal and occipital white matter (arrows) compared to normal. Diffusion imaging (C&G) 
demonstrates increased signal in white matter compared to cortex (arrows). MRS in the 
occipital white matter (D&H) demonstrates a relatively normal choline (Cho) /creatine (Cr) 
ratio, but marked reduction in the relative N-acetyl aspartate peak (NAA-red arrow), 
consistent with delayed myelin maturation. Figure 5-5b: Selected images from Patient 2-
II:1 at 4 months (A&B) and 29 months (C&D). The axial T1 and T2 images show delayed 
myelin maturation in the white matter (A arrow & B arrowhead). By 29 months (C arrow 
and D arrowhead), myelination has progressed. However coronal T2 (D) shows significant 
prominence of the extra-axial CSF space due to a reduction in overall brain volume (red 
a 
b 
  172 
 
arrow) in keeping with global cerebral atrophy. Adapted from McTague et al Nat Commun. 
2015 Sep 3;6:803. 
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Figure 5-6 Homozygous region on chromosome 20. The 7 MB region begins at 40,900,992 
(top row) and ends at 47,171,338 (bottom row). 
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Chromosome Start of 
homozygous 
region 
End of 
homozygous 
region 
Size 
of 
region 
(Mb) 
Candidate genes from 
whole exome 
(homozygous model) 
before filtering using 
dbSNP135 
Candidate 
genes from 
whole exome 
(homozygous 
model) after 
filtering with 
dbSNP135 
Filtering by 
ExAC/gnomAD 
Nature of 
candidate gene 
Nature of 
mutation 
in 
candidate 
gene 
Polyphen2, SIFT 
Provean2, 
Mutation 
Taster, CADD 
scaled scores 
(if applicable) 
3 156,581,034 172,339,752 16 None None - - - - 
4 48,283 10,728,759 10 CPZ, LOC650293 CPZ 
 
 
 
 
 
 
 
 
LOC0650293 
Not in ExAC/ 
gnomAD  
 
 
 
 
 
 
 
Not in ExAC/ 
gnomAD  
Carboxypeptidase 
Widely expressed 
in tissues 
Role in 
proteolysis and 
Wnt signalling 
pathway  
 
 
Pseudogene with 
one exon only.  
Missense 
 
 
 
 
 
 
 
 
Missense 
PolyPhen2 = 0 
(benign) 
SIFT= 0.09 
(tolerated) 
Mutation Taster 
= 1.05 (N- 
denotes 
polymorphism) 
CADD 5.548 
- 
6 13,361,927 56,208,751 43 ZNF187, HLA-H, 
AK309533, HLA-A, 
HLA-L, PSORS1C1, 
HLA-B, MICA, HLA-
DRB1, HLA-DQA1, 
SLC26A8, KIAA0240 
 
SLC26A8  
 
 
 
 
 
 
 
 
PSORS1C1 
 
 
 
 
gnomAD: MAF 
0.00003 no 
homozygotes 
 
 
 
 
 
 
rs375095896 
MAF 0.00002558 
in gnomAD, no 
homozygotes 
 
Testis anion 
transporter- 
implicated in 
spermatogenic 
failure 
 
 
 
 
Psoriasis 
susceptibility 
variant, widely 
expressed, 
weakly in brain  
Missense 
 
 
 
 
 
 
 
 
Frameshift 
insertion 
 
 
 
PolyPhen2 = 
0.071 (benign) 
SIFT= 0.81 
(tolerated) 
Mutation Taster 
=3.06 (N- 
denotes 
polymorphism) 
CADD 9.3601 
- 
CADD 19.09 
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MICA 
 
 
 
 
 
HLA-DQ1 
 
 
rs41293539 MAF 
0.2145 in 
gnomAD, 
frequently 
homozygous  
 
Not in ExAC/ 
gnomAD  
 
 
Major 
histocompatibility 
complex type 1 
related gene, role 
in immunity 
 
Major 
histocompatibility 
complex gene, 
role in immunity 
 
 
Frameshift 
insertion  
 
 
 
 
Stop loss 
SNV 
 
 
- 
CADD 23.0 
 
 
 
- 
7 146,711,789 152,600,817 6 KRBA1, SSPO, ABP1, 
ATG9B, 
ABP1 rs529653297 
(dbSNP142) 
MAF 0.0002 in 
ExAc, one 
homozygote 
(South Asian) 
Metal-binding 
membrane 
glycoprotein, 
mostly expressed 
in kidney, not 
expressed in 
brain.  
 
Missense PolyPhen2= 
0.959 (probably 
damaging) 
Provean -1.43 
(neutral) 
SIFT=0.174 
(Tolerated) 
Mutation 
Taster=0.985901 
(D- denotes 
disease causing)  
16 49,866,005 65,809,044 15 None None - - - - 
20 40,900,992 47,171,338 7 SLC12A5 SLC12A5 Not in ExAC/ 
gnomAD  
Neuronal-specific 
potassium-
chloride co-
transporter 
Missense PolyPhen2 = 
0.994 (probably 
damaging) 
SIFT = 0.0 
(deleterious) 
Provean = -
4.420 
(damaging) 
CADD 27.3 
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(deleterious) 
 
21 10,734,842 26,514,597 15 POTED POTED Not in ExAC/ 
gnomAD  
Ankyrin repeat 
domain-
containing 
protein 21, 
prostate-, ovary-, 
testis-, and 
placenta-
expressed gene 
4 
Missense 
changes in 
exon 1 
PolyPhen2 = 
0.04, 0.001, 0, 
0.022 (all 
benign) 
SIFT = 0, 0, 0.66 
(all tolerated), 
0.98 
(deleterious) 
Mutation Taster 
= 0.001146, 1, 
2.2, 3.8 (N- 
denotes 
polymorphism) 
CADD 8.954 
 
 
Table 5.7 Homozygous regions and filtering of whole exome data for candidate genes in Family 1. Whole exome data were filtered for exonic, damaging 
(non-synonymous missense, frameshift deletion or insertion, stop-gain or stop-loss), rare (MAF<0.01 in 1000 Genomes and EVS) variants. Variants were 
then also assessed by presence of other databases, including dbSNP135, ExAC and gnomAD, biological function and predicted pathogenicity using in silico 
tools Polyphen2, SIFT, Provean and Mutation Taster. MAF mean allele frequency SNV single nucleotide variant.  
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5.3.5 Whole exome sequencing 
Exome sequencing was performed in Patient 1-II:4 from Family 1. An average 32.7-fold 
coverage of the exome (2x coverage in 93.5% of bases and 10x coverage in 84.0% of bases, 
Methods 2.5). Overall, 21,381 exonic or splice site variants were identified, of which 1173 
were non-synonymous or stop-gain. Of these, 262 variants fitted a recessive model 
(homozygous or compound heterozygous inheritance). My analysis for changes within the 
7 identified homozygous regions revealed 20 potential candidate genes. After filtering 
against dbSNP135 excluding all variants with a mean allele frequency of greater than or 
equal to 0.01, I found that 9 rare variants in candidate genes remained (SLC12A5, CPZ, 
SLC26A8, POTED, LOC0650293D, PSORS1C1, MICA, HLA-DQ1 and ABP). When the data was 
first filtered, the next step of variant assessment involved assessing the gene function and 
pathogenicity as predicted by in silico tools Polyphen2, SIFT and Provean. It was possible 
using this approach to exclude several of the variants on the basis of biological function and 
known disease associations; for example, SLC26A8 and POTED have roles in testicular and 
ovarian tissue and are not known to be expressed in brain. The disadvantage of this 
approach would be falsely excluding a gene whose function or role is unknown. The ExAC 
and gnomAD databases of normal genetic variation, which have become available since this 
data was first filtered, were subsequently interrogated for the presence of these variants. 
They were particularly helpful in excluding the MICA variant which was not present in 
dbSNP135 but present in ExAc and gnomAD, with a MAF of 0.2145 and frequently found in 
the homozygous state in the normal population.  
Based on biological function, absence in databases of normal genetic variation, in silico 
predictions of pathogenicity and data from animal models (see discussion), SLC12A5 was 
determined to be by far the most likely and biologically plausible candidate gene for our 
clinical phenotype of infantile onset epilepsy (Table 5.7). The single homozygous variant 
identified in SLC12A5, c.932T>A, results in the missense change L311H (Figure 5-7) 
occurring within the 7Mb homozygous region on chromosome 20. Appropriate familial 
segregation was verified by Sanger sequencing (Figure 5-7). This variant is not reported in 
established variant databases (including dbSNP137, 1000 Genomes SNP calls, the NHLBI 
Exome Sequencing Project, ExAC and gnomAD) and is highly conserved (Figure 5-8). Further 
analysis indicated that L311H is predicted to be damaging with a PolyPhen2 score of 0.994 
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(sensitivity: 0.69; specificity: 0.97), SIFT score of 0.00 (≤0.05 predicted to be deleterious) 
and Provean score of -4.420 (≤-2.5 is considered "deleterious”).  
Whole exome filtering performed by our Swedish collaborators is described in detail in 
Appendix. In brief, the Mutation Identification Pipeline (MIP) weighted sum model (which 
uses multiple parameters, but emphasizes Mendelian inheritance patterns, conserved, rare 
and protein damaging variants) was utilised. Filtering resulted in only one gene, SLC12A5, 
with adequate coverage in all sequenced individuals that conformed to autosomal 
recessive inheritance. SLC12A5 was also marked out as a likely candidate gene, due to its 
predicted critical function in neuronal chloride homeostasis and role in GABAergic and 
glycinergic transmission. The two affected children from Family 2 were found to harbor 
compound heterozygous mutations of SLC12A5, with variants c.1277T>C (L426P) and 
c.1652G>A (G551D). Sanger sequencing confirmed these changes in both affected siblings 
from Family 2 (Figure 5-7). L426P was inherited maternally and G551D paternally. Neither 
variant is reported in established variant databases (including dbSNP137, 1000 Genomes 
SNP calls, the NHLBI Exome Sequencing Project, ExAC and gnomAD) and both are highly 
conserved (Figure 5-8). L426P is predicted to be damaging using PolyPhen2 (score 1.000, 
sensitivity: 0.00; specificity: 1.00), PROVEAN score was -6.554 and SIFT score was 0. G551D 
was also predicted to be damaging, with a PolyPhen2 score of 0.931 (sensitivity: 0.81; 
specificity: 0.94) and PROVEAN score -4.020.  
In addition, no pathogenic variants in genes associated with EIMFS and other early infantile 
epileptic encephalopathies (see Chapter 1 and Chapter 6) were identified on exome 
sequencing analysis in any of the affected children from Families 1 and 2.  
No mutations were identified in the additional patients who were screened from the UK, 
Swedish, Australian and American EIMFS/EOEE cohorts, and variants R952H and R1049C 
(see Discussion) were also not identified in the screened cohorts. 
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Figure 5-7 Schematic of SLC12A5 gene with mutations identified in four patients. SLC12A5 consists of 26 exons (blue rectangles). Both wild type (WT) and 
mutant DNA sequence is displayed. Three point mutations were identified in four patients with EIMFS (wild-type sequence indicated by black arrow, 
mutated base by orange arrow). The children from Family 1 were homozygous for missense variant c.932T>A (L311H) in exon 8, whilst the two affected 
Family 2 patients harboured missense mutations in exon 9 (c.1277T>C, L426P) and 13 (c.1652G>A, G551D). Adapted from McTague et al Nat Commun. 2015 
Sep 3;6:803. 
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272 VKYVNKFALVFLGCVILSILAIYAGVIKSAFDPPNFPICLLGNRTLSRHG 321 SLC12A5, H. SAPIENS 
249 VKYVNKFALVFLGCVILSILAIYAGVIKSAFDPPNFPICLLGNRTLSRHG 298 SLC12A5, P. TROGLODYTES 
302 VKYVNKFALVFLGCVILSILAIYAGVIKSAFDPPNFPICLLGNRTLSRHG 351 SLC12A5, C. LUPUS 
242 VKYVNKFALVFLGCVILSILAIYAGVIKSAFDPPNFPICLLGNRTLSRHG 291 SLC12A5, B. TAURUS 
249 VKYVNKFALVFLGCVILSILAIYAGVIKSAFDPPNFPICLLGNRTLSRHG 298 SLC12A5, M. MUSCULUS 
272 VKYVNKFALVFLGCVILSILAIYAGVIKSAFDPPNFPICLLGNRTLSRHG 321 SLC12A5, R. NORVEGICUS 
268 VKYVNKFALVFLGCVILSILAIYAGVIKSAFDPPSFPICLLGNRTLSRHG 317 SLC12A5, G. GALLUS 
236 VKYVNKLALVFLACVILSILAIYAGVIKTSFDPPDFPVCVLGNRTLVSKA 285 LOC797331, D. RERIO 
207 VKYVNKLALVFLACVICSILAVYAGVIKTAFEPPVFPVCVLGNRTLVWKG 256 LOC572215, D. RERIO 
L311 
422 YFTLLVGIYFPSVTGIMAGSNRSGDLRDAQKSIPTGTILAIATTSAVYIS 471 SLC12A5, H. SAPIENS  
399 YFTLLVGIYFPSVTGIMAGSNRSGDLRDAQKSIPTGTILAIATTSAVYIS 448 SLC12A5, P. TROGLODYTES  
452 YFTLLVGIYFPSVTGIMAGSNRSGDLRDAQKSIPTGTILAIATTSAVYIS 501 SLC12A5, C. LUPUS   
392 YFTLLVGIYFPSVTGIMAGSNRSGDLRDAQKSIPTGTILAIATTSAVYIS 441 SLC12A5, B. TAURUS  
399 YFTLLVGIYFPSVTGIMAGSNRSGDLRDAQKSIPTGTILAIATTSAVYIS 448 SLC12A5, M. MUSCULUS  
422 YFTLLVGIYFPSVTGIMAGSNRSGDLRDAQKSIPTGTILAIATTSAVYIS 471 SLC12A5, R. NORVEGICUS  
417 YFTLLVGIYFPSVTGIMAGSNRSGDLRDAQKSIPTGTILAIATTSAVYIS 466 SLC12A5, G. GALLUS  
385 FFTLLVGIYFPSVTGIMAGSNRSGDLQDAQKSIPVGTILAITTTSIIYMS 434 LOC797331, D. RERIO  
356 FFTMLVGIYFPSVTGIMAGSNRSGDLRDAQKSIPIGTILAITTTSIIYMS 405 LOC572215, D. RERIO  
L426 
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522 GLQSLTGAPRLLQAISRDGIVPFLQVFGHGKANGEPTWALLLTACICEIG 571 SLC12A5, H. SAPIENS   
499 GLQSLTGAPRLLQAISRDGIVPFLQVFGHGKANGEPTWALLLTACICEIG 548 SLC12A5, P. TROGLODYTES  
552 GLQSLTGAPRLLQAISRDGIVPFLQVFGHGKANGEPTWALLLTACICEIG 601 SLC12A5, C. LUPUS    
492 GLQSLTGAPRLLQAISRDGIVPFLQVFGHGKANGEPTWALLLTACICEIG 541 SLC12A5, B. TAURUS    
499 GLQSLTGAPRLLQAISRDGIVPFLQVFGHGKANGEPTWALLLTACICEIG 548 SLC12A5, M. MUSCULUS   
522 GLQSLTGAPRLLQAISRDGIVPFLQVFGHGKANGEPTWALLLTACICEIG 571 SLC12A5, R. NORVEGICUS  
517 GLQSLTGAPRLLQAISRDGIVPFLRVFGHGKANGEPTWALLLTACICEIG 566 SLC12A5, G. GALLUS    
485 GLQSLTGAPRLLQAIARDGIIPFLRVFGHGKANGEPTWALLLTACICESG 534 LOC572215, D. RERIO   
456 GLQSLTGAPRLMQAIARDGIVPFLRVFGHGKANGEPTWALLLTACICESG 505 LOC572215, D. RERIO  
 
 
  
	 G551 
Figure 5-8 Conservation in species for identified SLC12A5 mutations. The mutated amino acid residues L311, L426 and G551 are highly conserved throughout 
species. ENSEMBL-id for the different species are: H. sapiens, ENSP00000387694; P. troglydytes, ENSPTRP00000023337; C. lupus, ENSCAFP00000014673; B. 
taurus, ENSBTAP00000018852; M. musculus, ENSMUSP00000096690; R. norvegicus, ENSRNOP00000062103; G. gallus, ENSGALP00000011213; D. rerio 
(loc797331), ENSDARP00000119636; D. rerio (loc572215), ENSDARP00000057257. Adapted from McTague et al Nat Commun. 2015 Sep 3;6:803. 
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5.3.6 Protein homology modelling 
KCC2 consists of 12 transmembrane (TM) helices interconnected by a series of extracellular 
and intracellular loops (Figure 5-9). Two isoforms KCC2a and KCC2b, differing by an extra 
40 amino acids in the N-terminus of KCC2b arise due to differential splicing (Uvarov et al. 
2007). The protein can exist as either a monomer or oligomer (Blaesse et al. 2006). 
 
Figure 5-9 Schematic representation of KCC2. The structure consists of 12 transmembrane 
(TM) helices (numbered blue cylinders) interconnected by a series of extracellular and 
intracellular loops. Sites of phosphorylation at the C-terminus are depicted as light green 
hexagons. N-linked glycosylated sites are indicated as dark green Y-shaped structures 
present at the extracellular loop between TM5 and TM6. The EIMFS mutations are 
indicated in red circles, located in the extracellular loop between TM5 and TM6 (L311H), 
within TM6 (L426P) and in the intracellular loop between TM8 and TM9 (G551D). Adapted 
from from McTague et al Nat Commun. 2015 Sep 3;6:803.  
 KCC2b expression is strongly up-regulated during post-natal development in rodent 
models and is the most abundant transcript in the adult brain (Uvarov et al. 2007). The 
variants identified in our patients are present in both isoforms. Computational protein 
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homology modelling studies were undertaken by our collaborators Maya Topf and Sony 
Malhotra to study the impact of the pathogenic variants on the structure-function 
properties of KCC2. L426 is situated in TM6 and is almost universally conserved in the one 
hundred most similar proteins. Mutation to a proline residue is predicted to disrupt this TM 
helix (Figure 5-10). G551 is located in the intracellular loop between TM8-TM9 (Figure 5-
10) is also well conserved, and mutation to a much larger negatively-charged aspartate 
residue may alter the interactions with other residues in the loop region or limit other 
molecular interactions. It was not possible to accurately model L311H due to a lack of 
sequence identity for the extended loop region between residues 303 and 407. However, 
the majority of the homologous proteins possess a hydrophobic residue at the 311 
position. Thus, substitution with histidine would be predicted to potentially disrupt 
hydrophobic interactions, and potentially structural integrity, of the TM5-TM6 loop. Four 
evolutionarily conserved cysteines (C310, C325, C345 and C354) in the TM5-TM6 region are 
vital for KCC2 transport activity and are located close to L311 (Hartmann et al. 2010). L311 
may form a hydrophobic pocket with a cysteine disulphide bond, in which case L311H 
would interfere with this process. 
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Figure 5-10 Homology modelling of mutations in SLC12A5. 5.10a: A homology model of 
KCC2 showing a transmembrane protein consisting of 12 transmembrane (TM) helices 
interconnected by intracellular and extracellular loops. 5.10b: L426 (shown in a surface 
representation) is located in the unwound TM6 (TM6a). This helix, together with TM1, is 
pivotal for transporter function. In the L426P mutant, the substitution of a leucine with a 
proline (not shown) is likely to introduce a kink in TM6, which will result in alteration of the 
interaction with TM1b. A comparative analysis of different structures of transporters (LeuT, 
vSGLT and ApcT structures) shows that the conformation of TM1b plays a key role in 
allowing access to the substrate binding pocket (maintaining a conformation that 
completely occludes access to the post-synaptic space but only partially occludes access to 
the cytosolic side). Thus, the presence of a proline in KCC2 TM6 could lead to an alteration 
of the extracellular occlusion formed by TM1b and TM6. 5.10c: Our KCC2 model predicts 
that G551 (shown in a surface representation) is located in the intracellular loop between 
TM8 and TM9 (residues 539-557). In the G551D mutant, the substitution of the glycine with 
an aspartic acid – a larger and negatively-charged amino acid – is likely to introduce a 
distortion in the orientation of TM8. The latter helix contains the putative substrate binding 
residues A521 and S525, based on homology to the amino acid, polyamine, and 
organocation ApcT receptor (A287 and T291, respectively (Protein Data Bank Reference 
3GIA) (Shaffer et al. 2009). Therefore, introducing an aspartic acid in position 551 could 
lead to disruption of the binding site thereby affecting substrate binding. Modelling 
interpreted by Dr Malhotra and Dr Topf. Adapted from McTague et al Nat Commun. 2015 
Sep 3;6:803. 
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5.3.7 Evaluation of KCC2 expression by immunoblotting and immunocytochemistry  
Using a heterologous expression system, a myc-tagged construct was created by Dr Meyer 
to assess total and surface expression of KCC2 by Western blotting and biotinylation in the 
Reith laboratory by Dr Zhen (see Appendix, (Figure 5-11). All three mutants displayed 
significantly reduced cell surface protein expression compared to wild type (WT). Two 
bands are visible on immunoblotting, with the upper band likely to represent mature 
glycosylated KCC2 (~130 kDa). There was also a significant difference between the 
proportion of glycosylated (i.e. mature) versus unglycosylated protein in all three mutants 
both in in the cell surface protein fraction and in total cell lysate, compared to WT (Table 
5.8). All variants therefore appear to affect both cell surface expression and post-
translational modification of KCC2.  
To further evaluate KCC2 cell surface expression, LLC-PK1 cells were transfected with KCC2, 
using a construct FLAG-tagged at the second extracellular loop by Dr Long in the Harvey 
laboratory (see Appendix). When permeabilised cells were stained with an anti-FLAG 
antibody, KCC2 expression in the three mutants was similar to wild type KCC2 (Figure 5-12). 
However, in non-permeabilised cells, reduced immunostaining was seen in cells transfected 
with KCC2-L311H, -L426P or -G551D versus WT KCC2 transfected cells, again reflecting 
decreased cell surface expression (Figure 5-12).  
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Figure 5-11 Immunoblotting studies including cell surface biotinylation and total cell 
lysate studies. Two bands are observed for WT and the three mutant KCC2 proteins closely 
located to each other at ~130kDa and corresponding to glycosylated (upper band) and 
unglycosylated (lower band) states. Adapted from McTague et al Nat Commun. 2015 Sep 
3;6:803. 
 
 Glycosylated plus unglycosylated 
KCC2 at the surface  
(fraction of total, % of wild-type) 
 
Glycosylated KCC2  
(% of glycoslyated plus unglycosylated) 
Surface fraction Total fraction 
WT 100±±0% 50±13% 43±1% 
L311H 34±7%** 22±5%* 17±1%** 
G551D 41±10%* 32±7% 38±1%* 
L426P 55±13%* 10±3%** 16±4%* 
 
Table 5.8 Quantification of total and glycosylated sub-fraction of KCC2 at the cell surface 
and in whole cell lysate. All three mutants showed significantly reduced levels of cell-
surface over total expression of KCC2 when compared to WT with reduced levels of 
glycosylated KCC2 protein evident at the cell surface and also in total cell lysates. n=4 * P < 
0.05, ** P < 0.005 (compared with WT, one-sample Student’s t-test). 
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Figure 5-12 L311H, L426P and G551D substitutions impair cell-surface expression of KCC2. HEK293 cells were co-transfected with KCC2-FLAG and 
HsRed-NLS and immunostained using anti-FLAG and AlexaFluor 488 antibodies. KCC2 WT is detected at the cell surface of intact cells (A), whereas 
KCC2-L311H, -L426P and -G551D display very little cell surface expression (B, C, D). Expression of KCC2-WT,-L311H,-L426P and -G551D is detected 
in permeabilised cells (E, F, G, H). Scale bar = 20 μm. Adapted from McTague et al Nat Commun. 2015 Sep 3;6:803. 
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5.3.8 Electrophysiology 
Given the importance of KCC2 in neuronal chloride homeostasis, I wished to investigate the 
impact of the EIMFS mutations on chloride transport function. As described above, a cell-
based system was devised in collaboration with Dr Ruiz. I performed transient transfection 
of HEK293 cells with GFP, the a2 subunit of the glycine receptor (GlyR) and either empty 
vector, WT KCC2 or mutant KCC2. As described in Methods 2.10, I assisted Dr Ruiz in the 
experiments and analysis including patching several cells which generated data that was 
included in the overall data analysis. We were able to measure glycine induced large 
inward currents (IGly) at -80mV in GFP positive cells but not in GFP negative, presumably 
untransfected, cells. A linear relationship between the membrane potential at which the 
cell was clamped (the holding potential) and the amplitude of IGly was seen, and a reversal 
in polarity with changes in holding potential occurred. From the current-voltage, or I-V, 
relationship we were able to calculate the chloride reversal potential (ECl-), that is the 
membrane potential at which there is no net flow of chloride across the cell membrane and 
therefore at which it is in equilibrium. In cells transfected with both GlyR a2 and wild-type 
KCC2 a more negative, hyperpolarising ECl was seen than in cells solely expressing GlyR a2 
(Figure 5-13a). For the KCC2 mutants, a depolarised ECl relative to wild type KCC2 was seen. 
The ECl was similar in all mutants and resembled the ECl- seen in cells without KCC2 (Figure 
5-13b and c), consistent with passive equilibration of Cl- ions as predicted from the pipette 
and extracellular solutions. In order to measure transporter function under dynamic 
conditions, we measured the ability of transfected cells to recover from chloride loading, as 
described previously (Staley & Proctor 1999). Cells were held at -80 then +40mV while 
glycine puffs were applied at intervals of 30 seconds to load with chloride (Figure 5-13d). 
When the holding potential was returned to -80mV, the glycine-evoked currents were 
larger due to the increased driving force provided by higher intracellular chloride. In cells 
transfected with wild-type KCC2, glycine-evoked currents IGly returned over time to the 
initial amplitude consistent with transporter-mediated extrusion of chloride. The rate of IGly 
amplitude recovery for the three KCC2 mutants was much longer (Figure 5-13e and f). In 
cells expressing L426P and G551D mutants, recovery time was not significantly different 
from cells without KCC2 (that is, transfected with GlyR a2 and eGFP alone). This appears to 
be consistent with near complete loss of KCC2 function. However, the recovery rate for 
L311H was intermediate between WT and the other mutants, suggesting some residual 
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KCC2 activity. Therefore, the three missense variants appear to alter ECl- with variable 
abnormal recovery from chloride loading. This impairment of KCC2 function may lead to 
intracellular Cl- accumulation in neurons with loss of a hyperpolarizing driving force for 
GABAA and glycine receptors. 
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Figure 5-13 Assays of KCC2 function in a HEK293 cell system. 5-13a Examples of I-V relationships in HEK293 cells transfected either with GlyR a2 alone (no 
KCC2), or GlyR a2 with a wild type KCC2 construct. IGly amplitude was plotted against the holding potential and the intercept of the line of fit of this relation 
with the abscissa was taken as ECl. Superimposed traces show examples of glycine-evoked currents recorded from individual cells at different holding 
potentials (–80 mV to +20 mV). 5-13b: Examples of I-V relationships in HEK293 cells co-transfected with GlyR a2 and mutant KCC2, as indicated. ECl in mutant 
KCC2 is depolarised in comparison to wild type (fit of I-V relation indicated by dashed-line). Calibration bars for 3a and 3b: 1nA, 1sec. 5-13c: Summary chart 
plotting the distribution of ECl for each cell group: no KCC2: –14.7 ± 0.8 mV (n = 5), GlyR-KCC2: –29 ± 3.5 mV (n = 9), G551D: –17.4 ± 1.2 mV (n = 5), L426P: –
17.9 ± 2.9 mV (n = 5), L311H: –15 ± 3.1 mV (n = 9); *P = 0.006, one-way ANOVA. Grey symbols represent measurements from individual cells. Boxes 
represent the mean ± standard error of the mean. GlyR a2: glycine receptor a2, Wt KCC2: wild type K+-Cl- co-transporter. Adapted from McTague et al Nat 
Commun. 2015 Sep 3;6:803. 
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Figure 5-13 continued: 5-13d: IGly amplitude plotted against time in a HEK293 cell co-transfected with GlyRa2 and wild type KCC2 and held at different 
membrane potentials as indicated in the top image. Vertical bars indicate the times of successive glycine applications. Example traces show glycine-evoked 
currents at times indicated by letters in italic. Calibration bars: 1nA, 300ms. 5-13e: Rate of recovery of IGly amplitude after switching back the holding 
potential from +40mV to -80mV. Fine lines replace symbols and error bars are omitted for legibility. An exponential decay function was used to fit IGly 
amplitude ratio in each cell group. 5-13f: Summary bar graph of the time-constant of IGly recovery in each group (no KCC2: 224 ± 56.7 s, n = 6; WT KCC2: 59.5 
± 7.7 s, n = 13; L426P: 162.5 ± 42.1 s, n = 4; G551D: 340.1 ± 137 s, n = 4; L311H: 88.1 ± 11.5 s, n = 7). *Different from WT KCC2 (P < 0.01), ANOVA. Adapted 
from McTague et al Nat Commun. 2015 Sep 3;6:803. 
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5.3.9 Zebrafish model 
In collaboration with Dr Hiromi Hirata (Aoyama Gakuin University, Japan) a zebrafish 
disease model was generated (see Appendix) to study the impact of KCC2 loss of function. 
Zebrafish have two KCC2 orthologues, KCC2a and KCC2b (due to ancestral gene 
duplication). TALEN-mediated genome editing was undertaken to generate knockout 
zebrafish models. An 8-bp deletion was induced in exon 4 of KCC2a to disrupt KCC2a and 
similarly, a 5-bp deletion was induced in exon 4 of KCC2b to disrupt KCC2b. A phenotype 
was not seen in neither single KCC2a nor KCC2b knockout zebrafish with normal survival 
into adulthood. A KCC2a-KCC2b double knockout zebrafish model was then generated, and 
tactile-induced motor behaviour was assessed. Wild type zebrafish larvae at 2 days post-
fertilization (dpf), showed a typical escape swimming response upon touch, with rhythmic 
side-to-side contraction of the trunk. In contrast to wild type, the KCC2a-KCC2b double 
knockout zebrafish showed abnormal jerky spasmodic movements during the escape 
response. 
5.4 Discussion 
SLC12A5 encodes KCC2, the neuronal-specific potassium chloride co-transporter which is a 
member of the cation-chloride co-transporter (CCC) family that includes NKCC1 (Payne et 
al. 1996). KCC2 may exist in monomeric or oligomeric forms (Blaesse et al. 2006). Until 
pancreatic expression was demonstrated in a recent study (Kursan et al. 2017), KCC2 was 
thought to show specific neuronal expression. Of note, hypoglycaemia was not reported for 
any of the patients in this study although two of the patients required nasogastric or 
gastrostomy feeding and therefore did not have significant periods of fasting.  In the 
central nervous system it is expressed in mature neurons from all layers of the cortex, CA1-
4 layers of the hippocampus and the cerebellum (Chamma et al. 2012) (Figure 5-14).  
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Figure 5-14 SLC12A5 (transcript variant 2, KCC2b) expression across the human brain. 
SLC12A5 is highly expressed in the cerebral cortex, cerebellum, basal ganglia and 
hippocampus, with levels in the cerebral cortex nine times higher than the intralobular 
white matter. Data derived from UK Brain Expression Consortium server 
(http://www.braineac.org), a repository of RNA expression data from 134 normal human 
brains. OCTX occipital cortex, FCTX frontal cortex, TCTC temporal cortex, CRBL cerebellum, 
THAL thalamus, PUTM putamen, HIPP hippocampus, SNIG substantia nigra, MEDU medulla, 
WHMT intralobular white matter.  
KCC2 is the major extruder of chloride in neurons and thus mediates the inhibitory effects 
of GABA/glycine. In the presence of low intraneuronal chloride levels, the binding of 
GABA/glycine to their receptors results in an influx of chloride and subsequent 
hyperpolarization, thereby contributing to neuronal inhibition (Figure 5-15) (Rivera et al. 
1999). 
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Figure 5-15 Schematic representation of the function of KCC2. In mature neurons (left panel), KCC2 maintains low intraneuronal chloride thus with 
GABA binding, there is chloride influx leading to hyperpolarization. In immature neurons/pathological states such as post-hypoxia (right panel), low KCC2 
and higher NKCC1 expression lead to higher intraneuronal chloride, so GABA binding results in chloride efflux, contributing to depolarization (Vanhatalo 
et al. 2005; Kahle et al. 2008; Ben-Ari et al. 2012).   
KCC2 function in the mature brain
KCC2 GABA-A
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Hyperpolarisation
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KCC2 is thought to be integral to the “developmental switch”, a concept whereby GABA 
and glycine switch from depolarizing to hyperpolarizing neurotransmitters. This conversion 
is purported to result from a gradual decrease in the chloride electrochemical equilibrium 
potential (ECl) of developing neurons, associated with an up-regulation of KCC2 and a 
downregulation of NKCC1 (Vanhatalo et al. 2005; Ben-Ari et al. 2012). In addition to its 
critical role governing neuronal inhibition, KCC2 also has a role in early brain neuronal and 
network development (Blaesse et al. 2009; Hübner et al. 2001).   
Although the findings of this study represent the first recessive disease-causing mutations 
in SLC12A5, two independent groups previously identified rare heterozygous variants in the 
carboxy terminus domain of SLC12A5 as putative disease-susceptibility alleles for idiopathic 
generalised epilepsy and febrile seizures. Enrichment of two rare non-synonymous KCC2 
variants was identified in a cohort of patients with idiopathic generalized epilepsy (IGE) 
(Kahle et al. 2014) compared to a cohort of healthy controls. The heterozygous variant 
R1049C was identified in three individuals with IGE (inherited from an unaffected mother in 
two cases) and in one control patient with no family history of IGE. The second variant 
identified, R952H, was identified in five IGE cases but also in five controls. For all three 
patients where parental DNA was available, the variant was found to be inherited from an 
unaffected parent. An independent research group (Puskarjovet al. 2014) also identified 
the variant R952H, but in a family with febrile seizures affecting multiple members of the 
pedigree. In 3/4 probands where DNA was available, the variant was identified as a 
heterozygous change. Affected individuals had infrequent febrile seizures (1–3 brief 
episodes on average) occurring between 12 months and 2.5 years of age. The variant was 
inherited from an affected mother who had inherited the change from an unaffected 
grandparent. Functional assessment of the impact of the R952H variant revealed decreased 
cell surface expression and altered transporter function in both studies, albeit in over-
expression systems (Kahle et al. 2014; Puskarjov et al. 2014). In addition, an alteration in 
the ability of R952H-KCC2 to induce dendritic spine formation in cultured neurons from 
KCC2 knockout mice was seen (Puskarjov, Seja, et al. 2014). R1049C did not result in 
altered cell surface expression and had a similar impact on Eglycine to R952H when solely 
expressed, but reduced impact when co-expressed with WT KCC2 in an attempt to mimic 
the in vivo status of the variant (Kahle et al. 2014). Interestingly, both R952H and R1049C 
were shown to have decreased serine 940 phosphorylation, a major regulatory mechanism 
for KCC2 expression (see below) (Kahle et al. 2014). Subsequently, a further paper from the 
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same group examined large cohorts of individuals with autistic spectrum disorder (ASD) 
and schizophrenia and found an enrichment of the R952H and R1049C variants, and a 
further C-terminal domain variant, R1048W, in the patient cohorts when compared to 
controls (Merner et al. 2015). Of note R1048W, while closely located to R1049C and 
predicted by in silico tools to be pathogenic, has not undergone functional validation. 
Overall studies to date have shown that these rare non-synonymous variants are found in 
the heterozygous state in both healthy carriers and for some variants in unaffected 
transmitting parents as well as in individuals with IGE, febrile seizures, ASD and 
schizophrenia. The clinical significance of these variants remains yet to be fully understood, 
but it is possible they represent susceptibility alleles within a complex genetic framework 
that contributes to the multifactorial aetiology underpinning these epilepsies.  To 
investigate these variants further, larger cohorts of patients with IGE from international 
consortia could be interrogated to see if these findings are replicable in larger populations. 
However, to fully understand the contribution of these variants to epilepsy, we would need 
to study them in better model systems. One possible way that this could be achieved is by 
generating a knock-in mouse harbouring these reported variants. Alternatively it would be 
interesting to generate cortical neurons from an IGE patient-derived iPSC with the R952H 
variant in tandem with an age-matched and CRISPR-corrected control as well as an 
unaffected family member with the same variant , to assess the impact on transporter 
function and dendritic branching in a human model system  
Since our identification of biallelic disease-causing mutations in SLC12A5 (Stödberg et al. 
2015), five similar patients with EIMFS or EIMFS-like phenotypes have been described 
(Saitsu et al. 2016; Saito et al. 2017). The clinical features are in keeping with our 
description of a classical EIMFS phenotype (Table 5.9). One patient (Patient 4 in Table 5.9) 
had clinical features in keeping with EIMFS but early ictal EEGs were not available to make 
a formal diagnosis. In keeping with our patients, cerebral atrophy and delayed myelination 
was seen on MR brain imaging. However, some additional imaging features were also 
noted in these patients. Unilateral hippocampal sclerosis was noted at the age of four years 
(Saito et al. 2017). In another patient who was imaged at 10 and 20 years of age, cerebellar 
atrophy and bilateral hippocampal atrophy with increased signal on FLAIR imaging was 
seen (Saitsu et al. 2016). It is unclear whether this latter case represents long-term 
radiological sequelae of SLC12A5-EIMFS as, except for this case, the oldest age at reported 
imaging is 4 years. Focal MRI changes have only rarely been described in EIMFS (Fasulo et 
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al. 2012; Coppola et al. 2007) as discussed in Chapter 2 and it is not clear whether this may 
be a secondary phenomenon related to frequent focal seizures or due to underlying 
aetiology. While most reported patients showed severe neurological impairment, one 
patient achieved independent ambulation and others regained some neurodevelopmental 
skills with seizure control (Table 5.9). This is also in keeping with our patients, indeed 
Patient 2-II:1 walked and also made some developmental gains.  
The type of the mutations identified in these five further cases is of interest (Saitsu et al. 
2016; Saito et al. 2017). Three of the patients harbour loss of function (LOF) variants in 
SLC12A5, namely a splice site mutation leading to an in-frame deletion with loss of exon 3 
in two individuals, and a three base-pair deletion leading to an in-frame loss of one amino 
acid in another. Both these LOF variants occur as compound heterozygous variants in 
conjunction with a missense variant (Table 5.9). This lends further weight to our assertion 
that the disease mechanism in SLC12A5-epilepsy is related to loss of normal transporter 
function. As in our cases and in contrast to the C-terminus variants discussed above, the 
presence of a heterozygous variant in both parents and siblings does not seem to confer 
disease susceptibility in these individuals. While all previous mutations including those 
detected in our cases have been inherited from unaffected parents, one of the variants in a 
patient bearing compound heterozygous mutations was de novo (Saito et al. 2017).  
Electrophysiological assessment of these newly reported SLC12A5 variants in a 
heterologous system, where cells were co-transfected with different mutant constructs to 
recapitulate the compound heterozygous in vivo state, demonstrated that the mutants led 
to a depolarised ECl- compared to wild type, albeit not to the same degree as the 
untransfected cells without KCC2. This partial loss of transporter function with depolarized 
ECl- (Saitsu et al. 2016) is in keeping with our study. However, they did not identify a deficit 
in surface expression using both confocal microscopy, surface biotinylation studies and 
immunoblotting. It may be that these variants do not affect transporter trafficking to the 
same degree as we observed for our mutations. The newly described mutations are located 
in the N-terminal domain (E50_Q93del), transmembrane domains (A191V and M415V) and 
the largest extracellular loop (S323P) (Figure 5-16). Two of the compound heterozygous 
variants in this study (W318S/S748del) and the most recently identified compound 
heterozygous mutations (S399L/R880L) have not yet been functionally validated.  
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Figure 5-16 Schematic representation of KCC2 structure with location of mutations from 
this study and recently published studies. Mutations from this study are depicted in red 
circles, those identified from subsequent studies in blue circles and C-terminus 
“susceptibility” variants in purple circles. All variants are annotated according to 
ENST00000454036.2. Adapted from McTague et al Nat Commun. 2015 Sep 3;6:803. 
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 Mutation   EC 
diagnosis 
Inheritance Seizure 
Onset 
Sz at onset Peak Sz 
frequency 
Ictal EEG 
(age) 
MRI (age) Other 
features 
Effective 
treatments 
Best 
developmental 
stage attained 
Seizure 
outcome 
1 c.279 + 1G > C  
A191V 
c.572C > T 
E50_Q93del  
 
EIMFS Recessive 
(parents 
carriers) 
unaffected 
sib het for 
c.279 + 1G 
> C 
D1 Clonic 
seizures, 
apnoeas, 
facial 
flushing 
9w Migrating 
ictal focus 
(2m) 
Thin CC, FL 
and TL 
atrophy and 
DM (2m and 
13m) 
Post-natal 
microcephaly 
Hypotonia 
 
High-dose 
PB and 
KBR 
AZM for 
apnoeas 
Some head 
control and 
rolling (4y8m) 
SF 1y4m 
to 3y4m- 
currently 
daily 
tonic sz 
(4y8m) 
2 c.279 + 1G > C  
A191V  
c.572C > T  
E50_Q93del  
 
EIMFS Recessive 
(parents 
carriers) 
unaffected 
sib het for 
c.279 + 1G 
> C 
D3 Tonic 
seizures, 
ED 
8w Migrating 
ictal focus 
(2m) 
Thin CC, FL 
atrophy, 
DM, 
arachnoid 
cyst L 
posterior 
fossa (5m) 
Post-natal 
microcephaly 
Hypotonia 
 
KBr, high-
dose PB, 
SVA  
 
No head 
control or 
rolling 
SF 3 to 
11 
months; 
clonic 
migrating 
and tonic 
seizures 
11m till 
current 
age 
(3y1m) 
 
3 c.967T > C 
S323P  
c.1243A > G 
M415V  
 
EIMFS Recessive 
(parents 
carriers) 
1.5m Apnoea, 
staring 
episodes 
5m Migrating 
ictal focus 
(6.5m 
Mild atrophy 
(3m) 
Post-natal 
microcephaly 
Hypotonia- 
improved 
with Sz 
control 
KD, LEV Regained 
abilities from 
9m. At 23m 
can crawl, sit, 
grasp and 
vocalise.   
SF from 
20m on 
KD 
4 c.953G > C EOEE Recessive D1  Eye 6m Early ictal Subdural - None Unable to sit Ongoing 
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W318S 
c.2242_2244del  
S748del 
(parents 
carriers) 
deviation, 
cyanosis, 
tonic-clonic 
seizures, 
asymmetric 
tonic 
seizures 
EEG not 
available. 
Later 
interictal 
EEG sharp 
waves over 
L central 
and frontal 
and slow 
background. 
hygroma, 
bilateral 
hippocampal 
atrophy with 
increased 
FLAIR signal, 
mild 
cerebellar 
atrophy, DM 
of TL (10y 
and 20y). 
Progressive 
cerebellar 
atrophy 
(20y). 
or speak (20 y) seizures 
5 c.1196C>T 
R880L 
c.2639G>T 
S399L 
 
EIMFS Recessive 
(one 
inherited 
allele, one 
de novo 
allele) 
4m GTCS and 
apnoeas 
evolving to 
refractory 
focal with 
ED and 
tonic Sz 
6m Migrating 
ictal focus 
at 6m 
FL and TL 
atrophy(6m) 
L HS (4y) 
 
- KBr Walked at 4 
years spoke 
single word 6 y 
SF from 
10 years 
Table 5.9 Subsequently published cases of SLC12A5-epilepsy AZM acetazolamide, D day, DM delayed myelination, EC electroclinical ED eye deviation, FL 
frontal lobe, HS hippocampal sclerosis, KBR potassium bromide, L left, m months, PB phenobarbitone Sz seizure, SF seizure free, SVA sodium valproate, TL 
temporal lobe, w weeks y years. 
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Reports of these additional cases strongly support the notion that biallelic loss of function 
SLC12A5 mutations lead to EIMFS. This is also supported by phenotypic and 
electrophysiological data from established animal models of KCC2 dysfunction. Complete 
knockout of Slc12a5 in mice leads to neonatal lethality due to respiratory insufficiency 
caused by abnormal central pattern generator function (Hübner et al. 2001).  Patch 
clamping of spinal cord motoneurons in Slc12a5-/- mice revealed an abnormal excitatory 
effect of GABA and glycine, which was not seen in the wild type mice. In another murine 
model, the homozygous knock-outs retain approximately 5% KCC2 function and survive 
beyond the neonatal period (Woo et al. 2002). These animals display frequent spontaneous 
seizures and abnormal excitability in hippocampal slices. It subsequently became clear that 
the mice survived for the first few weeks of post-natal life due to expression of KCC2a, the 
immature transcript which was not affected by the targeted disruption of the first exon of 
Slc12a5b (Uvarov et al. 2007). The generation of a hypomorphic allele producing 
approximately 20-30% of Kcc2 protein levels resulted in a viable murine model but 
phenotypic information, other than a description of abnormal EEG activity, is limited (Vilen 
et al. 2001).  Mice with one null and one hypomorphic allele, resulting in overall 15-20% of 
normal KCC2 protein production have also been generated (Tornberg et al. 2005). These 
mice showed normal locomotor function and coordination but increased susceptibility to 
induced seizures and abnormal cognitive function. The epileptic phenotype is also evident 
in a Drosophila melanogaster kcc mutant model (Hekmat-Scafe et al. 2006). Null mutations 
in Kazachoc, the drosophila ortholog of SLC12A5, leads to lethality, whilst partial loss of 
function causes increased seizure susceptibility mediated by GABA-A dysfunction.   
Further evidence for the role of KCC2 in epileptogenesis comes from acute slice 
electrophysiology work in rodent studies, where application of specific KCC2 inhibitors 
promotes the development of continuous seizure-like activity (Sivakumaran et al. 2015; 
Kelley et al. 2016). Recently, it was shown that focal knockdown of KCC2 in the cortex using 
injection of AAV2-Cre-GFP in a floxed-Slc12a5 mouse model is sufficient to induce seizures 
(MacKenzie et al. 2016). In hippocampal slices from patients with temporal lobe epilepsy, 
interictal activity was attributable to GABA-A depolarising transmission, which was 
subsequently linked to downregulation of KCC2 (Cohen et al. 2002). Subsequent studies 
have confirmed decreased KCC2 expression in brain tumours and peri-tumoural tissue, 
particularly gliomatous lesions ( Pallud et al. 2014; Campbell et al. 2015). Although there is 
strong evidence for down-regulation of KCC2 in epileptogenic tissue such as gliomas, it has 
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been unclear whether this represents a primary event in epileptogenesis or a response to 
seizures. A recent elegant study dissected this temporal relationship and found in a rodent 
seizure model that KCC2 down-regulation and loss of function occurs prior to the 
emergence of synchronous bursting and therefore appears to play a more primary role in 
epileptogenesis (Chen et al. 2017).  
KCC2 dysfunction has been widely implicated in a variety of other neurological disorders 
including spinal cord injury, trauma and neuropathic pain (Kaila et al. 2014) where 
downregulation of KCC2 leads to increased intra-neuronal chloride concentration and a 
depolarizing shift in the reversal potential of GABA. The resultant excessive levels of 
excitation are thought to contribute to the excitotoxic damage seen following trauma or 
hypoxic injury. KCC2 also postulated to play an important role in other 
neurodevelopmental disorders. The identification of significantly reduced levels of KCC2 
with low KCC2/NKCC1 ratios in Rett syndrome implicated KCC2 dysfunction in disease 
pathogenesis (Duarte et al. 2013). Subsequent studies in MECP2-Rett patient neurons 
derived from induced pluripotent stem cells showed a significant deficit in KCC2 expression 
and a delayed GABA functional switch from excitation to inhibition (Tang et al. 2016).  
There is therefore strong evidence for the physiological role of KCC2 in normal 
neurodevelopment. KCC2 dysfunction is associated with epileptogenesis and other 
neurodevelopmental defects. The mechanism by which loss of function of KCC2 leads to 
epilepsy in my EIMFS patients remains to be fully elucidated. However, decreased cell 
surface expression appears to be a potential disease mechanism for some if not all KCC2-
EIMFS patients. The regulation of KCC2 expression is complex and includes both BDNF and 
activity-dependent up-regulation in addition to many other putative transcription factors 
(Medina et al. 2014). The cytoplasmic terminus is critical for membrane trafficking (Zhao et 
al. 2008). However, one of the most important mechanisms for regulation of KCC2 
expression is phosphorylation of key residues such as serine 940 in the cytoplasmic 
terminus, which increases plasmalemmal KCC2. Other mechanisms by which a loss of KCC2 
function might occur may be altered oligomerization, abnormal interaction with other 
chloride co-transporters or perturbation of the function of other transporters, leading to 
dysregulated ion binding. KCC2 plays a significant role at excitatory neurons, in synapse 
formation and dendritic branching (Chamma et al. 2012). This is clearly evident in animal 
models (see above), where abnormal dendritic branching can be rescued by KCC2 over-
expression. Abnormalities of dendrite morphology or altered branching appear to be 
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common to many neurodevelopmental disorders including Down syndrome, autistic 
spectrum disorder and Fragile X syndrome (Kulkarni & Firestein 2012). It is now well 
established that dendritic spine formation and maintenance contribute to synaptic 
plasticity and memory formation after learning (Moser et al. 1994; Parajuli et al. 2017). 
Therefore, although this area requires further study, it may provide a link to the post-natal 
microcephaly, cerebral atrophy and observed neurodevelopmental and cognitive issues 
noted in KCC2-EIMFS. 
There are many non-specific modulators of KCC2 including the loop diuretics frusemide and 
bumetanide which are weak KCC2 antagonists with significant antagonist activity against 
NKCC1. Bumetanide as a therapy for neonatal seizures has not lived up to the promise of 
early animal studies, largely due to lack of efficacy and serious adverse reactions including 
ototoxicity (Pressler et al. 2015). Development of more bioavailable lipophilic prodrugs of 
bumetanide may overcome some of these issues (Erker et al. 2016). There has been a great 
deal of interest in identifying a specific KCC2 modulator as KCC2 down-regulation is 
implicated in a range of severe intractable conditions such as neuropathic pain as well as 
representing a possible anti-epileptic target in more common acquired epilepsies as 
discussed above (Moore et al. 2017; Puskarjov, Kahle, et al. 2014; Löscher et al. 2013). 
There has also been interest in KCC2 as a drug target for hypoxic injury such as following 
stroke (Martín-Aragón Baudel et al. 2017). Gagnon et al used a high throughput chloride 
flux assay in NG-108 (modified neuroblastoma/glioma) cells to screen for KCC2 modulators 
for neuropathic pain(Gagnon et al. 2013). Further experiments led to identification of 
CLP257, a unique compound which lowered intracellular chloride and appeared to reverse 
KCC2 hypofunction in mature rat spinal neurons treated with BDNF (which down-regulates 
KCC2) by increasing cell surface expression. However, another group was unable to 
reproduce the effects of CLP257 on intracellular chloride or to show KCC2 expression in 
NG-108 cells, suggesting the action of CLP257 in animal models may occur via other 
receptors such as GABAA or MAO1 (Cardarelli et al. 2017; Gagnon et al. 2017). It therefore 
remains to be seen whether CLP257 will develop into a useful KCC2 agonist. The CLP257 
story also highlights the issue of setting the level of KCC2 expression in model systems used 
to screen for novel KCC2 modulators. Further possible approaches to KCC2 modulation are 
likely to exploit the major regulatory pathways of phosphorylation/dephosphorylation of 
key residues such as serine 940 by kinases such as protein kinase C (Lee et al. 2007). N-
ethylmaleimide (NEM) is a KCC2 agonist which has been used in animal work for many 
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years (Payne 1997) and is an alkylating agent thought to modify cysteine residues of a 
range of proteins including KCC2. Recently it was shown to act via dephosphorylation of the 
threonine 1007 residue via the WNK/SPAK pathway, leading to increased KCC2 cell surface 
expression in neurons and altered chloride extrusion capacity  (Conway et al. 2017). NEM 
itself is unlikely to be a viable treatment as it is an alkylating agent with non-specific effects 
across other cation co-transporters including NKCC1, but development of a specific KCC2 
activator which works via phosphorylation shows promise. Other possible drug targets 
include a number of G-protein coupled receptors including metabotropic glutamate 
receptors and zinc receptors which are known to activate phospholipase B, leading to 
protein kinase C activation and serine 940 phosphorylation (Mahadevan & Woodin 2016).  
In conclusion, I have shown in this chapter that biallelic mutations of SLC12A5 result in a 
severe early onset epilepsy and developmental delay as revealed by this study and further 
validated by subsequently published cases. Heterozygous C-terminus variants may 
represent susceptibility alleles for epilepsy and other neurodevelopmental disorders but 
their true role in epilepsy susceptibility requires further investigation and validation. A 
significant impact on transporter function for the mutations identified in this study has 
been demonstrated with a range of functional assays. Protein homology modelling predicts 
a significant impact of the compound heterozygous mutations on substrate binding. In 
addition, mutations lead to reduced cell surface expression in both immunoblotting and 
confocal studies. Reduced glycosylation revealed by biotinylation studies indicates altered 
post-translational processing and the presence of less mature protein at the cell surface. 
Electrophysiology experiments demonstrated an impact on chloride reversal potential and 
the assessment of the transporter under the stress of a chloride load. Lastly, a knockout 
zebrafish model displayed abnormal movements on the touch response test. All these 
complementary data point to a loss of transporter function, which I suggest leads to an 
increase in intraneuronal chloride, altering the polarity and strength of GABAergic 
inhibition on the brain and leading to epilepsy and developmental delay. In addition, the 
impact of these mutations on excitatory synapse formation and dendritic spine morphology 
warrants further investigation. For SLC12A5-EIMFS, the severe epileptic encephalopathy is 
likely due to disruption of both KCC2-driven neuronal inhibition and KCC2-mediated brain 
and neuronal network development. In addition to shedding light on a pathogenic 
mechanism in EIMFS, the identification of SLC12A5 mutations also supports the long-
standing notion that KCC2 dysfunction plays an integral role in epileptogenesis and 
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neurological disorders. While SLC12A5 mutations represent a rare cause of epilepsy, 
further research is likely to have impact in more common epilepsies and many neurological 
disorders with significant morbidity. This will require the development of disease models 
which can act as platforms for drug discovery. Although there are current murine Slc12a5 
knockout models which exhibit seizures, they have severely limited survival, with neonatal 
lethality in loss of both the immature (KCC2a) and mature (KCC2b) isoforms of KCC2 and 
survival until just P18-21 in selective KCC2b knockout (Woo et al. 2002; Hübner et al. 2001; 
Vilen et al. 2001).  A model system where the disease-causing mutation is expressed in the 
native genetic milieu, such as a patient–derived induced pluripotent stem (IPSC) cell model, 
may overcome these difficulties of genetic background and mutation dosing. This would be 
complemented by the development of knock-in mouse models which are not currently 
available. IPSC models have provided valuable insights in several severe epilepsies such as 
Dravet syndrome and STXBP1-encephalopathy (Barral & Kurian 2016; Sun et al. 2016). In 
addition, establishment of a neuronal disease model would provide an ideal future 
platform for compound screening and drug discovery. Furthermore, this model would be 
ideal for the development and assessment of novel therapies such as new small molecules 
or gene therapy, whether mutation-specific RNA manipulation strategies or emerging 
genome editing techniques, or cell-based therapies (Kullmann et al. 2014; Maljevic et al. 
2017). 
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Chapter 6 Conclusion and future perspectives: the heterogenous 
genetic landscape of epilepsy of infancy with migrating focal 
seizures  
6.1 Molecular genetic investigation of the EIMFS cohort 
In my PhD, I have studied the phenotype and investigated the underlying genetic aetiology 
in a cohort of 34 patients with the electroclinical syndrome of EIMFS. My clinical work has 
delineated both typical and atypical clinical features. During the molecular genetic 
investigation of this cohort (29 patients), I identified mutations in a previously reported 
disease gene, KCNT1, in ten patients, and found mutations in a novel gene, SLC12A5, in two 
patients.  
The remaining 17 patients have undergone molecular genetic investigation by a variety of 
methods including diagnostic multiple gene NGS panel and research-based whole exome 
sequencing (Table 6.1). A genetic aetiology was identified in 4 of these 17 cases. Overall in 
16/29 (55%) patients with EIMFS where genetic testing was possible, a putative genetic 
aetiology was identified.  
Heterozygous de novo mutations of SCN2A were identified in two patients, Patient 24 and 
Patient 31. In Patient 24, local diagnostic NGS multiple gene panel testing at St. Thomas’ 
Hospital, London identified a novel heterozygous de novo variant in SCN2A (c.640T>C 
S214P). In silico tools were predictive of pathogenicity; Polyphen2 0.999 (damaging), 
Provean -4.88 (deleterious, range ≤-2.5), SIFT 0 (≤ 0.05).  Additional clinical features in this 
patient included severe gastrointestinal dysmotility and a dystonic movement disorder. 
Patient 31 was investigated with the Great Ormond Street Regional Genetics NGS multiple 
gene panel, revealing a heterozygous de novo variant in SCN2A, c.2995 G>A, E999K. In silico 
tools also indicated possible pathogenicity; Polyphen2 0.973 (probably damaging), Provean 
-3.74, SIFT 0.001. This variant has previously been reported in two patients; in a patient 
with Ohtahara syndrome (Nakamura et al. 2013) and most recently a patient with non-
specific EOEE with suppression-burst pattern (Wolff et al. 2017). De novo heterozygous 
SCN2A mutations have been reported in a wide range of epilepsies (Table 1.2, Table 1.4), 
including EIMFS (Wolff et al. 2017; Dhamija et al. 2013; Howell et al. 2015). Indeed, 
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mutations in SCN2A have been found to be the second commonest cause (after KCNT1) in 
some cohorts with variants identified in 7/27 EIMFS cases (Howell et al. 2015). SCN2A 
encodes the a2 subunit of the voltage gated sodium channel and variants associated with 
the early onset severe form of SCN2A-epilepsy, as opposed to other later-onset or self-
limiting phenotypes, appear to be associated with a marked gain of function in 
electrophysiological studies (Ogiwara et al. 2009; Wolff et al. 2017). Interestingly, several of 
these patients, have been shown to respond well, and indeed become seizure free, when 
treated with anti-epileptic medications that act via sodium channel blockade such as 
Carbamazepine and Phenytoin (Howell et al. 2015; Wolff et al. 2017). This was also the case 
in Patient 31, who became seizure free with Carbamazepine and relapsed on withdrawal. 
Patient 24 unfortunately did not show any such response. Other phenotypic features of 
SCN2A-EIMFS include a dystonic movement disorder and severe gastrointestinal features 
such as vomiting or dysmotility, as evident in Patients 24 and 31. Notably, in published 
cases SCN2A-EIMFS appears to have a less severe neurodevelopmental profile compared to 
KCNT1-EIMFS, with 2/5 cases manifesting mild intellectual disability in a recent study 
(Wolff et al. 2017). These two patients had become seizure free at two and 10 months on 
treatment with vigabatrin and phenytoin, respectively. Unfortunately, both patients in this 
study showed severe neurodevelopmental impairment. While the reports of treatment 
response are encouraging, longitudinal studies are now required to investigate whether 
early use of sodium-channel blockers could improve both seizure and cognitive outcome in 
SCN2A-epilepsy.  
A missense variant in GABRB3 (c.372A>C, L124F) was identified by whole exome 
sequencing in Patient 7 and confirmed on Sanger sequencing to be de novo. The variant 
occurs at a highly conserved residue and in silico tools Polyphen2 (0.947, possibly 
damaging) and SIFT (Damaging 0.022) indicate possible pathogenicity although the Provean 
score is neutral (2.19, <-2.5). It is not present in 1000 Genomes, EVS, ExAC or gnomAD. 
Patient 7, as described in Chapter 1, had several features atypical for EIMFS including 
marked basal ganglia changes with bilateral putaminal atrophy on brain MR imaging 
(Figure 3-4).  The same GABRB3 variant was also recently identified in a patient with EOEE 
characterised by onset of focal, migrating seizures at 2.5 months (but not meeting the 
diagnostic criteria for EIMFS) and severe global atrophy (Møller et al. 2017), but without 
basal ganglia imaging abnormalities. Functional validation of the pathogenicity of this 
variant has not been performed to date. Heterozygous mutations of GABRB3, which 
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encodes the ß3 subunit of the GABAA receptor, have been implicated in a wide spectrum of 
epilepsies, from severe epileptic encephalopathies including Dravet syndrome to febrile 
seizures (Allen et al. 2013; Myers et al. 2016; Trump et al. 2016; Møller et al. 2017; Warrier 
et al. 2013; Zhang et al. 2015; Le et al. 2017; Hamdan et al. 2014). Only a small number of 
mutations have been functionally characterised, but the majority result in a loss of function 
which is postulated to lead to a lack of GABAergic inhibition (Møller et al. 2017; Janve et al. 
2016; Hirose 2014). Therefore, while the confirmation of the GABRB3 variant identified in 
Patient 7 in another patient may strengthen the case for pathogenicity, further functional 
validation is required.  
Following recruitment to the BPNSU study, Patient 12 was recruited to another whole 
exome sequencing study which identified a de novo novel heterozygous deletion in SMC1A, 
c.1114delG, resulting in a premature stop codon (pVal372*) (Gorman et al. 2017). The 
deleted nucleotide occupies a splice acceptor site and is predicted to result in non-sense 
mediated messenger RNA decay. SMC1A encodes the Structural Maintenance of 
Chromosome 1 protein, which forms part of a cohesin ring vital to the structural integrity 
of chromosomes during mitosis and meiosis. Missense variants and in-frame deletions of 
SMC1A account for approximately 5% of Cornelia du Lange syndrome, a multisystem 
disorder with features including facial dysmorphism, growth abnormalities, small hands 
and feet and cardiac anomalies ((Huisman et al. 2017). Recently, truncating mutations in 
SMC1A have emerged in females with epileptic encephalopathy characterised by 
treatment-resistant seizures with onset from the neonatal period to 3 years of age 
occurring in clusters, mild or no dysmorphic features and developmental delay (Lebrun et 
al. 2015; Huisman et al. 2017; Symonds et al. 2017; Goldstein et al. 2015; Jansen et al. 
2016; Gorman et al. 2017). Therefore, although it is possible that SMC1A represents 
another disease gene for EIMFS, further cases are awaited to confirm this.  
Analysis is currently ongoing for the remaining, unsolved cases (Table 6.1) and although 
many of the known EIMFS/EOEE genes have been excluded, it is likely that further genetic 
aetiologies will be elucidated.  
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EIMFS 
Cohort 
Patient 
No 
Phenotype Genetic Investigation  Diagnostic chromosomal 
microarray* 
Diagnostic 
karyotype 
Genetic cause 
identified?  Sanger 
sequencing 
KCNT1 
Sanger 
sequencng 
SLC12A5 
NGS1 
Pilot 
Panel 
NGS2  
Diagnostic 
Panel 
WES 
1 EIMFS + - - - + - N KCNT1 
2 EIMFS   No DNA No DNA 
3 EIMFS + - - - + - N KCNT1 
4 EIMFS   No DNA No DNA 
5 EIMFS   No DNA No DNA 
6 EIMFS + - + - - N - KCNT1 
7 EIMFS + - + - + N - GABRB3 
8 EIMFS + + +  - N - WES analysis 
ongoing 
9 EIMFS + - +  + N - WES analysis 
ongoing 
10 EIMFS  - No DNA No DNA 
11 EIMFS + + -  - N - Awaiting WES 
12 EIMFS + + + - - - N SMC1A 
13 EIMFS + - +  + N - WES analysis 
ongoing 
14 EIMFS  - Parents did not consent to further testing No further 
testing 
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15 EIMFS + - - + - - - KCNT1 
16 EIMFS + - - - - - N KCNT1 
17 EIMFS + - - - - N - KCNT1 
18 EIMFS - - - + - N - KCNT1 
19 EIMFS + - - - - N - KCNT1 
20 EIMFS - - - + - N - KCNT1 
21 EIMFS - - - + - N - KCNT1 
22 EIMFS + + - - - N - WES analysis 
ongoing 
23 EIMFS + + - - - N - WES analysis 
ongoing 
24 EIMFS + + - - - N - SCN2A 
25 EIMFS + + - - - N - WES analysis 
ongoing 
26 EIMFS + + - - - N - WES analysis 
ongoing 
27 EIMFS + + - - - N - WES analysis 
ongoing 
28 EIMFS + + - + - 11.8 Mb heterozygous 
deletion  
Chr 20q11 copy number 
variant of uncertain 
significance 
- WES analysis 
ongoing 
29 EIMFS - - - + - N - WES analysis 
ongoing 
30 EIMFS - - - + - N - WES analysis 
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ongoing 
31 EIMFS - - - + - N  SCN2A 
32 EIMFS - + - - + N  SLC12A5 
33 EIMFS - + - - - N - SLC12A5 
34 EIMFS - + - - + N - WES analysis 
ongoing 
Table 6.1 Molecular Genetic Investigation of the EIMFS cohort. A variety of genetic techniques were used including Sanger sequencing of known 
and novel EIMFS genes, NGS panel and whole exome sequencing. Patients where a likely genetic cause has been identified are highlighted in 
green, those with a possible genetic aetiology requiring further validation in pale orange and those where further investigation is not possible in 
grey.  
1. Pilot NGS panel included NGS sequencing and exon-level CNV analysis of CDKL5, MECP2, ARX, ATRX, SLC9A6, SLC16A2, ADSL, CNTNAP2, NRXN1, 
PNKP, KIAA1279, UBE3A, EHMT1, FOXG1, MEF2C, SIP1, ZEB2, TCF4, STXBP1, SLC25A22, PCDH19, SCN1A, PLCB1, SPTAN1, KCNQ2, ARHGEF9, SCN2A, 
MAGI2 (Trump et al, 2016). 
2. NGS diagnostic 45 gene panel included sequencing of ADSL, ALG13, ARHGEF9, ARX, ATP1A3, ATRX, CDKL5, CHD2, CHRNA4, CHRNB2, CNTNAP2, 
EHMT1, FOXG1, GABRB3, GRIN2A, GRIN2B, KCNQ2, KCNT1, KIAA1279, LGI1, MAGI2, MBD5, MECP2, MEF2C, NRXN1, PCDH19, PLCB1, PNKP, POLG, 
PRRT2, SCN1A, SCN2A, SCN8A, SIP1 [ZEB2], SLC16A2, SLC25A22, SLC2A1 [GLUT1], SLC9A6, SPTAN1, STXBP1, SYNGAP1, TBC1D24, TCF4, 
UBE2A, UBE3A (Trump et al, 2016).  
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6.2 The complex genetic landscape of EIMFS  
The first evidence of a genetic aetiology for EIMFS came in 2011 from the finding of de 
novo missense mutations in two patients (Carranza Rojo et al. 2011; Freilich et al. 2011). 
Since then, the genetic landscape has become increasingly complex, with a number of 
dominantly and recessively inherited genes identified in patients with EIMFS (Table 6.2). 
Gene 
 
Number 
of 
reported 
cases 
(including 
this 
study) 
Mode of 
inheritance 
Effect of 
mutation 
on 
protein 
function 
Protein Protein function 
KCNT1 
 
47 AD, usually 
de novo 
Gain-of-
function 
Sodium 
activated 
potassium 
channel (KNa) 
Outwardly rectifying potassium 
channel subunit, required for 
hyperpolarisation following 
repetitive firing 
Interaction with wider protein 
network including FMRP 
SCN2A 
 
15 AD, usually 
de novo 
Likely to 
be gain-
of-
function 
Type 2 
voltage-gated 
sodium 
channel alpha 
subunit 
Initiation and propagation of 
neuronal action potentials, 
located at axon initial segment 
SCN1A 
 
3 AD, usually 
de novo 
Likely to 
be loss-
of-
function 
Type 1 
voltage-gated 
sodium 
channel alpha 
subunit 
Initiation and propagation of 
neuronal action potentials, 
particularly in GABAergic 
interneurons 
SCN8A 
 
1 AD, usually 
de novo 
Likely to 
be gain-
of-
function 
Type 8 
voltage-gated 
sodium 
channel alpha 
subunit 
Initiation and propagation of 
neuronal action potentials, 
particularly in GABAergic 
interneurons; expressed later in 
post-natal development than 
SCN2A 
SLC12A5 9 AR Loss of 
function 
Neuronal 
potassium 
chloride co-
transporter 
Determines strength and 
polarity of GABA signaling. 
Important in dendrite and 
excitatory synapse formation.  
TBC1D24 
 
2 AR Loss-of-
function 
TBC domain 
containing 
RAB-specific 
GTPAse 
activating 
protein 
Regulation of neurite growth 
and branching, morphological 
and functional maturation of 
neuronal circuits 
SLC25A22 
 
2 AR Loss-of-
function 
Mitochondrial 
glutamate 
transporter 
Catalyses the co-transport of 
glutamate with H+ or exchanges 
glutamate for OH- 
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PLCB1 
 
1 AR Loss-of-
function 
Phospholipase 
C-beta type 1 
Catalyzes the generation of 
inositol 1,4,5-trisphosphate 
(IP3) and diacylglycerol (DAG) 
from phosphatidylinositol 4,5-
bisphosphate (IP2), important 
in the intracellular transduction 
of many extracellular signals 
QARS 
 
2 AR Loss-of-
function 
Amino-acyl 
tRNA 
synthetase 
Ensure translational fidelity by 
matching of tRNA with correct 
amino acids 
Loss of function leads to 
impaired neuronal survival 
Table 6.2 Genes implicated in EIMFS. AD autosomal dominant AR autosomal recessive.  
6.3 What does a clinical diagnosis of EIMFS mean in the new era of genomic medicine? 
Given the disparate genetic aetiologies now identified, can EIMFS still be considered as one 
disorder, or does it merely reflect the age-related manifestation of a range of different 
insults, both genetic and metabolic, to cerebral function? These concepts are not 
necessarily mutually exclusive. Firstly, the question of whether all patients reported in the 
literature have the same disorder is related to the quality of the phenotypic data that is 
published, which is variable. There is also very likely to be reporting bias, where EIMFS 
patients with interesting genetic diagnoses are published as opposed to gene-negative 
patients. This may have been skewing the literature in EIMFS in recent years. However, 
despite this the patients do seem to share a specific ictal EEG signature which is 
consistently seen across different genetic aetiologies, while other clinical features may vary 
slightly, such as the increased presence of movement disorders in KCNT1-EIMFS. Selioutski 
et al performed sequential EEGs in two patients with EIMFS, one with a KCNT1 and one 
with a SCN2A mutation and showed that they both had delayed maturation of normal EEG 
patterns, with delayed development of a normal continuous EEG. Furthermore, they 
demonstrated that the characteristic migrating foci could only be seen when the EEG 
became continuous at 70-100 postnatal days, perhaps explaining the time lag between 
onset of clinical seizures and the characteristic EEG abnormality (Selioutski et al. 2015). This 
shared EEG maturational abnormality is further evidence of the shared EEG phenotype 
between these different aetiologies.  
Why do the seizures migrate in EIMFS and not in other EEs such as Dravet syndrome? I 
postulate that this may be a reflection of an abnormal functional or anatomical network 
specific to EIMFS and resulting from the underlying genetic abnormality. As a result of an 
abnormal neuronal network, ictal spread may not occur as it would in a more normal 
  214 
 
system. In fact, the seizures may not be migratory but, rather, unable to migrate. Neuronal 
networks potentially represent a final common pathway for convergent aetiologies and 
have been investigated using EEG coupled with functional MRI in several epileptic 
encephalopathies, including West syndrome. In patients with West syndrome of both 
structural and “cryptogenic” causes, a “fingerprint” network of brain activation associated 
with hypsarrhythmia could be discerned (Siniatchkin & Capovilla 2013; Siniatchkin et al. 
2007). This is an area that requires further research by analysing network properties in 
EIMFS of diverse genetic aetiologies using a source analysis method such as dynamic 
imaging of coherent source analysis (DICS), which has the advantage of using EEG data 
alone rather than requiring functional MRI data which might be technically challenging in 
infants (Japaridze et al. 2015).  
If EIMFS does represent a discrete phenotype, how do these different aetiologies 
converge? It is clear is that mutations in a number of important synaptic proteins can lead 
to EIMFS but in reality the synapse is dynamic and complex with these proteins working in 
concert, not isolation. For example, voltage gated sodium channels allow influx of sodium, 
which activates KCNT1 channels. Therefore it is possible that a gain of SCN2A function leads 
to increased KCNT1 activation, hence the resultant similar phenotype. It is notable that 
many EIMFS genes, such as SLC12A5 and KCNT1, have potentially much wider effects 
beyond the immediate excitation-inhibition imbalance leading to seizures, such as effects 
on dendritic branching and excitatory synapse formation. The post-natal microcephaly and 
severe cognitive impact of EIMFS points to a significant effect of these genes on early brain 
development including synapse and network formation.  
Therefore, I suggest that the electroclinical syndromic diagnosis of EIMFS still has merit. For 
the 30-50% of patients where we are currently unable to make a genetic diagnosis, it 
allows us to give families reasonable prognostic information regarding seizure control and 
the impact on neurodevelopment. It is possible that as further genetic causes are 
discovered, sub-groups with slightly differing outcomes will emerge.  
The story of genetic discovery in EIMFS has implications for other rare EEs. Firstly, it 
highlights the importance of rigorous phenotyping and gathering a cohort of similar 
patients, as this is most likely to lead to genetic discovery, as was the case for KCNT1 and 
SLC12A5. Secondly, although de novo dominant mutations remain important in the EEs, 
study of families with more than one affected child can lead to genetic discovery in both 
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consanguineous and outbred populations. This study also adds to the emerging evidence 
that transporters, in addition to channels, are important in the epileptic encephalopathies 
(Thevenon et al. 2014; Kodera et al. 2013; Leen et al. 2010; A. Poduri, Heinzen, et al. 2013).  
I hope that my further research into network abnormalities in EIMFS and the generation of 
better disease models will have relevance for other epileptic encephalopathies, in which 
there remain many unanswered questions.  
6.4 Conclusion 
The current era of genetic discovery makes this an exciting and rewarding time to be a 
clinician scientist in training in the field of epilepsy genetics. However, while diagnostics 
have improved immeasurably, for my patients and their families the daily realities of severe 
early onset epilepsy remain bleak. It is now vital that we harness the possibilities of the 
genomic age and translate them into therapies and interventions with real, tangible 
benefits for children and young people with severe epilepsy, who are the most deserving of 
recipients.  
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Chapter 8 Appendix 
8.1 BPNSU study: Migrating Partial Seizures in Infancy – Research Proforma  
Notifying consultant:      Tertiary Centre: 
First part of child’s post code (up to 4 letters/figures): 
Date of birth:       Sex:   Male / Female 
Ethnic Group: 
Age when MPSI considered most likely diagnosis:  
Current age (give date of death if deceased): 
Birth details: 
Weight: ……….. 
Gestation: ……………. 
Type of delivery: Normal vaginal / Assisted vaginal / Elective LSCS / Emergency LSCS 
Perinatal difficulties: resuscitation / Ventilation / Feeding difficulties 
Occipitofrontal circumference (OFC) at birth 
Mum’s age 
Dad’s age 
Mum’s pregnancy history –    Gravida ….. Para…. 
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Any miscarriages, terminations or still births? 
 
Ages of other siblings 
Do any of the siblings have any neurological or other health problems? 
If yes, give details 
 
 
Any other important family history? 
If yes, give details 
 
 
Age at presentation with epilepsy ………….. 
 
Describe seizures at presentation: 
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Semiology of each seizure type & date first noticed 
 
1. 
 
2. 
 
3. 
 
4.  
Frequency of seizures: Awake …………………..           Asleep………………………. 
 
Do seizures occur in clusters? 
 
Has the child had episodes of convulsive status epilepticus?  Y / N 
 
Give number of episodes here ………… 
 
Has child had episodes of non-convulsive status epilepticus?  Y   / N 
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Give number of episodes here ………… 
 
Has the child had episode of complex partial status epilepticus? Y / N 
Give number of episodes here ………… 
 
 
Were autonomic features present? Give details 
Rash: 
Epiphora (production of tears): 
Pupillary changes: 
Salivation: 
Other: 
 
Examination findings at presentation 
Any abnormal physical or neurological findings? 
 
Any dysmorphic features? 
If yes, give details here 
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Did the child as a baby have a ‘coarse’ facial appearance?  Y / N 
Investigations 
 
How many EEGs has child had?  ...................... 
 
Was the first EEG normal? Y / N 
 
Has the child had an ictal EEG? Y / N 
If yes, were seizures captured from at least 2 different ‘foci’? Y / N 
 
Please attach copies of EEG reports with this form 
 
Has the child had a CT scan? Y / N (Give ages when performed) 
 
Has the child had an MRI scan? Y / N (Give ages when performed) 
 
Has the child had MR spectroscopy performed? Y / N (Give ages when performed) 
Please attach copies of MRI or CT results with this form 
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Please fill in the table below regarding possible investigation list – and please give levels of 
any tests results if possible: 
Please list any other investigations in table as well (space at the bottom) 
Chromosomes  
Skin chromosomes  
Any other cytogenetic tests   
Ammonia  
Plasma lactate  
 
Plasma amino acids 
 
Liver function tests  
Acyl carnitine/carnitine profile  
Biotinidase  
Copper and caeruloplasmin  
White cell enzymes  
Very long chain fatty acids  
Sialated transferrins  
Urine amino and organic acids  
Urinary sulfites  
Mucopolysaccharide screen  
CSF lactate  
CSF fasting blood/glucose ratio  
CSF amino acids 
 
 
CSF neurotransmitters 
Investigation table MPSI 
Continued. 
 
 
TORCH screen 
 
 
MECP2 analysis  
CDKL5 mutation  
SCN1A mutation  
MERFF or MELAS  
Mitochondrial genome 
sequencing 
 
Any other molecular genetic 
tests (please describe) 
 
 
Muscle biopsy  
Liver biopsy  
PDH  fibroblast activity  
Others, give details  
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Please fill in table below regarding possible treatments the child has received: 
Please list any other treatments tried at the bottom of the table 
 Length of 
treatment 
Max 
dose 
m/Kg 
Reason for 
withdrawal 
List drugs given in 
combination with this 
treatment 
Pyridoxine 
 
    
Pyridoxal phosphate     
Biotin 
 
    
Folinic acid 
 
    
     
Carbamazepine 
 
    
Oxcarbamazine 
 
    
Phenytoin  
 
    
Phenobarbitone  
 
    
Sodium valproate  
 
    
Stiripentol 
 
    
Clobazam 
 
    
Clonazepam 
 
    
Nitrazepam 
 
    
Vigabatrin 
 
    
Levetiracetam 
 
    
Topiramate 
 
    
Lamotrigine 
 
    
Bromide Salts 
 
    
Zonisamide 
 
    
Gabapentin 
 
    
 Length of 
treatment 
Max 
dose 
m/Kg 
Reason for 
withdrawal 
List drugs given in 
combination with this 
treatment 
Ketogenic Diet (KD)     
Course(s) of 
prednisolone 
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Course(s) of other 
steroid (give details) 
    
Course(s) of 
Immunoglobulin 
    
Vagal Nerve 
Stimulator 
    
Trial without 
medication 
    
Others 
 
 
    
 
Please list the treatment or combination of treatments used to produce the ‘best’ periods 
of seizure control 
How old was the child during this period? ……………. 
 
Which rescue medications, if any, have you found to be useful? 
 
 
Course of condition: 
 
What was the maximum number of seizures per day recorded? 
 
How old was the child at this time? 
 
Did seizure frequency decrease with time?  Y / N 
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Please give details 
 
Has child lost developmental milestones? Y / N 
 
 
When did this happen? 
 
Give details of developmental progress: 
 
Please attach any relevant developmental assessments 
Milestone Age achieved Age lost skill Age regained skill 
Social smile    
Visually alert    
Good head control    
Rolling over    
Sits with support    
Sits without support    
Pull to stand    
Crawling    
Cruising    
Walks with support    
Walks independently    
Makes babbling speech     
Recognisable single words    
Puts 2 words together    
Talks in sentences    
Waves bye bye    
Claps hands    
Feeds with fingers    
Feeds with spoon    
Toilet trained    
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Did child develop any focal neurological signs? Y / N 
 
Give details here including age first noticed 
 
 
 
Give details of occipitofrontal circumference: 
Birth  
Age   
Age  
Age  
Age  
 
If permission has been given for medical photographs to be used for research by parents, 
please send a photo of the child either as a print or via email as an attachment to Rachel 
Kneen or Amy McTague. Thanks for your help in filling out this form. 
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8.2 Web- based resources  
1000 Genomes http://browser.1000genomes.org/index.html  
Exome Aggregation Consortium (ExAC) http://exac.broadinstitute.org/ 
Genome Aggregation Consortium (gnomAD) http://gnomad.broadinstitute.org/ 
Exome Variant Server http://evs.gs.washington.edu/EVS/ 
Polyphen2 http://genetics.bwh.harvard.edu/pph2/, 
SIFT/Provean http://provean.jcvi.org/genome_submit_2.php) 
Ensembl http://www.ensembl.org/index.html 
OMIM https://www.omim.org/ 
ClinVar https://www.ncbi.nlm.nih.gov/clinvar/ 
 
8.3 Single nucleotide polymorphism(SNP) arrays 
Illumina CytoSNP12 arrays were performed by the local UCL Genomics Service in both 
parents, affected and unaffected children from Family 1 (Chapter 5). All processing was 
carried out in accordance with the Infinium HD Ultra Assay protocol (Rev B, 2010, Illumina 
Inc, San Diego, USA).  The whole genome of 300ng of high quality genomic DNA was 
amplified overnight (370C, 20-24 hours), subsequently fragmented (370C for 1 hour and 
15mins in hybridisation oven), precipitated and resuspended in hybridisation buffer. 
Samples were denatured and loaded onto the chips using a liquid handling robot (Freedom 
Evo, Tecan Ltd, Switzerland). Hybridisation took place overnight (16-20 hours) at 48°C. The 
probes on the chip were extended by a single hapten-labelled dideoxynucleotide (ddNTP) 
base complementary to the hybridised DNA. ddATP and ddTTP bases were labelled with 
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DNP (2,4-Dinitrophenol), ddCTP and ddGTP were labelled with Biotin. The DNA sample was 
then stripped off the chip using formamide. The staining procedure involved signal 
amplification by multi-layer immunohistochemical staining. The haptens were detected 
simultaneously by Streptavidin and an anti-DNP primary antibody conjugated to green and 
red fluorophores respectively (STM reagent, Illumina). They were then counterstained with 
biotinylated anti-streptavidin and a DNP-labelled secondary antibody to the anti-DNP 
primary antibody (ATM reagent, Illumina) to amplify the fluorescent signals. The last layer 
of stain was the STM, containing the fluorophores to allow signal detection. Finally the 
stained chips were coated to protect the dyes, and scanned using the iScan scanner with 
autoloader (Illumina Inc, San Diego, USA). Data was initially analysed using the Illumina 
Genomestudio software. This generates genotypes, and copy number and loss of 
heterozygosity data (cnvPartition v3.1.6, Illumina). Quality control checks were performed 
to assess the data quality. Samples were assessed for their call rate which should be >98% 
and >99% average across the batch. Specially designed control probes were also checked.  
8.4 Great Ormond Street NGS multiple gene EIEE panel:  methods  
Custom TSCA method: a custom SureSelect library was created using Illumina’s Design 
Studio tool (http://designstudio.illumina.com/truseqca/project). Briefly, genomic 
coordinates of 48 genes were uploaded to Design Studio to create the targeted panel. 
Libraries were made following the TruSeq Custom Amplicon Kit protocol (Illumina 
Technologies) and sequenced in-house on an Illumina MiSeq.  
Sure Select method: a custom SureSelect library was created using Agilent's SureDesign 
tool (https://earray.chem.agilent.com/suredesign/). Briefly, genomic coordinates of either 
45 (3 patients) or 66 (1 patient) genes were uploaded to SureDesign to create the targeted 
panel.  Libraries were made following the SureSelectXT Custom Capture protocol (Agilent 
Technologies) and sequenced in-house on an Illumina MiSeq. For both panel designs 
sequence data were analysed using an in-house pipeline. Regions of interest were defined 
in BED file format by uploading HGNC genes names to the UCSC table browser (Karolchik et 
al. 2004). Sequence reads in FASTQ format were aligned to the reference human genome 
(hg19) using BWA (0.6.1-r104) and default settings (Li & Durbin 2009). Variant calling was 
performed across the entire region of interest using VarScan2 (v2.3.7) with the following 
settings: minimum 30X coverage, minimum 5 alternate reads, minimum phred-like base-
quality of 20) (Koboldt et al. 2012; Koboldt et al. 2009). Variant calls in VCF format were 
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then annotated using Ensembl Variant Effect Predictor (v73) and the output parsed using 
an in-house script, converting the annotated VCF file into Excel format for subsequent 
variant filtering and prioritization (McLaren et al. 2010). For each case, coverage was 
assessed across the coding exons of the target genes and their intron-exon boundaries 
(+6bp and -12bp) and expressed as the percentage of bases covered at ≥30X. 
8.5 Whole exome sequencing (WES) methods 
8.5.1 WES at Institute of Neurology, London 
Automated library construction was undertaken using an Agilent Bravo liquid handling 
workstation. TruSeq chemistry (Illumina Inc., San Diego, CA) was used to prepare single 
indexed, paired-end libraries from 2µg of genomic DNA that were subsequently enriched 
according to standard protocols supplied by Illumina (Illumina Inc., San Diego, CA). The 
enriched DNA libraries were sequenced, 2 x 101 bases on a HiSeq 1000 sequencing system 
(Illumina, Inc., San Diego, CA). The sequencing data was mapped to the human reference 
assembly, hg19 (GRCh37; downloaded from the UCSC genome browser) by Novoalign 
Software (Hansen 2016). After removal of PCR duplicates (Picard) and reads without a 
unique mapping location, variants were extracted using the Maq model in SAMtools (Li et 
al. 2009) and filtered by the following criteria: consensus quality >30, SNP quality >30 and 
root mean square mapping quality >30. These variants were further filtered by Annovar 
(Hansen 2016) against dbSNP build 135 (UCSC genome browser), 1000 Genomes and 
Exome Variant Server and intronic and non-coding variants were excluded. 
8.5.2 WES at Duke University, USA 
DNA was sheared for paired-end Illumina library preparation then enriched for target 
capture according to the manufacturer’s instructions. Enriched libraries were sequenced 
using the HiSeq platform. Variants were called on each sample individually and filtering was 
applied for quality variables. Calls were merged, then annotated with allele frequencies 
from 1000 Genomes and Exome Variant Server (EVS) and with dbSNP132 unique rs 
identification numbers, if available. SIFT and PolyPhen scores for missense mutations were 
also included. All variants with a mean allele frequency of >0.01 in 1000 Genomes or EVS 
were excluded. 
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8.5.3 WES at Karolinska Institute, Sweden 
Exome sequencing was undertaken for the parents and the affected siblings in Family 2 and 
bioinformatic analysis was performed using the Mutation Identification Pipeline v.1.5.6 
http://mip-api.readthedocs.org/en/latest/index.html. Approximately 50 gigabases (Gb) of 
sequencing data was produced, generating an average 90-190 fold coverage of the exome 
within the family. The exome was sufficiently covered at 95.8% of the bases according to 
our cut-off limits (10x read depth) and 135,851 variants were called. 86% (116,691 variants) 
were single nucleotide variants (SNV) and 14% (19,160 variants) were indels. All variants 
were scored and ranked  
8.6 Homology modelling methods 
8.6.1 Homology modelling of mutations in KCNT1 
 HMMscan (Eddy 2011) against Pfam (database of sequence-based domain families) 
identified two domains in the sequence of human KCNT1 (isoform 1), (i) Ion channel 
(PF07885, at position 278-346) and (ii) calcium-activated BK potassium channel alpha-
subunit family (PF03493, at position 495-598) (Bateman et al. 2000; Finn et al. 2009).  Of 
the five novel mutations identified it was possible to model two; F346L (in the ion channel 
domain) and F502V in the gating ring containing RCK1 and RCK2 domains. HHPred was used 
for template-based structure prediction for the individual domains (Söding et al. 2005). 
MODELLER-9v14 was used for homology modelling (Sali & Blundell 1993). For the 
modelling of the region possessing ion channel domain (residues 270-353), 20 models were 
built and assessed using DOPE (Discrete Optimized Protein Energy) score (Shen & Sali 
2006). The best scoring model was then selected and examined for its quality using QMEAN 
(Benkert et al. 2011) . The side chain conformations for the selected model were further 
refined using a method based on backbone-dependent rotamer library – SCWRL4 (Krivov et 
al. 2009). The model of the gating region (residues 372-1044) was almost identical to the 
EM model except only seven and six residue substitutions in RCK1 and RCK2, respectively. 
This model has coordinates for both RCK1 and RCK2 domains but is missing a 163 amino 
acid linker (residues 633-796).  A dimer model was generated by structure superimposition 
of individual models on the template dimer. This model was further subjected to 1000 
steps (steepest descent) of energy minimization to reduce steric clashes and optimize the 
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positioning of side chains. Mutations were inserted into the respective models (F502V in 
gating region and F346L in ion channel) using the swapaa command in Chimera (Pettersen 
et al. 2004) with Dunbrack rotamer library and the rotamer was selected based on lowest 
clashes, highest number of H-bonds and highest probability. 
Modelling of F346L:  For F346L, the final homology model of the four-subunit ion-channel 
domain (in open conformation) was of reasonable quality with QMEAN Z-score of -3.97. 
The spatial position of the membrane is predicted using the PPM2.0 server (Lomize et al. 
2012). The potassium-bound structure (open form) of calcium-gated potassium channel 
MthK from Methanothermobacter thermaautotrophicus (PDB ID: 1LNQ) was used as a 
template for modelling the ion channel domain (residues 270-353) (Jiang et al. 2002) . This 
template structure was identified upon sensitive sequence-based profile-profile 
comparison method-HHPred (Söding et al. 2005). The probability score (significance of the 
alignment) of 99% and 50% sequence similarity asserted the homologous relationship 
between the selected template and human KCNT1 ion channel domain. Further to model 
the tetramer of the ion channel domain, the biological assembly from the Protein Data 
Bank (PDB: 3LDC) was used (Ye et al. 2010). We also modeled the closed form of the ion-
channel domain using the structure of potassium channel from Streptomyces lividans 
(PDBID: 2A9H), which shares 20% identity (31% similarity) with the KCNT1 ion-channel 
domain (Yu et al. 2005).  
Modelling of mutation F502V: F502V is a conserved residue among homologs (CONSURF) 
(Glaser et al. 2003). The residue stretch (372-1044) which lies in the KCNT1 gating region 
(373-1174) was modelled using an almost identical (95%) recent cryo-EM structure of 
Slo2.2 channel from Gallus gallus in a closed form (without calcium) (PDB ID: 5A6F) (Hite et 
al. 2015). This appeared to be a suitable model (QMEAN aZ-Score = -1.82).  Human KCNT1 
gating region and the cryo-EM model share a sequence identity of ~95%. A template dimer 
was built from the cryoEM model by fitting a second copy (5A6F) in the EM density map 
(EMD: 3063), using the fit_in_map tool in Chimera based on which a model of the dimer of 
KCNT1 gating ring was generated (Pettersen et al. 2004). 
8.6.2 Protein homology methods for mutations of SLC12A5: 
Fold recognition of KCC2 was performed with HHPRED (Söding et al. 2005). The crystal 
structure of the Methanocaldococcus jannaschii ApcT Transporter (PDB: 3GIA; 2.35Å 
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resolution) was identified as the best template for residues 115-682 (TM middle domain), 
(HHPred e-value: 2.4×10-36). The HHpred alignment was used as preliminary pairwise 
sequence alignment for homology modelling. The extended loop region between TM5 and 
TM6 (residues 303-407) could not be accurately modelled due to lack of sequence identity 
and was therefore removed. A preliminary homology model of KCC2 middle domain was 
calculated using MODELLER-9v10 (Eswar et al. 2007). The ConSurf web server (Ashkenazy 
et al. 2010) with default parameters, was used to evaluate the evolutionary conservation 
and improve the quality of the alignment accordingly. This alignment was then used to 
create 1000 homology models that were further assessed with the DOPE statistical 
potential score(Shen & Sali 2006). The model based on the lowest score (Normalized DOPE 
z-score: -0.464) was selected. Additional evaluation using the ProSA web server showed 
that the model quality (Z-score =  -2.63) fell within a range typically found for native 
proteins of similar size(Sippl 1993). Next, selected non-synonymous substitutions were 
modeled into the KCC2 homology model with the swapaa command in Chimera (Pettersen 
et al. 2004) using the Dunbrack backbone-dependent rotamer library (Dunbrack 2002) and 
taking into account the lowest clash score, highest number of H-bonds and highest rotamer 
probability. 
8.7 Xenopus oocyte cell model for KCNT1: electrophysiology methods 
Variants were introduced into a wild-type human KCNT1 expression construct using 
QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent Technologies) according to 
manufacturer instructions (Milligan et al. 2014). Construct fidelity was confirmed by DNA 
sequencing. cDNAs were transcribed in vitro (mMessage mMachine; Ambion, Austin, TX). 
Oocytes (Dumont stage V or VI) were surgically removed from Xenopus laevis frogs and 
prepared (Petrou, S, Ugur, M, Drummond, RM, Singer, JJ, Walsh, JVJr 1997). Oocytes were 
kept in ND96 solution and stored at 17°C. Fifty nanoliters (0.2 ng/nl) of capped cRNA was 
injected into each oocyte using the Roboocyte system (Multi Channel Systems, Reutlingen, 
Germany) and oocytes incubated at 17°C.  Electrodes containing1.5M K-acetate and 0.5M 
KCl were used to impale oocytes that were held at −90mV and perfused with bath solution 
containing 96mM NaCl, 2mM KCl, 1.8mM CaCl2, 1mM MgCl2, and 5mM HEPES, pH 7.5. 2-
electrode voltage clamp recording was performed after 14-24 hours of expression. 
Recording frequency was 1kHz, and temperature was maintained between 20 and 22°C. To 
record expressed membrane currents, oocytes were held at −90mV, and test 
depolarizations lasting for 600-milliseconds were applied in 10mV increments, from −80mV 
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to +80mV, at 5 second intervals. Contemporaneous measurement of wild type (WT) 
currents was performed with the same batch of oocytes injected with mutant channels to 
maintain an internal control of possible variability in expression from different batches of 
oocytes. Quinidine (Sigma, St Louis, MO) was dissolved in ethanol to a concentration of 300 
µM and was perfused continuously to the oocytes for 1 minute, following with 5 minute 
incubation. Currents were recorded before and after the application of the compound. 
Peak currents were measured at the end of each sweep for all clones, however in many of 
the mutants, saturation of the amplifiers was observed at +80mV, due to large currents so 
current at +10mV was set as a comparison point across all mutants and WT. Representative 
current traces and current voltage relationship curves were obtained using recordings that 
did not saturate the amplifier at +80mV. AxoGraph (AxoGraph Scientific, Sydney, Australia) 
was used to analyse the electrophysiological data, which is presented as mean ± standard 
error of the mean. Student t test was used to test statistical significance, performed on 
Prism 6 (GraphPad Software, La Jolla, CA). 
8.8 SLC12A5 Immunoblotting studies: methods 
The full-length human wild-type KCC2 and the three mutant KCC2 sequences were cloned 
into the mammalian expression vector, pCMV-Myc. We amplified the sequences from the 
Origene KCC2 wild-type expression vector and the mutagenized vectors using the 
Platinum® Taq DNA Polymerase High Fidelity (Life Technologies), custom-designed cloning 
primers (available on request) and 94°C for 2 min followed by 30 cycles of 94°C for 30 sec, 
55°C for 30 sec and 68°C for 3 min 30 sec. Then using the QIAquick Gel Extraction Kit 
(QIAGEN) purified PCR products and the pCMV-Myc plasmid were successively digested 
first with EcoRI and then with Acc65I (isoschizomer of KpnI) according to manufacturer’s 
protocol. Following purification with the QIAquick Gel Extraction Kit the PCR products were 
ligated into the EcoRI and KpnI sites of the vector pCMV-Myc (which was kindly provided 
from Dr Paul Gissen) using T4 DNA ligase (Promega). For amplification of Myc-tagged KCC2 
constructs we transformed NEB 10-beta competent E.coli cells (New England BioLabs) with 
the plasmids and subsequently isolated the plasmids with the QIAGEN Plasmid Maxi Kit 
(QIAGEN). All expression constructs were confirmed by Sanger sequencing of the entire 
coding region, to ensure that during PCR amplification no additional mutations had been 
introduced. LLC-PK cells (non-transfected LLC-PK1 cells kindly supplied by Dr. Roxanne A. 
Vaughan, University of North Dakota) were then transiently transfected with equal 
amounts of WT, L311H, L426P and G551D constructs. 24hrs later, surface proteins were 
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labeled with biotin and cells were lysed. Biotinylated fraction and total cell lysates were 
eluted with 8% Tris-glycine, separated on a SDS polyacrylamide gel, transferred to 
nitrocellulose membrane and blotted with anti-myc antibodies. Control beta-actin bands 
were observed in the total cell lysate but not in the biotinylation assay. Densitometric 
analysis with NIH Image J yielded Area-Under-Curve (AUC) for each Western blot band.. 
Two analyses were undertaken to determine the effect of mutations.  
1. Calculation of cell-surface KCC2 relative to the total level of KCC2 and normalization with 
WT values. In this analysis both bands are taken together for both surface and total 
expression, assuming full and equal recovery through biotinylation steps in work-up. 
 
2. Calculation of the fraction of glycosylated state in the cell-surface (i), or total expression, 
(ii):     
(                        (i) 
(                                 (ii) 
8.9 SLC12A5 Immunostaining and confocal microscopy  
HEK293 cells were transfected with pCAGGS-KCC2-FLAG (Chamma et al. 2012) (gift from S. 
Levi, Institut National de la Santé et de la Recherche Médicale, Paris, France), pCAGGS-
KCC2-FLAG-L311H, pCAGGS-KCC2-FLAG L426P or pCAGGS-KCC2-FLAG G551D and HcRed 
NLS using FuGENE (Promega). After 24 hours, cells were fixed in 4% (w/v) 
paraformaldehyde in phosphate buffered saline (PBS) for 15 sec, washed with PBS, 
incubated with 50 mM NH4Cl for 10 min, washed with PBS and blocked for 30 min in PBS 
supplemented with 2% (w/v) bovine serum albumin (BSA) and 10% (v/v) goat serum. Total 
KCC2-FLAG in cells was assessed by the addition of 1% (v/v) Triton X-100 to blocking media. 
Cells were incubated for 1 hour with rabbit anti-FLAG antibody (1:200; Sigma, catalogue 
number F7425) in PBS with 2% BSA, washed in PBS, incubated with AlexaFluor 488-
conjugated goat anti-rabbit antibody (1:600; Invitrogen, catalogue number A-11008) in 
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PBS-BSA, washed with PBS and mounted on slides. Images were collected using a Zeiss LSM 
710 confocal microscope using x63 objective. 
8.10 Slc12a5 Zebrafish models and behavioural analysis: methods 
Zebrafish (Danio rerio, AB strain) obtained from the Zebrafish International Resource 
Center (Eugene, OR) were maintained at 28.5°C following established procedures. The 
experiments were performed in accordance with the approved guidelines of the 
Committee on Animal Use and Care at the National Institute of Genetics, Japan. Zebrafish 
have two KCC2 orthologs (KCC2a and KCC2b), due to an ancient gene duplication. TALENs 
for zebrafish KCC2a and KCC2b were designed to target the fourth exon of both KCC2a and 
KCC2b genes. To construct TALEN plasmid, TAL effector repeats were assembled in pFUS 
plasmid by BsaI (New England Labs) digestion and following T4 DNA ligase reaction were 
subsequently subcloned into pCS2+ vector using BsmBI (New England Labs) restriction sites 
(Sakuma et al. 2013). The TALEN constructs were linearized by NotI digestion and used for 
in vitro transcription. Capped RNAs were synthesized using mMESSAGEmMACHINE SP6 kit 
(Life Technologies) according to the manufacturer’s instruction. TALEN RNAs (200 pg for 
each TALEN) were injected into 1-cell stage zebrafish embryos and gene disruption of 
KCC2a (8 bp deletion) and KCC2b (5 base deletion) was confirmed by sequencing the F1 
fish. KCC2a-KCC2b double knockout larvae were obtained by crossing double heterozygous 
carrier fish. Genotyping was done using following primers and PCR products were 
separated by 15~20% polyacrylamide gel electrophoresis. 
KCC2a (genotyping, forward): 5’-TGGGTGTGTACCTGCCC-3’ 
KCC2a (genotyping, reverse): 5’-CCTGAGGAATAGAATCACACCC-3’ 
KCC2b (genotyping, forward): 5’-CGTTTACCTACCATGTCTTCAAAACAT-3’ 
KCC2b (genotyping, reverse): 5’-CCAGGTCATCCTGAGGAACAAA-3’ 
At 2 days post fertilization (dpf), the embryonic behavior of the wild-type and KCC2a-KCC2b 
double knockout embryos (both male and female, 10 per group) were investigated by a 
tactile response assay in which mechanosensory stimulation was applied to the tail. The 
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response was recorded using a dissection microscope (MZ16, Leica) and a high-speed CCD 
camera (HAS-220, Ditect). 
 
